[{"id": 60001, "ingredient1": "Iron", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "INTERVAL: The oral bioavailability of cefdinir may be significantly decreased by concomitant administration of iron preparations. The proposed mechanism is chelation of cefdinir by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products. However, this separation time may not be sufficient to prevent the interaction when sustained-release iron products are used, especially in higher dosages. Patients should be advised that reddish stools may occur due to formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "mechanism_text": "Absorption", "recommendation": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60083/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[2] Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I \"Impairment of cefdinir absorption by iron ion.\" Clin Pharmacol Ther 54 (1993): 473-5", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 60002, "ingredient1": "Chloramphenicol", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60084/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60003, "ingredient1": "Cefdinir", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60085/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60004, "ingredient1": "Dicoumarol", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60086/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60005, "ingredient1": "Entecavir", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60087/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan", "updated_at": 1767369485}, {"id": 60006, "ingredient1": "Etacrynic acid", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60088/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60007, "ingredient1": "Cefdinir", "ingredient2": "Tetraferric tricitrate decahydrate", "severity": "Moderate", "effect": "INTERVAL: The oral bioavailability of cefdinir may be significantly decreased by concomitant administration of iron preparations. The proposed mechanism is chelation of cefdinir by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products. However, this separation time may not be sufficient to prevent the interaction when sustained-release iron products are used, especially in higher dosages. Patients should be advised that reddish stools may occur due to formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "mechanism_text": "Absorption", "recommendation": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60089/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[2] Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I \"Impairment of cefdinir absorption by iron ion.\" Clin Pharmacol Ther 54 (1993): 473-5", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 60008, "ingredient1": "Ferrous fumarate", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "INTERVAL: The oral bioavailability of cefdinir may be significantly decreased by concomitant administration of iron preparations. The proposed mechanism is chelation of cefdinir by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products. However, this separation time may not be sufficient to prevent the interaction when sustained-release iron products are used, especially in higher dosages. Patients should be advised that reddish stools may occur due to formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "mechanism_text": "Absorption", "recommendation": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60090/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[2] Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I \"Impairment of cefdinir absorption by iron ion.\" Clin Pharmacol Ther 54 (1993): 473-5", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 60009, "ingredient1": "Ferrous gluconate", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "INTERVAL: The oral bioavailability of cefdinir may be significantly decreased by concomitant administration of iron preparations. The proposed mechanism is chelation of cefdinir by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products. However, this separation time may not be sufficient to prevent the interaction when sustained-release iron products are used, especially in higher dosages. Patients should be advised that reddish stools may occur due to formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "mechanism_text": "Absorption", "recommendation": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60091/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[2] Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I \"Impairment of cefdinir absorption by iron ion.\" Clin Pharmacol Ther 54 (1993): 473-5", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 60010, "ingredient1": "Ferrous sulfate anhydrous", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "INTERVAL: The oral bioavailability of cefdinir may be significantly decreased by concomitant administration of iron preparations. The proposed mechanism is chelation of cefdinir by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products. However, this separation time may not be sufficient to prevent the interaction when sustained-release iron products are used, especially in higher dosages. Patients should be advised that reddish stools may occur due to formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "mechanism_text": "Absorption", "recommendation": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60092/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[2] Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I \"Impairment of cefdinir absorption by iron ion.\" Clin Pharmacol Ther 54 (1993): 473-5", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60011, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60093/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60012, "ingredient1": "Iron protein succinylate", "ingredient2": "Cefdinir", "severity": "Moderate", "effect": "INTERVAL: The oral bioavailability of cefdinir may be significantly decreased by concomitant administration of iron preparations. The proposed mechanism is chelation of cefdinir by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products. However, this separation time may not be sufficient to prevent the interaction when sustained-release iron products are used, especially in higher dosages. Patients should be advised that reddish stools may occur due to formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "mechanism_text": "Absorption", "recommendation": "To minimize potential interaction with iron, the product labeling recommends that cefdinir be taken at least 2 hours before or 2 hours after administration of iron-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60094/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[2] Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I \"Impairment of cefdinir absorption by iron ion.\" Clin Pharmacol Ther 54 (1993): 473-5", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Iron sucrose, Cyanocobalamin", "updated_at": 1767369485}, {"id": 60013, "ingredient1": "Cefdinir", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60095/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60014, "ingredient1": "Cefdinir", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "INTERVAL: Aluminum- or magnesium-containing antacids may interfere with the rate and extent of absorption of cefdinir. The mechanism has not been described but is most likely due to a chelation effect by the antacid or a change in intragastric pH.", "source": "DDInter", "management_text": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "mechanism_text": "Absorption", "recommendation": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60096/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Calcium carbonate", "updated_at": 1767369485}, {"id": 60015, "ingredient1": "Cefdinir", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "INTERVAL: Aluminum- or magnesium-containing antacids may interfere with the rate and extent of absorption of cefdinir. The mechanism has not been described but is most likely due to a chelation effect by the antacid or a change in intragastric pH.", "source": "DDInter", "management_text": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "mechanism_text": "Absorption", "recommendation": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60097/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Calcium carbonate, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, More", "updated_at": 1767369485}, {"id": 60016, "ingredient1": "Cefdinir", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "INTERVAL: Aluminum- or magnesium-containing antacids may interfere with the rate and extent of absorption of cefdinir. The mechanism has not been described but is most likely due to a chelation effect by the antacid or a change in intragastric pH.", "source": "DDInter", "management_text": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "mechanism_text": "Absorption", "recommendation": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60098/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 60017, "ingredient1": "Cefdinir", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Aluminum- or magnesium-containing antacids may interfere with the rate and extent of absorption of cefdinir. The mechanism has not been described but is most likely due to a chelation effect by the antacid or a change in intragastric pH.", "source": "DDInter", "management_text": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "mechanism_text": "Absorption", "recommendation": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60099/", "reference_text": "[1] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Calcium carbonate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "updated_at": 1767369485}, {"id": 60018, "ingredient1": "Cefdinir", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60100/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60019, "ingredient1": "Cefdinir", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60101/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60020, "ingredient1": "Cefdinir", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60102/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan", "alternatives_b": "Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More", "updated_at": 1767369485}, {"id": 60021, "ingredient1": "Cefdinir", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60103/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "updated_at": 1767369485}, {"id": 60022, "ingredient1": "Cefdinir", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60104/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60023, "ingredient1": "Cefdinir", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60105/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60024, "ingredient1": "Cefdinir", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60106/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Meropenem, Doripenem", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "updated_at": 1767369485}, {"id": 60025, "ingredient1": "Aluminum hydroxide", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60107/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60026, "ingredient1": "Anisindione", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60108/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60027, "ingredient1": "Cefditoren", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60109/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60028, "ingredient1": "Cefditoren", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60110/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate", "updated_at": 1767369485}, {"id": 60029, "ingredient1": "Chloramphenicol", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60111/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60030, "ingredient1": "Cefditoren", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60112/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60031, "ingredient1": "Cimetidine", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60113/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefdinir, Cefalotin, More", "updated_at": 1767369485}, {"id": 60032, "ingredient1": "Dexlansoprazole", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60114/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "updated_at": 1767369485}, {"id": 60033, "ingredient1": "Dicoumarol", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60115/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60034, "ingredient1": "Didanosine", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60116/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "updated_at": 1767369485}, {"id": 60035, "ingredient1": "Entecavir", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60117/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan", "updated_at": 1767369485}, {"id": 60036, "ingredient1": "Esomeprazole", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60118/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "updated_at": 1767369485}, {"id": 60037, "ingredient1": "Etacrynic acid", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60119/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60038, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefditoren", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60120/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60039, "ingredient1": "Cefditoren", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60121/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60040, "ingredient1": "Cefditoren", "ingredient2": "Lansoprazole", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60122/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Imipenem, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefoperazone, Cefamandole, Cefradine, Cefiderocol, Meropenem, Ertapenem, More", "updated_at": 1767369485}, {"id": 60041, "ingredient1": "Cefditoren", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60123/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60042, "ingredient1": "Cefditoren", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60124/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 60043, "ingredient1": "Cefditoren", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60125/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 60044, "ingredient1": "Cefditoren", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60126/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 60045, "ingredient1": "Cefditoren", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60127/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60046, "ingredient1": "Cefditoren", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60128/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60047, "ingredient1": "Cefditoren", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60129/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefdinir, Cefalotin, More", "updated_at": 1767369485}, {"id": 60048, "ingredient1": "Cefditoren", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60130/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Cefoxitin, Imipenem, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefoperazone, Cefamandole, Cefradine, Cefiderocol, Meropenem, More", "updated_at": 1767369485}, {"id": 60049, "ingredient1": "Cefditoren", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60131/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Methotrexate, Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan", "updated_at": 1767369485}, {"id": 60050, "ingredient1": "Cefditoren", "ingredient2": "Probenecid", "severity": "Minor", "effect": "Like other beta-lactam antibiotics, the coadministration with probenecid may increase the plasma concentrations of cefditoren pivoxil. The mechanism is competitive inhibition by probenecid of the renal tubular secretion of these antibiotics. While this interaction may be exploited to enhance the antibacterial effect of cefditoren pivoxil, the potential for toxicity should be considered if the normal dosage of cefditoren pivoxil is administered with probenecid. A reduced dosage of cefditoren pivoxil may be required.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60132/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "updated_at": 1767369485}, {"id": 60051, "ingredient1": "Cefditoren", "ingredient2": "Ranitidine (bismuth citrate)", "severity": "Moderate", "effect": "Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with H2-receptor antagonists or other agents that reduce stomach acid.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60133/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60052, "ingredient1": "Cefditoren", "ingredient2": "Sodium bicarbonate", "severity": "Moderate", "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.", "source": "DDInter", "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60134/", "reference_text": "[1] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, Cefdinir, Cefalotin, More", "alternatives_b": "Sorbitol, Sulfamethizole, Magnesium citrate, Sodium chloride, Mannitol, Chlorhexidine, Neomycin, Calcium chloride, Potassium chloride, Magnesium sulfate, Sodium acetate, More", "updated_at": 1767369485}, {"id": 60053, "ingredient1": "Cefditoren", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60135/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60054, "ingredient1": "Cefditoren", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60136/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60055, "ingredient1": "Cefditoren", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60137/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60056, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60138/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, Sulfisoxazole, Levofloxacin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60057, "ingredient1": "Anisindione", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60139/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole, Amikacin, Secnidazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60058, "ingredient1": "Chloramphenicol", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60140/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Miconazole, Vitamin A, Isotretinoin, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem, Tetracycline, Norfloxacin, Levofloxacin, Amikacin", "updated_at": 1767369485}, {"id": 60059, "ingredient1": "Cefepime", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60141/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60060, "ingredient1": "Dicoumarol", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60142/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole, Amikacin, Secnidazole", "updated_at": 1767369485}, {"id": 60061, "ingredient1": "Etacrynic acid", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60143/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem, Tinidazole, Fluconazole, Metronidazole, Secnidazole, Azithromycin, Levofloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60062, "ingredient1": "Gentamicin", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60144/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, Sulfisoxazole, Levofloxacin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60063, "ingredient1": "Givosiran", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60145/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60064, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefepime", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60146/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60065, "ingredient1": "Cefepime", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60147/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, Sulfisoxazole, Levofloxacin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60066, "ingredient1": "Cefepime", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60148/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60067, "ingredient1": "Cefepime", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60149/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60068, "ingredient1": "Cefepime", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60150/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Miconazole, Fidaxomicin, Rifaximin, Paromomycin, Flurbiprofen, Povidone-iodine, Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60069, "ingredient1": "Cefepime", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60151/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "updated_at": 1767369485}, {"id": 60070, "ingredient1": "Cefepime", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60152/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Felodipine, Nisoldipine, Isradipine, Clevidipine, Levamlodipine, Nifedipine, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60071, "ingredient1": "Cefepime", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60153/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60072, "ingredient1": "Cefepime", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60154/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Rosuvastatin, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol, Tinidazole, Tetracycline, Metronidazole, Secnidazole, Azithromycin, Amikacin", "updated_at": 1767369485}, {"id": 60073, "ingredient1": "Cefepime", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60155/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60074, "ingredient1": "Cefepime", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60156/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem, Tinidazole, More", "updated_at": 1767369485}, {"id": 60075, "ingredient1": "Cefepime", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60157/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem, Tinidazole, Levofloxacin, Secnidazole, Azithromycin", "updated_at": 1767369485}, {"id": 60076, "ingredient1": "Cefepime", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60158/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60077, "ingredient1": "Cefepime", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60159/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Meropenem, Doripenem, Amikacin, Secnidazole", "updated_at": 1767369485}, {"id": 60078, "ingredient1": "Anisindione", "ingredient2": "Cefiderocol", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60160/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60079, "ingredient1": "Cefiderocol", "ingredient2": "Berotralstat", "severity": "Major", "effect": "Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations and pharmacologic effects of berotralstat, a substrate of this efflux transporter.", "source": "DDInter", "management_text": "Due to the potential for diminished pharmacologic effects of berotralstat, its concomitant use with P-gp inducers, including but not limited to rifampin and St. John's wort, should be avoided. Alternative therapeutic agents with less P-gp induction potential should be considered whenever possible.", "mechanism_text": "Excretion", "recommendation": "Due to the potential for diminished pharmacologic effects of berotralstat, its concomitant use with P-gp inducers, including but not limited to rifampin and St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60161/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 60080, "ingredient1": "Chloramphenicol", "ingredient2": "Cefiderocol", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60162/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60081, "ingredient1": "Cefiderocol", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60163/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60082, "ingredient1": "Dicoumarol", "ingredient2": "Cefiderocol", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60164/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60083, "ingredient1": "Fluphenazine", "ingredient2": "Cefiderocol", "severity": "Moderate", "effect": "The risk of seizures may be increased during coadministration of fluphenazine with any substance that can reduce the seizure threshold, such as aminophylline, antidepressants, antipsychotics, opioids, carbapenems, etc. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with fluphenazine.", "source": "DDInter", "management_text": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60165/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "alternatives_b": "Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, Cefdinir, More", "updated_at": 1767369485}, {"id": 60084, "ingredient1": "Ginkgo biloba", "ingredient2": "Cefiderocol", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60166/", "reference_text": "[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002): 325-7[2] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001): 523-5[3] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006): 323-9[6] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005): 755-8", "alternatives_a": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "alternatives_b": "Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, Cefdinir, More", "updated_at": 1767369485}, {"id": 60085, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefiderocol", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60167/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60086, "ingredient1": "Iohexol", "ingredient2": "Cefiderocol", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60168/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, Cefdinir, More", "updated_at": 1767369485}, {"id": 60087, "ingredient1": "Iopamidol", "ingredient2": "Cefiderocol", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60169/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, Cefdinir, More", "updated_at": 1767369485}, {"id": 60088, "ingredient1": "Cefiderocol", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60170/", "reference_text": "[1] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981): 98-9[3] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991): 41-3[7] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977): 1050-4", "alternatives_a": "Disulfiram", "alternatives_b": "Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, Cefdinir, More", "updated_at": 1767369485}, {"id": 60089, "ingredient1": "Cefiderocol", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of lonafarnib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of lonafarnib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60171/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "updated_at": 1767369485}, {"id": 60090, "ingredient1": "Cefiderocol", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60172/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60091, "ingredient1": "Cefiderocol", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60173/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60092, "ingredient1": "Cefiderocol", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60174/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[5] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[11] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[12] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Naltrexone, Oxymorphone, Methadone, Pentazocine, Buprenorphine, Morphine, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 60093, "ingredient1": "Cefiderocol", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60175/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[5] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[11] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[12] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Naltrexone, Oxymorphone, Methadone, Pentazocine, Buprenorphine, Morphine, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Dihydrocodeine, More", "alternatives_b": "Imipenem, Aztreonam, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefalotin, Cefpodoxime, More", "updated_at": 1767369485}, {"id": 60094, "ingredient1": "Cefiderocol", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60176/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefdinir, Cefalotin, Cefmetazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60095, "ingredient1": "Cefiderocol", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "Coadministration with dual inducers of CYP450 3A4 and P-glycoprotein (P-gp) may decrease the plasma concentrations of relugolix. In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8. Relugolix is also a substrate for intestinal P-gp.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of relugolix should be considered during coadministration with dual CYP450 3A4 and P-gp inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of relugolix should be considered during coadministration with dual CYP450 3A4 and P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60177/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Tamoxifen, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "updated_at": 1767369485}, {"id": 60096, "ingredient1": "Cefiderocol", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the ripretinib dosage adjusted as necessary. Patients should be monitored for loss of anti-tumor activity.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60178/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "updated_at": 1767369485}, {"id": 60097, "ingredient1": "Cefiderocol", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60179/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60098, "ingredient1": "Cefiderocol", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60180/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60099, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60181/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60100, "ingredient1": "Anisindione", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60182/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole, Amikacin, Secnidazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60101, "ingredient1": "Cefixime", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60183/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60102, "ingredient1": "Chloramphenicol", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60184/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Miconazole, Polymyxin B, Chlorhexidine, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem, Tetracycline, Norfloxacin, Levofloxacin, Amikacin", "updated_at": 1767369485}, {"id": 60103, "ingredient1": "Cefixime", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60185/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60104, "ingredient1": "Dicoumarol", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60186/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole, Amikacin, Secnidazole", "updated_at": 1767369485}, {"id": 60105, "ingredient1": "Entecavir", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60187/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan, Tinidazole, Tetracycline, Cefepime, Fluconazole, More", "updated_at": 1767369485}, {"id": 60106, "ingredient1": "Etacrynic acid", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60188/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem, Tinidazole, Fluconazole, Metronidazole, Secnidazole, Azithromycin, Levofloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60107, "ingredient1": "Gentamicin", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60189/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, More", "updated_at": 1767369485}, {"id": 60108, "ingredient1": "Givosiran", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60190/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60109, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefixime", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60191/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60110, "ingredient1": "Cefixime", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60192/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, More", "updated_at": 1767369485}, {"id": 60111, "ingredient1": "Cefixime", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60193/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60112, "ingredient1": "Cefixime", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60194/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60113, "ingredient1": "Cefixime", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60195/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60114, "ingredient1": "Cefixime", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60196/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Rifamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Flurbiprofen, Ibuprofen, More", "updated_at": 1767369485}, {"id": 60115, "ingredient1": "Cefixime", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60197/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, More", "updated_at": 1767369485}, {"id": 60116, "ingredient1": "Cefixime", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60198/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Felodipine, Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Celecoxib, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60117, "ingredient1": "Cefixime", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60199/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Methotrexate, Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan, Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Azithromycin", "updated_at": 1767369485}, {"id": 60118, "ingredient1": "Cefixime", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60200/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60119, "ingredient1": "Cefixime", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60201/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol, Tinidazole, Tetracycline, Metronidazole, Secnidazole, Azithromycin, Amikacin", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "updated_at": 1767369485}, {"id": 60120, "ingredient1": "Cefixime", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60202/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "updated_at": 1767369485}, {"id": 60121, "ingredient1": "Cefixime", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60203/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem, Tinidazole, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, More", "updated_at": 1767369485}, {"id": 60122, "ingredient1": "Cefixime", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60204/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem, Tinidazole, Levofloxacin, Secnidazole, Azithromycin", "updated_at": 1767369485}, {"id": 60123, "ingredient1": "Cefixime", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60205/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60124, "ingredient1": "Cefixime", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60206/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Meropenem, Doripenem, Amikacin, Secnidazole", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "updated_at": 1767369485}, {"id": 60125, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60207/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60126, "ingredient1": "Anisindione", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60208/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60127, "ingredient1": "Chloramphenicol", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60209/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Chlorhexidine, Minocycline, Vitamin A, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60128, "ingredient1": "Cefotaxime", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60210/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60129, "ingredient1": "Dicoumarol", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60211/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60130, "ingredient1": "Entecavir", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60212/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan", "updated_at": 1767369485}, {"id": 60131, "ingredient1": "Etacrynic acid", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60213/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60132, "ingredient1": "Gentamicin", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60214/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60133, "ingredient1": "Givosiran", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60215/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60134, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefotaxime", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60216/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60135, "ingredient1": "Cefotaxime", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60217/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60136, "ingredient1": "Cefotaxime", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60218/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60137, "ingredient1": "Cefotaxime", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60219/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60138, "ingredient1": "Cefotaxime", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60220/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "alternatives_b": "Paromomycin, Rifamycin, Fidaxomicin, Rifaximin, Lidocaine, Flurbiprofen, Chlorhexidine, Povidone-iodine, Tetracycline, Mupirocin, Rifamycin, More", "updated_at": 1767369485}, {"id": 60139, "ingredient1": "Cefotaxime", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60221/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60140, "ingredient1": "Cefotaxime", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60222/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Felodipine, Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Celecoxib, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60141, "ingredient1": "Cefotaxime", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60223/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan", "alternatives_b": "Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More", "updated_at": 1767369485}, {"id": 60142, "ingredient1": "Cefotaxime", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60224/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60143, "ingredient1": "Cefotaxime", "ingredient2": "Porfimer sodium", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60225/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivity—an update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 60144, "ingredient1": "Cefotaxime", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60226/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "updated_at": 1767369485}, {"id": 60145, "ingredient1": "Cefotaxime", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60227/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "updated_at": 1767369485}, {"id": 60146, "ingredient1": "Cefotaxime", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60228/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60147, "ingredient1": "Cefotaxime", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60229/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60148, "ingredient1": "Cefotaxime", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60230/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60149, "ingredient1": "Cefotaxime", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60231/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Meropenem, Doripenem", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "updated_at": 1767369485}, {"id": 60150, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60232/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60151, "ingredient1": "Anisindione", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60233/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60152, "ingredient1": "Chloramphenicol", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60234/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Miconazole, Polymyxin B, Ciprofloxacin, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60153, "ingredient1": "Cefotetan", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60235/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60154, "ingredient1": "Dicoumarol", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60236/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60155, "ingredient1": "Etacrynic acid", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60237/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60156, "ingredient1": "Gentamicin", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60238/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60157, "ingredient1": "Givosiran", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60239/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60158, "ingredient1": "Heparin", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Cefamandole, cefoperazone, and cefotetan contain a methylthiotetrazole (MTT) side chain that may interfere with the biosynthesis of prothrombin. These agents have rarely been associated with bleeding and with significant increases in prothrombin times. These effects may potentiate the effects of heparin. Patients who are elderly, renally impaired, or undernourished appear to be at a greater risk.", "source": "DDInter", "management_text": "Usually, no special management is necessary, but the patient should be monitored for bleeding if heparin must be given concurrently. Vitamin K is effective in treating cephalosporin-induced coagulopathies.", "mechanism_text": "Synergism", "recommendation": "Usually, no special management is necessary, but the patient should be monitored for bleeding if heparin must be given concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60240/", "reference_text": "[1] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[2] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[3] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[4] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[5] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[6] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[7] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[8] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[9] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[10] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Imipenem, Cefprozil, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefradine, Cefiderocol, Cefditoren, Meropenem, Cefixime, More", "updated_at": 1767369485}, {"id": 60159, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefotetan", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60241/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60160, "ingredient1": "Cefotetan", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60242/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60161, "ingredient1": "Cefotetan", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60243/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60162, "ingredient1": "Cefotetan", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60244/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60163, "ingredient1": "Cefotetan", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60245/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Flurbiprofen, Ibuprofen, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60164, "ingredient1": "Cefotetan", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60246/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "updated_at": 1767369485}, {"id": 60165, "ingredient1": "Cefotetan", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60247/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Felodipine, Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Nifedipine, Celecoxib, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60166, "ingredient1": "Cefotetan", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60248/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60167, "ingredient1": "Cefotetan", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60249/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "updated_at": 1767369485}, {"id": 60168, "ingredient1": "Cefotetan", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration of rifampin with other antibiotics which cause vitamin K dependent coagulopathy, such as cephalosporins with the N-methyl-thiotetrazole (NMTT) side chain, may increase the risk of severe coagulation disorders, which may result in fatal outcomes (particularly with high doses). The mechanism for this interaction has not been clearly delineated; however, proposed mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors, interference with the biosynthesis of prothrombin, and/or inhibited platelet activity. Risk factors may include the elderly, renal or hepatic impairment, poor nutritional state, protracted antimicrobial therapy, and chronic anticoagulation therapy.", "source": "DDInter", "management_text": "The concomitant use of rifampin with other antibiotics which cause vitamin K dependent coagulopathy, such as cephalosporins, should be avoided. If coadministration is unavoidable, monitoring of prothrombin time and INR should be considered and the patient should be observed for signs of bleeding. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "The concomitant use of rifampin with other antibiotics which cause vitamin K dependent coagulopathy, such as cephalosporins, should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60250/", "reference_text": "[1] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[2] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[3] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[4] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[7] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[8] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[9] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[10] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[11] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[12] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[13] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[14] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] Cerner Multum, Inc. \"Australian Product Information.\" O 0[17] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[18] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[19] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[20] Askgaard DS, Wilcke T, Dossing M \"Hepatotoxicity caused by the combined action of isoniazid and rifampicin.\" Thorax 50 (1995): 213-4[21] Yamamoto T, Suou T, Hirayama C \"Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.\" Hepatology 6 (1986): 295-8[22] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn, Kalamazoo, MI.[23] \"Product Information. INH (isoniazid).\" Ciba Pharmaceuticals, Summit, NJ.[24] Steele MA, Burk RF, Des Prez RM \"Toxic hepatitis with isoniazid and rifampin.\" Chest 99 (1991): 465-71[25] Acocella G, Bonollo L, Garimoldi M, et al \"Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.\" Gut 13 (1972): 47-53[26] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[27] Sarma G, Immanuel C, Kailasam S, Narayana AS, Venkatesan P \"Rifampin-induced release of hydrazine from isoniazid.\" Am Rev Respir Dis 133 (1986): 1072-5[28] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[29] O'Brien RJ, Long MW, Cross FS, et al \"Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.\" Pediatrics 72 (1983): 491-9[30] Abadie-Kemmerly S, Pankey GA, Dalvisio JR \"Failure of ketoconazole treatment of blastomyces dermatidis due to interaction of isoniazid and rifampin.\" Ann Intern Med 109 (1988): 844-5[31] Kumar A, Misra PK, Mehotra R, et al \"Hepatotoxicity of rifampin and isoniazid.\" Am Rev Respir Dis 143 (1991): 1350-2[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] Dimartini A \"Isoniazid, tricyclics and the ''cheese reaction''.\" Int Clin Psychopharmacol 10 (1995): 197-8[35] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[36] \"Product Information. INH (isoniazid).\" Ciba Pharmaceuticals, Summit, NJ.[37] Self TH, Chrisman CR, Baciewicz AM, Bronze MS \"Isoniazid drug and food interactions.\" Am J Med Sci 317 (1999): 304-11[38] Uragoda CG, Kottegoda SR \"Adverse reactions to isoniazid on ingestion of fish with a high histamine content.\" Tubercle 58 (1977): 83-9[39] Smith CK, Durack DT \"Isoniazid and reaction to cheese.\" Ann Intern Med 88 (1978): 520-1", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 60169, "ingredient1": "Cefotetan", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, and tipranavir capsules all contain alcohol, which may produce a disulfiram-like reaction when coadministered with drugs that can inhibit aldehyde dehydrogenase (ALDH) such as nitroimidazoles (e.g., metronidazole, tinidazole), nitrofurans (e.g., furazolidone, nifurtimox), and cephalosporins with an N-methylthiotetrazole (NMTT) side chain that structurally resembles disulfiram. Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the 'disulfiram reaction'. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmia, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death. The interaction is well established for disulfiram.", "source": "DDInter", "management_text": "Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.", "mechanism_text": "Others", "recommendation": "Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60251/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[3] Uri JV, Parks DB \"Disulfiram-like reaction to certain cephalosporins.\" Ther Drug Monit 5 (1983): 219-24[4] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[5] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[6] \"Product Information. Metrogel-Vaginal (metronidazole).\" Curatek Pharmaceuticals Ltd, Elk Grove Village, IL.[7] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[8] \"Product Information. Tindamax (tinidazole).\" Presutti Laboratories Inc, Arlington Heights, IL.[9] Neu HC, Prince AS \"Interaction between moxalactam and alcohol.\" Lancet June (1980): 1422[10] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[11] Cina SJ, Russell RA, Conradi SE \"Sudden death due to metronidazole/ethanol interaction.\" Am J Forensic Med Pathol 17 (1996): 343-6[12] Elenbaas RM \"Drug therapy reviews: management of the disulfiram-alcohol reaction.\" Am J Hosp Pharm 34 (1977): 827-31[13] Freundt KJ, Schreiner E, Christmann-Kleiss U \"Cefamandole: a competitive inhibitor of aldehyde dehydrogenase.\" Infection 13 (1985): 91[14] van Ieperen L \"Sudden death during disulfiram-ethanol reaction.\" S Afr Med J 66 (1984): 165[15] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[16] Foster TS, Raehl CL, Wilson HD \"Disulfiram-like reaction associated with a parenteral cephalosporin.\" Am J Hosp Pharm 37 (1980): 858-9[17] Buening MK, et al \"Disulfiram-like reaction to beta-lactams.\" JAMA 245 (1981): 2047[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Kline SS, Mauro VF, Forney RB Jr, et al \"Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia.\" Antimicrob Agents Chemother 31 (1987): 1328-31[20] Freundt KJ, Kitson TM \"Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole.\" Infection 14 (1986): 44-7[21] McMahon FG, Ryan JR, Jain AK, LaCorte W, Ginzler F \"Absence of disulfiram-type reactions to single and multiple doses of cefonicid: a placebo-controlled study.\" J Antimicrob Chemother 20 (1987): 913-8[22] Umeda S, Arai T \"Disulfiram-like reaction to moxalactam after celiac plexus alcohol block.\" Anesth Analg 64 (1985): 377[23] Reeves DS, Davies AJ \"Antabuse effect with cephalosporins.\" Lancet 2 (1980): 540[24] McMahon FG \"Disulfiram-like reaction to a cephalosporin.\" JAMA 243 (1980): 2397[25] Portier H, Chalopin JM, Freysz M, Tanter Y \"Interaction between cephalosporins and alcohol.\" Lancet 08/02/80 (1980): 263[26] Shimada J, Hayashi Y, Nakamura K \"Cefmetazole: clinical evaluation of efficacy and safety in Japan.\" Drugs Exp Clin Res 11 (1985): 181-94[27] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[28] Brown KR, Guglielmo BJ, Pons VG, Jacobs RA \"Theophylline elixir, moxalactam, and a disulfiram reaction.\" Ann Intern Med 97 (1982): 621-2[29] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[30] Jones RO \"Death following the ingestion of alcohol in an antabuse treated patient.\" Can Med Assoc J 60 (1949): 609-12[31] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[32] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[33] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefditoren, Meropenem, Cefdinir, Cefalotin, More", "updated_at": 1767369485}, {"id": 60170, "ingredient1": "Cefotetan", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60252/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60171, "ingredient1": "Cefotetan", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, and tipranavir capsules all contain alcohol, which may produce a disulfiram-like reaction when coadministered with drugs that can inhibit aldehyde dehydrogenase (ALDH) such as nitroimidazoles (e.g., metronidazole, tinidazole), nitrofurans (e.g., furazolidone, nifurtimox), and cephalosporins with an N-methylthiotetrazole (NMTT) side chain that structurally resembles disulfiram. Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the 'disulfiram reaction'. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmia, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death. The interaction is well established for disulfiram.", "source": "DDInter", "management_text": "Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.", "mechanism_text": "Others", "recommendation": "Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60253/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[3] Uri JV, Parks DB \"Disulfiram-like reaction to certain cephalosporins.\" Ther Drug Monit 5 (1983): 219-24[4] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[5] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[6] \"Product Information. Metrogel-Vaginal (metronidazole).\" Curatek Pharmaceuticals Ltd, Elk Grove Village, IL.[7] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[8] \"Product Information. Tindamax (tinidazole).\" Presutti Laboratories Inc, Arlington Heights, IL.[9] Neu HC, Prince AS \"Interaction between moxalactam and alcohol.\" Lancet June (1980): 1422[10] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[11] Cina SJ, Russell RA, Conradi SE \"Sudden death due to metronidazole/ethanol interaction.\" Am J Forensic Med Pathol 17 (1996): 343-6[12] Elenbaas RM \"Drug therapy reviews: management of the disulfiram-alcohol reaction.\" Am J Hosp Pharm 34 (1977): 827-31[13] Freundt KJ, Schreiner E, Christmann-Kleiss U \"Cefamandole: a competitive inhibitor of aldehyde dehydrogenase.\" Infection 13 (1985): 91[14] van Ieperen L \"Sudden death during disulfiram-ethanol reaction.\" S Afr Med J 66 (1984): 165[15] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[16] Foster TS, Raehl CL, Wilson HD \"Disulfiram-like reaction associated with a parenteral cephalosporin.\" Am J Hosp Pharm 37 (1980): 858-9[17] Buening MK, et al \"Disulfiram-like reaction to beta-lactams.\" JAMA 245 (1981): 2047[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Kline SS, Mauro VF, Forney RB Jr, et al \"Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia.\" Antimicrob Agents Chemother 31 (1987): 1328-31[20] Freundt KJ, Kitson TM \"Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole.\" Infection 14 (1986): 44-7[21] McMahon FG, Ryan JR, Jain AK, LaCorte W, Ginzler F \"Absence of disulfiram-type reactions to single and multiple doses of cefonicid: a placebo-controlled study.\" J Antimicrob Chemother 20 (1987): 913-8[22] Umeda S, Arai T \"Disulfiram-like reaction to moxalactam after celiac plexus alcohol block.\" Anesth Analg 64 (1985): 377[23] Reeves DS, Davies AJ \"Antabuse effect with cephalosporins.\" Lancet 2 (1980): 540[24] McMahon FG \"Disulfiram-like reaction to a cephalosporin.\" JAMA 243 (1980): 2397[25] Portier H, Chalopin JM, Freysz M, Tanter Y \"Interaction between cephalosporins and alcohol.\" Lancet 08/02/80 (1980): 263[26] Shimada J, Hayashi Y, Nakamura K \"Cefmetazole: clinical evaluation of efficacy and safety in Japan.\" Drugs Exp Clin Res 11 (1985): 181-94[27] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[28] Brown KR, Guglielmo BJ, Pons VG, Jacobs RA \"Theophylline elixir, moxalactam, and a disulfiram reaction.\" Ann Intern Med 97 (1982): 621-2[29] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[30] Jones RO \"Death following the ingestion of alcohol in an antabuse treated patient.\" Can Med Assoc J 60 (1949): 609-12[31] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[32] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[33] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefuroxime, Cefditoren, Meropenem, More", "updated_at": 1767369485}, {"id": 60172, "ingredient1": "Cefotetan", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60254/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60173, "ingredient1": "Cefotetan", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60255/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60174, "ingredient1": "Cefotetan", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60256/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60175, "ingredient1": "Cefotetan", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60257/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60176, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60258/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60177, "ingredient1": "Anisindione", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60259/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60178, "ingredient1": "Chloramphenicol", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60260/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Miconazole, Chlorhexidine, Ofloxacin, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60179, "ingredient1": "Cefoxitin", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60261/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60180, "ingredient1": "Dicoumarol", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60262/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60181, "ingredient1": "Entecavir", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60263/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan", "updated_at": 1767369485}, {"id": 60182, "ingredient1": "Etacrynic acid", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60264/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60183, "ingredient1": "Gentamicin", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60265/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60184, "ingredient1": "Givosiran", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60266/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60185, "ingredient1": "Heparin", "ingredient2": "Cefoxitin", "severity": "Minor", "effect": "Cefoxitin has been associated with an increase in prothrombin time and episodes of bleeding. These effects may potentiate the effects of heparin. Usually, no special management is necessary, but the patient should be monitored for bleeding if cefoxitin and heparin must be given together. Vitamin K has been successfully used to treat cephalosporin-induced coagulopathies.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60267/", "reference_text": "[1] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[2] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Imipenem, Cefprozil, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefradine, Cefiderocol, Cefditoren, Meropenem, Cefixime, More", "updated_at": 1767369485}, {"id": 60186, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefoxitin", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60268/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60187, "ingredient1": "Cefoxitin", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60269/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60188, "ingredient1": "Cefoxitin", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60270/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60189, "ingredient1": "Cefoxitin", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60271/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60190, "ingredient1": "Cefoxitin", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60272/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Amphotericin B, Miconazole, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Tetracycline, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60191, "ingredient1": "Cefoxitin", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60273/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "updated_at": 1767369485}, {"id": 60192, "ingredient1": "Cefoxitin", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60274/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Felodipine, Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Nifedipine, Celecoxib, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60193, "ingredient1": "Cefoxitin", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60275/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Methotrexate, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan", "updated_at": 1767369485}, {"id": 60194, "ingredient1": "Cefoxitin", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60276/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60195, "ingredient1": "Cefoxitin", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60277/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "updated_at": 1767369485}, {"id": 60196, "ingredient1": "Cefoxitin", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60278/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Pyridoxine, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60197, "ingredient1": "Cefoxitin", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60279/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60198, "ingredient1": "Cefoxitin", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60280/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60199, "ingredient1": "Cefoxitin", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60281/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60200, "ingredient1": "Cefoxitin", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60282/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60201, "ingredient1": "Aluminum hydroxide", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60283/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60202, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60284/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Ampicillin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60203, "ingredient1": "Anisindione", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60285/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60204, "ingredient1": "Cefpodoxime", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60286/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60205, "ingredient1": "Cefpodoxime", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60287/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate", "updated_at": 1767369485}, {"id": 60206, "ingredient1": "Chloramphenicol", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60288/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Chlorhexidine, Miconazole, Minocycline, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60207, "ingredient1": "Cefpodoxime", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60289/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60208, "ingredient1": "Cimetidine", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60290/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefdinir, Cefalotin, More", "updated_at": 1767369485}, {"id": 60209, "ingredient1": "Dexlansoprazole", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60291/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "updated_at": 1767369485}, {"id": 60210, "ingredient1": "Dicoumarol", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60292/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60211, "ingredient1": "Didanosine", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60293/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "updated_at": 1767369485}, {"id": 60212, "ingredient1": "Entecavir", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60294/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan", "updated_at": 1767369485}, {"id": 60213, "ingredient1": "Esomeprazole", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60295/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin, Ketoprofen, Piroxicam, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "updated_at": 1767369485}, {"id": 60214, "ingredient1": "Etacrynic acid", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60296/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60215, "ingredient1": "Gentamicin", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60297/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Ampicillin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60216, "ingredient1": "Givosiran", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60298/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60217, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefpodoxime", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60299/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60218, "ingredient1": "Cefpodoxime", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60300/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Ampicillin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60219, "ingredient1": "Cefpodoxime", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60301/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60220, "ingredient1": "Cefpodoxime", "ingredient2": "Lansoprazole", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60302/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "alternatives_b": "Imipenem, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefoperazone, Cefamandole, Cefradine, Cefiderocol, Meropenem, Ertapenem, More", "updated_at": 1767369485}, {"id": 60221, "ingredient1": "Cefpodoxime", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60303/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60222, "ingredient1": "Cefpodoxime", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60304/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 60223, "ingredient1": "Cefpodoxime", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60305/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 60224, "ingredient1": "Cefpodoxime", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60306/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "updated_at": 1767369485}, {"id": 60225, "ingredient1": "Cefpodoxime", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60307/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60226, "ingredient1": "Cefpodoxime", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60308/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60227, "ingredient1": "Cefpodoxime", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60309/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Amphotericin B, Miconazole, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Tetracycline, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60228, "ingredient1": "Cefpodoxime", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60310/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Ampicillin, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "updated_at": 1767369485}, {"id": 60229, "ingredient1": "Cefpodoxime", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60311/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Felodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Nifedipine, Celecoxib, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60230, "ingredient1": "Cefpodoxime", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60312/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefdinir, Cefalotin, More", "updated_at": 1767369485}, {"id": 60231, "ingredient1": "Cefpodoxime", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60313/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "alternatives_b": "Cefoxitin, Imipenem, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefoperazone, Cefamandole, Cefradine, Cefiderocol, Meropenem, More", "updated_at": 1767369485}, {"id": 60232, "ingredient1": "Cefpodoxime", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60314/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan", "updated_at": 1767369485}, {"id": 60233, "ingredient1": "Cefpodoxime", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60315/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60234, "ingredient1": "Cefpodoxime", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60316/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "updated_at": 1767369485}, {"id": 60235, "ingredient1": "Cefpodoxime", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "INTERVAL: Administration of quinapril with some oral medications may significantly decrease their absorption and may result in subtherapeutic serum concentrations. The proposed mechanism is chelation of the drug by the magnesium hydroxide excipient in quinapril tablets.", "source": "DDInter", "management_text": "The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.", "mechanism_text": "Absorption", "recommendation": "The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60317/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[4] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[5] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[7] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6", "alternatives_a": "Enalapril, Moexipril, Perindopril, Benazepril, Trandolapril, Captopril, Fosinopril, Felodipine, Enalapril, Moexipril, Verapamil, More", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, More", "updated_at": 1767369485}, {"id": 60236, "ingredient1": "Cefpodoxime", "ingredient2": "Ranitidine (bismuth citrate)", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60318/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60237, "ingredient1": "Cefpodoxime", "ingredient2": "Sodium bicarbonate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60319/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Sorbitol, Sulfamethizole, Magnesium citrate, Sodium chloride, Mannitol, Chlorhexidine, Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Arginine, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Meropenem, Cefdinir, Cefalotin, More", "updated_at": 1767369485}, {"id": 60238, "ingredient1": "Cefpodoxime", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60320/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60239, "ingredient1": "Cefpodoxime", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60321/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Ampicillin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60240, "ingredient1": "Cefpodoxime", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60322/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60241, "ingredient1": "Cefpodoxime", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60323/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60242, "ingredient1": "Cefpodoxime", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60324/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60243, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60325/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Gatifloxacin, Acyclovir, Rifamycin, Oxytetracycline, Ganciclovir, Norfloxacin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60244, "ingredient1": "Anisindione", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60326/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60245, "ingredient1": "Cefprozil", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60327/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60246, "ingredient1": "Chloramphenicol", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60328/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Polymyxin B, Rifamycin, Miconazole, Minocycline, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60247, "ingredient1": "Cefprozil", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60329/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60248, "ingredient1": "Dicoumarol", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60330/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60249, "ingredient1": "Entecavir", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60331/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan", "updated_at": 1767369485}, {"id": 60250, "ingredient1": "Etacrynic acid", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60332/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60251, "ingredient1": "Gentamicin", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60333/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Gatifloxacin, Acyclovir, Rifamycin, Oxytetracycline, Ganciclovir, Norfloxacin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60252, "ingredient1": "Givosiran", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60334/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60253, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefprozil", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60335/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60254, "ingredient1": "Cefprozil", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60336/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Tetracycline, Gatifloxacin, Acyclovir, Rifamycin, Oxytetracycline, Ganciclovir, Norfloxacin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More", "updated_at": 1767369485}, {"id": 60255, "ingredient1": "Cefprozil", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60337/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60256, "ingredient1": "Cefprozil", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60338/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60257, "ingredient1": "Cefprozil", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60339/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60258, "ingredient1": "Cefprozil", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60340/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Flurbiprofen, Povidone-iodine, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60259, "ingredient1": "Cefprozil", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60341/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Gatifloxacin, Acyclovir, Rifamycin, Oxytetracycline, Ganciclovir, Norfloxacin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "updated_at": 1767369485}, {"id": 60260, "ingredient1": "Cefprozil", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60342/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60261, "ingredient1": "Cefprozil", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60343/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Methotrexate, Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan", "updated_at": 1767369485}, {"id": 60262, "ingredient1": "Cefprozil", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60344/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60263, "ingredient1": "Cefprozil", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60345/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "updated_at": 1767369485}, {"id": 60264, "ingredient1": "Cefprozil", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60346/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60265, "ingredient1": "Cefprozil", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60347/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Tetracycline, Gatifloxacin, Acyclovir, Rifamycin, Oxytetracycline, Ganciclovir, Norfloxacin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60266, "ingredient1": "Cefprozil", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60348/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60267, "ingredient1": "Cefprozil", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60349/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60268, "ingredient1": "Cefprozil", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60350/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60269, "ingredient1": "Amikacin (liposome)", "ingredient2": "Ceftaroline fosamil", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60351/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60270, "ingredient1": "Anisindione", "ingredient2": "Ceftaroline fosamil", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60352/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60271, "ingredient1": "Chloramphenicol", "ingredient2": "Ceftaroline fosamil", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60353/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Miconazole, Polymyxin B, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60272, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60354/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60273, "ingredient1": "Dicoumarol", "ingredient2": "Ceftaroline fosamil", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60355/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60274, "ingredient1": "Etacrynic acid", "ingredient2": "Ceftaroline fosamil", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60356/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60275, "ingredient1": "Gentamicin", "ingredient2": "Ceftaroline fosamil", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60357/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60276, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Ceftaroline fosamil", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60358/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60277, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60359/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60278, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60360/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60279, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60361/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60280, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60362/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Bacitracin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60281, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60363/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "updated_at": 1767369485}, {"id": 60282, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60364/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60283, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60365/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "updated_at": 1767369485}, {"id": 60284, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60366/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60285, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60367/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60286, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60368/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60287, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60369/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60288, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60370/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60289, "ingredient1": "Ceftazidime", "ingredient2": "Acyclovir", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60371/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, Cefalotin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 60290, "ingredient1": "Amikacin (liposome)", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60372/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60291, "ingredient1": "Amphotericin B", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60373/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, Cefalotin, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 60292, "ingredient1": "Amphotericin B (cholesteryl sulfate)", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60374/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 60293, "ingredient1": "Amphotericin B (lipid complex)", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60375/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 60294, "ingredient1": "Amphotericin B (liposomal)", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60376/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 60295, "ingredient1": "Anisindione", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60377/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60296, "ingredient1": "Chloramphenicol", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60378/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "alternatives_b": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Chlorhexidine, Vitamin A, Isotretinoin, More", "updated_at": 1767369485}, {"id": 60297, "ingredient1": "Ceftazidime", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60379/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60298, "ingredient1": "Ciprofloxacin", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60380/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefoperazone, Cefamandole, Cefradine, Cefiderocol, Cefditoren, Meropenem, More", "alternatives_b": "Tinidazole, Tetracycline, Norfloxacin, Secnidazole, Cefixime, Levofloxacin, Tetracycline, Chlorhexidine, Enoxacin, Gatifloxacin, Norfloxacin, More", "updated_at": 1767369485}, {"id": 60299, "ingredient1": "Cisplatin", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60381/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 60300, "ingredient1": "Cyclophosphamide", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60382/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "alternatives_b": "Thiotepa, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide", "updated_at": 1767369485}, {"id": 60301, "ingredient1": "Cyclosporine", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60383/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefpodoxime, More", "updated_at": 1767369485}, {"id": 60302, "ingredient1": "Dicoumarol", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60384/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60303, "ingredient1": "Etacrynic acid", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60385/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60304, "ingredient1": "Gentamicin", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60386/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60305, "ingredient1": "Givosiran", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60387/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60306, "ingredient1": "Ifosfamide", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60388/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Thiotepa, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide", "updated_at": 1767369485}, {"id": 60307, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Ceftazidime", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60389/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60308, "ingredient1": "Ceftazidime", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60390/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60309, "ingredient1": "Ceftazidime", "ingredient2": "Melphalan", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60391/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, Meropenem, More", "alternatives_b": "Thiotepa, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide", "updated_at": 1767369485}, {"id": 60310, "ingredient1": "Ceftazidime", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60392/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefalotin, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 60311, "ingredient1": "Ceftazidime", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60393/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60312, "ingredient1": "Ceftazidime", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60394/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60313, "ingredient1": "Ceftazidime", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60395/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "updated_at": 1767369485}, {"id": 60314, "ingredient1": "Ceftazidime", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60396/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "alternatives_b": "Paromomycin, Rifamycin, Fidaxomicin, Rifaximin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 60315, "ingredient1": "Ceftazidime", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60397/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60316, "ingredient1": "Ceftazidime", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60398/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Felodipine, Nisoldipine, Isradipine, Clevidipine, Levamlodipine, Mibefradil", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Ceftizoxime, More", "updated_at": 1767369485}, {"id": 60317, "ingredient1": "Ceftazidime", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60399/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Miltefosine, Fexinidazole, Nifurtimox, Benznidazole", "updated_at": 1767369485}, {"id": 60318, "ingredient1": "Ceftazidime", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60400/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60319, "ingredient1": "Ceftazidime", "ingredient2": "Porfimer sodium", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60401/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivity—an update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 60320, "ingredient1": "Ceftazidime", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60402/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More", "updated_at": 1767369485}, {"id": 60321, "ingredient1": "Ceftazidime", "ingredient2": "Sulfamethoxazole", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60403/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Rifampicin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, More", "updated_at": 1767369485}, {"id": 60322, "ingredient1": "Ceftazidime", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60404/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Imipenem, Cefiderocol, Cefapirin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefalotin, Cefpodoxime, Cefmetazole, More", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 60323, "ingredient1": "Ceftazidime", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60405/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60324, "ingredient1": "Ceftazidime", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60406/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60325, "ingredient1": "Ceftazidime", "ingredient2": "Trimethoprim", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60407/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, More", "alternatives_b": "Sulfadiazine, Sulfamethizole, Sulfisoxazole, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Rifampicin, Cycloserine, Rifabutin, Ethambutol, More", "updated_at": 1767369485}, {"id": 60326, "ingredient1": "Ceftazidime", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60408/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60327, "ingredient1": "Ceftazidime", "ingredient2": "Uracil mustard", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60409/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Thiotepa, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide", "updated_at": 1767369485}, {"id": 60328, "ingredient1": "Ceftazidime", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60410/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Meropenem, Doripenem", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "updated_at": 1767369485}, {"id": 60329, "ingredient1": "Ceftazidime", "ingredient2": "Zidovudine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60411/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 60330, "ingredient1": "Anisindione", "ingredient2": "Ceftibuten", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60413/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60331, "ingredient1": "Ceftibuten", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60414/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60332, "ingredient1": "Chloramphenicol", "ingredient2": "Ceftibuten", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60415/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60333, "ingredient1": "Ceftibuten", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60416/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60334, "ingredient1": "Dicoumarol", "ingredient2": "Ceftibuten", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60417/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60335, "ingredient1": "Etacrynic acid", "ingredient2": "Ceftibuten", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60418/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60336, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Ceftibuten", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60419/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60337, "ingredient1": "Ceftibuten", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60420/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60338, "ingredient1": "Ceftibuten", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60421/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60339, "ingredient1": "Ceftibuten", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60422/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60340, "ingredient1": "Ceftibuten", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60423/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "updated_at": 1767369485}, {"id": 60341, "ingredient1": "Ceftibuten", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60424/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60342, "ingredient1": "Ceftibuten", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60425/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60343, "ingredient1": "Ceftibuten", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60426/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60344, "ingredient1": "Amikacin", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60427/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60345, "ingredient1": "Amikacin (liposome)", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60428/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60346, "ingredient1": "Anisindione", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60429/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60347, "ingredient1": "Ceftolozane", "ingredient2": "Bumetanide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60430/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60348, "ingredient1": "Chloramphenicol", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60431/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Tetracycline, Rifamycin, Miconazole, Polymyxin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60349, "ingredient1": "Ceftolozane", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60432/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60350, "ingredient1": "Dicoumarol", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60433/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60351, "ingredient1": "Estradiol", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.", "mechanism_text": "Antagonism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60435/", "reference_text": "[1] Barnett ML \"Inhibition of oral contraceptive effectiveness by concurrent antibiotic administration.\" J Periodontol 56 (1985): 18-20[2] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[3] King VJ \"OC failure rates and oral antibiotics.\" J Fam Pract 45 (1997): 104-5[4] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005): 139-51[5] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[6] Wermeling DP, Chandler MH, Sides GD, Collins D, Muse KN \"Dirithromycin increases ethinyl estradiol clearance without allowing ovulation.\" Obstet Gynecol 86 (1995): 78-84[7] Archer JS, Archer DF \"Oral contraceptive efficacy and antibiotic interaction: A myth debunked.\" J Am Acad Dermatol 46 (2002): 917-23[8] Back DJ, Tjia J, Martin C, Millar E, Mant T, Morrison P, Orme M \"The lack of interaction between temafloxacin and combined oral contraceptive steroids.\" Contraception 43 (1991): 317-23[9] Bauer KL, Wolf D, Patel M, Vinson DC \"Clinical inquiries. Do antibiotics interfere with the efficacy of oral contraceptives?\" J Fam Pract 54 (2005): 1079-80[10] Friedman CI, Huneke AL, Kim MH, Powell J \"The effect of ampicillin on oral contraceptive effectiveness.\" Obstet Gynecol 55 (1980): 33-7[11] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[12] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987): 5-6[13] DeRossi SS, Hersh EV \"Antibiotics and oral contraceptives.\" Dent Clin North Am 46 (2002): 653-64[14] Bint AJ, Burtt I \"Adverse antibiotic drug interactions.\" Drugs 20 (1980): 57-68[15] Back DJ, Breckenridge AM, MacIver M, et al \"The effects of ampicillin on oral contraceptive steroids in women.\" Br J Clin Pharmacol 14 (1982): 43-8[16] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[17] Orme M, Back DJ \"Oral contraceptive steroids--pharmacological issues of interest to the prescribing physician.\" Adv Contracept 7 (1991): 325-31[18] Fazio A \"Oral contraceptive drug interactions: important considerations.\" South Med J 84 (1991): 997-1002[19] Neely JL, Abate M, Swinker M, D'Angio R \"The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone.\" Obstet Gynecol 77 (1991): 416-20[20] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[21] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988): 527-32[22] Orme ML, Back DJ \"Interactions between oral contraceptive steroids and broad-spectrum antibiotics.\" Clin Exp Dermatol 11 (1986): 327-31[23] DeSano EA, Hurley SC \"Possible interactions of antihistamines and antibiotics with oral contraceptive effectiveness.\" Fertil Steril 37 (1982): 853-4[24] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[25] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[26] Bacon JF, Shenfield GM \"Pregnancy attributable to interaction between tetracycline and oral contraceptives.\" Br Med J 280 (1980): 293[27] Burroughs KE, Chambliss ML \"Antibiotics and oral contraceptive failure.\" Arch Fam 9 (2000): 81-2[28] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[29] Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I \"Oral contraceptive failure rates and oral antibiotics.\" J Am Acad Dermatol 36 (1997): 705-10[30] Silber TJ \"Apparent oral contraceptive failure associated with antibiotic administration.\" J Adolesc Health Care 4 (1983): 287-9[31] Joshi JV, Joshi UM, Sankholi GM, et al \"A study of interaction of low-dose combination oral contraceptive with ampicillin and metronidazole.\" Contraception 22 (1980): 643-52[32] Bollen M \"Use of antibiotics when taking the oral contraceptive pill.\" Aust Fam Physician 24 (1995): 928-9[33] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[34] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49(5 Suppl) (1988): s31-8[35] London BM, Lookingbill DP \"Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives.\" Arch Dermatol 130 (1994): 392-3[36] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Norethisterone, Progesterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Norgestrel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60352, "ingredient1": "Etacrynic acid", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60436/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60353, "ingredient1": "Ethinylestradiol", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.", "mechanism_text": "Antagonism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60437/", "reference_text": "[1] Barnett ML \"Inhibition of oral contraceptive effectiveness by concurrent antibiotic administration.\" J Periodontol 56 (1985): 18-20[2] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[3] King VJ \"OC failure rates and oral antibiotics.\" J Fam Pract 45 (1997): 104-5[4] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005): 139-51[5] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[6] Wermeling DP, Chandler MH, Sides GD, Collins D, Muse KN \"Dirithromycin increases ethinyl estradiol clearance without allowing ovulation.\" Obstet Gynecol 86 (1995): 78-84[7] Archer JS, Archer DF \"Oral contraceptive efficacy and antibiotic interaction: A myth debunked.\" J Am Acad Dermatol 46 (2002): 917-23[8] Back DJ, Tjia J, Martin C, Millar E, Mant T, Morrison P, Orme M \"The lack of interaction between temafloxacin and combined oral contraceptive steroids.\" Contraception 43 (1991): 317-23[9] Bauer KL, Wolf D, Patel M, Vinson DC \"Clinical inquiries. Do antibiotics interfere with the efficacy of oral contraceptives?\" J Fam Pract 54 (2005): 1079-80[10] Friedman CI, Huneke AL, Kim MH, Powell J \"The effect of ampicillin on oral contraceptive effectiveness.\" Obstet Gynecol 55 (1980): 33-7[11] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[12] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987): 5-6[13] DeRossi SS, Hersh EV \"Antibiotics and oral contraceptives.\" Dent Clin North Am 46 (2002): 653-64[14] Bint AJ, Burtt I \"Adverse antibiotic drug interactions.\" Drugs 20 (1980): 57-68[15] Back DJ, Breckenridge AM, MacIver M, et al \"The effects of ampicillin on oral contraceptive steroids in women.\" Br J Clin Pharmacol 14 (1982): 43-8[16] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[17] Orme M, Back DJ \"Oral contraceptive steroids--pharmacological issues of interest to the prescribing physician.\" Adv Contracept 7 (1991): 325-31[18] Fazio A \"Oral contraceptive drug interactions: important considerations.\" South Med J 84 (1991): 997-1002[19] Neely JL, Abate M, Swinker M, D'Angio R \"The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone.\" Obstet Gynecol 77 (1991): 416-20[20] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[21] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988): 527-32[22] Orme ML, Back DJ \"Interactions between oral contraceptive steroids and broad-spectrum antibiotics.\" Clin Exp Dermatol 11 (1986): 327-31[23] DeSano EA, Hurley SC \"Possible interactions of antihistamines and antibiotics with oral contraceptive effectiveness.\" Fertil Steril 37 (1982): 853-4[24] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[25] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[26] Bacon JF, Shenfield GM \"Pregnancy attributable to interaction between tetracycline and oral contraceptives.\" Br Med J 280 (1980): 293[27] Burroughs KE, Chambliss ML \"Antibiotics and oral contraceptive failure.\" Arch Fam 9 (2000): 81-2[28] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[29] Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I \"Oral contraceptive failure rates and oral antibiotics.\" J Am Acad Dermatol 36 (1997): 705-10[30] Silber TJ \"Apparent oral contraceptive failure associated with antibiotic administration.\" J Adolesc Health Care 4 (1983): 287-9[31] Joshi JV, Joshi UM, Sankholi GM, et al \"A study of interaction of low-dose combination oral contraceptive with ampicillin and metronidazole.\" Contraception 22 (1980): 643-52[32] Bollen M \"Use of antibiotics when taking the oral contraceptive pill.\" Aust Fam Physician 24 (1995): 928-9[33] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[34] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49(5 Suppl) (1988): s31-8[35] London BM, Lookingbill DP \"Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives.\" Arch Dermatol 130 (1994): 392-3[36] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60354, "ingredient1": "Furosemide", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60438/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Bendroflumethiazide, Trichlormethiazide, Chlorthalidone, Metolazone, Hydrochlorothiazide, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60355, "ingredient1": "Gentamicin", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60439/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60356, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Ceftolozane", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60440/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60357, "ingredient1": "Ceftolozane", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60441/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60358, "ingredient1": "Ceftolozane", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60442/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60359, "ingredient1": "Ceftolozane", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60443/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60360, "ingredient1": "Ceftolozane", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60444/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Bacitracin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60361, "ingredient1": "Ceftolozane", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60445/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60362, "ingredient1": "Ceftolozane", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60446/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60363, "ingredient1": "Ceftolozane", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60448/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60364, "ingredient1": "Ceftolozane", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60449/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Cefuroxime, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60365, "ingredient1": "Ceftolozane", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60450/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60366, "ingredient1": "Ceftolozane", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60451/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60367, "ingredient1": "Ceftolozane", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60452/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60368, "ingredient1": "Amikacin (liposome)", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60453/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine, Rifamycin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60369, "ingredient1": "Anisindione", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60454/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60370, "ingredient1": "Ceftriaxone", "ingredient2": "Calcium chloride", "severity": "Major", "effect": "Coadministration of ceftriaxone with calcium-containing solutions, even via different infusion lines, may cause precipitation of ceftriaxone-calcium salt. There have been cases of fatal reactions involving the presence of these precipitates in the lung and kidneys of both term and premature neonates as well as infants up to 1 year of age.", "source": "DDInter", "management_text": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.g., Ringer's or Hartmann's solution; parenteral nutrition containing calcium) via a Y-site in any patient regardless of age. Concomitant use of ceftriaxone and intravenous calcium-containing products (or within 48 hours of each other) is considered contraindicated in neonates 28 days of age or younger, even when administered via different infusion lines at different sites. Ceftriaxone should not be used in neonates if they are receiving, or are expected to receive, calcium-containing intravenous products. In patients older than 28 days, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. No data or recommendations are available for concomitant use of intravenous ceftriaxone and oral calcium-containing products or intramuscular ceftriaxone and calcium-containing products (IV or oral).", "mechanism_text": "Others", "recommendation": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60455/", "reference_text": "[1] CDER. Center for Drug Evaluation and Research. FDA. U.S. Food and Drug Admninistration \"Information for health care professionals: ceftriaxone (marketed as Rocephin and its generics). Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/ceftriaxone042009HCP.htm.\" ([2009 Apr 14]):[2] Bradley JS, Wassel RT, Lee L, Nambiar S \"Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events.\" Pediatrics (2009):[3] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[4] Canadian Vigilance program \"Notice to hospitals: Health Canada issued important safety informatin on ceftriaxone. Association of ceftriaxone with fatal outcome when administered intravenously with calcium-containing solutions. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/alt_\" ([2008 Jul 31]):", "alternatives_a": "Calcium lactate, Calcium glubionate anhydrous, Calcium citrate, Calcium carbonate, Calcium Phosphate, Ascorbic acid, Calcium citrate, Calcium carbonate, Calcium acetate, Calcium Phosphate, Darifenacin, More", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, More", "updated_at": 1767369485}, {"id": 60371, "ingredient1": "Ceftriaxone", "ingredient2": "Calcium glucoheptonate", "severity": "Major", "effect": "Coadministration of ceftriaxone with calcium-containing solutions, even via different infusion lines, may cause precipitation of ceftriaxone-calcium salt. There have been cases of fatal reactions involving the presence of these precipitates in the lung and kidneys of both term and premature neonates as well as infants up to 1 year of age.", "source": "DDInter", "management_text": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.g., Ringer's or Hartmann's solution; parenteral nutrition containing calcium) via a Y-site in any patient regardless of age. Concomitant use of ceftriaxone and intravenous calcium-containing products (or within 48 hours of each other) is considered contraindicated in neonates 28 days of age or younger, even when administered via different infusion lines at different sites. Ceftriaxone should not be used in neonates if they are receiving, or are expected to receive, calcium-containing intravenous products. In patients older than 28 days, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. No data or recommendations are available for concomitant use of intravenous ceftriaxone and oral calcium-containing products or intramuscular ceftriaxone and calcium-containing products (IV or oral).", "mechanism_text": "Others", "recommendation": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60456/", "reference_text": "[1] CDER. Center for Drug Evaluation and Research. FDA. U.S. Food and Drug Admninistration \"Information for health care professionals: ceftriaxone (marketed as Rocephin and its generics). Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/ceftriaxone042009HCP.htm.\" ([2009 Apr 14]):[2] Bradley JS, Wassel RT, Lee L, Nambiar S \"Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events.\" Pediatrics (2009):[3] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[4] Canadian Vigilance program \"Notice to hospitals: Health Canada issued important safety informatin on ceftriaxone. Association of ceftriaxone with fatal outcome when administered intravenously with calcium-containing solutions. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/alt_\" ([2008 Jul 31]):", "alternatives_a": "Calcium lactate, Calcium glubionate anhydrous, Calcium citrate, Calcium carbonate, Calcium Phosphate", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "updated_at": 1767369485}, {"id": 60372, "ingredient1": "Ceftriaxone", "ingredient2": "Calcium gluconate", "severity": "Major", "effect": "Coadministration of ceftriaxone with calcium-containing solutions, even via different infusion lines, may cause precipitation of ceftriaxone-calcium salt. There have been cases of fatal reactions involving the presence of these precipitates in the lung and kidneys of both term and premature neonates as well as infants up to 1 year of age.", "source": "DDInter", "management_text": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.g., Ringer's or Hartmann's solution; parenteral nutrition containing calcium) via a Y-site in any patient regardless of age. Concomitant use of ceftriaxone and intravenous calcium-containing products (or within 48 hours of each other) is considered contraindicated in neonates 28 days of age or younger, even when administered via different infusion lines at different sites. Ceftriaxone should not be used in neonates if they are receiving, or are expected to receive, calcium-containing intravenous products. In patients older than 28 days, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. No data or recommendations are available for concomitant use of intravenous ceftriaxone and oral calcium-containing products or intramuscular ceftriaxone and calcium-containing products (IV or oral).", "mechanism_text": "Others", "recommendation": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60457/", "reference_text": "[1] CDER. Center for Drug Evaluation and Research. FDA. U.S. Food and Drug Admninistration \"Information for health care professionals: ceftriaxone (marketed as Rocephin and its generics). Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/ceftriaxone042009HCP.htm.\" ([2009 Apr 14]):[2] Bradley JS, Wassel RT, Lee L, Nambiar S \"Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events.\" Pediatrics (2009):[3] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[4] Canadian Vigilance program \"Notice to hospitals: Health Canada issued important safety informatin on ceftriaxone. Association of ceftriaxone with fatal outcome when administered intravenously with calcium-containing solutions. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/alt_\" ([2008 Jul 31]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Calcium lactate, Calcium glubionate anhydrous, Calcium citrate, Calcium carbonate, Calcium Phosphate, Minoxidil, Deoxycholic acid, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, More", "updated_at": 1767369485}, {"id": 60373, "ingredient1": "Chloramphenicol", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60458/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Polymyxin B, Rifamycin, Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60374, "ingredient1": "Ceftriaxone", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60459/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60375, "ingredient1": "Cyclosporine", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Limited data suggest that ceftriaxone may increase cyclosporine serum concentrations. Risk of cyclosporine-induced neurotoxicity and nephrotoxicity may be increased. The mechanism is unknown.", "source": "DDInter", "management_text": "If cyclosporine and ceftriaxone are used together, cyclosporine levels and renal function, including serum creatinine, should be carefully monitored. Cyclosporine dosage should be adjusted as needed. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.", "mechanism_text": "Synergism", "recommendation": "If cyclosporine and ceftriaxone are used together, cyclosporine levels and renal function, including serum creatinine, should be carefully monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60460/", "reference_text": "[1] Alvarez JS, del Castillo JA, Ortiz MJ \"Interaction between ciclosporin and ceftriaxone.\" Nephron 59 (1991): 681-2[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefpodoxime, More", "updated_at": 1767369485}, {"id": 60376, "ingredient1": "Dicoumarol", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60461/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60377, "ingredient1": "Edetate calcium disodium anhydrous", "ingredient2": "Ceftriaxone", "severity": "Major", "effect": "Coadministration of ceftriaxone with calcium-containing solutions, even via different infusion lines, may cause precipitation of ceftriaxone-calcium salt. There have been cases of fatal reactions involving the presence of these precipitates in the lung and kidneys of both term and premature neonates as well as infants up to 1 year of age.", "source": "DDInter", "management_text": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.g., Ringer's or Hartmann's solution; parenteral nutrition containing calcium) via a Y-site in any patient regardless of age. Concomitant use of ceftriaxone and intravenous calcium-containing products (or within 48 hours of each other) is considered contraindicated in neonates 28 days of age or younger, even when administered via different infusion lines at different sites. Ceftriaxone should not be used in neonates if they are receiving, or are expected to receive, calcium-containing intravenous products. In patients older than 28 days, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. No data or recommendations are available for concomitant use of intravenous ceftriaxone and oral calcium-containing products or intramuscular ceftriaxone and calcium-containing products (IV or oral).", "mechanism_text": "Others", "recommendation": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60462/", "reference_text": "[1] CDER. Center for Drug Evaluation and Research. FDA. U.S. Food and Drug Admninistration \"Information for health care professionals: ceftriaxone (marketed as Rocephin and its generics). Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/ceftriaxone042009HCP.htm.\" ([2009 Apr 14]):[2] Bradley JS, Wassel RT, Lee L, Nambiar S \"Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events.\" Pediatrics (2009):[3] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[4] Canadian Vigilance program \"Notice to hospitals: Health Canada issued important safety informatin on ceftriaxone. Association of ceftriaxone with fatal outcome when administered intravenously with calcium-containing solutions. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/alt_\" ([2008 Jul 31]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60378, "ingredient1": "Etacrynic acid", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60463/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60379, "ingredient1": "Gentamicin", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60464/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine, Polymyxin B, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60380, "ingredient1": "Heparin", "ingredient2": "Ceftriaxone", "severity": "Minor", "effect": "Ceftriaxone has been associated with an increase in prothrombin time and episodes of bleeding. These effects may potentiate the effects of heparin. Usually, no special management is necessary, but the patient should be monitored for bleeding if ceftriaxone and heparin must be given together. Vitamin K has been successfully used to treat cephalosporin-induced coagulopathies.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60465/", "reference_text": "[1] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[2] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, More", "alternatives_b": "Imipenem, Cefprozil, Loracarbef, Cefonicid, Ceftizoxime, Ceftibuten, Cefradine, Cefiderocol, Cefditoren, Meropenem, Cefixime, More", "updated_at": 1767369485}, {"id": 60381, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Ceftriaxone", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60466/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60382, "ingredient1": "Ceftriaxone", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60467/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine, Rifamycin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60383, "ingredient1": "Ceftriaxone", "ingredient2": "Leucovorin", "severity": "Major", "effect": "Coadministration of ceftriaxone with calcium-containing solutions, even via different infusion lines, may cause precipitation of ceftriaxone-calcium salt. There have been cases of fatal reactions involving the presence of these precipitates in the lung and kidneys of both term and premature neonates as well as infants up to 1 year of age.", "source": "DDInter", "management_text": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.g., Ringer's or Hartmann's solution; parenteral nutrition containing calcium) via a Y-site in any patient regardless of age. Concomitant use of ceftriaxone and intravenous calcium-containing products (or within 48 hours of each other) is considered contraindicated in neonates 28 days of age or younger, even when administered via different infusion lines at different sites. Ceftriaxone should not be used in neonates if they are receiving, or are expected to receive, calcium-containing intravenous products. In patients older than 28 days, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. No data or recommendations are available for concomitant use of intravenous ceftriaxone and oral calcium-containing products or intramuscular ceftriaxone and calcium-containing products (IV or oral).", "mechanism_text": "Others", "recommendation": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60468/", "reference_text": "[1] CDER. Center for Drug Evaluation and Research. FDA. U.S. Food and Drug Admninistration \"Information for health care professionals: ceftriaxone (marketed as Rocephin and its generics). Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/ceftriaxone042009HCP.htm.\" ([2009 Apr 14]):[2] Bradley JS, Wassel RT, Lee L, Nambiar S \"Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events.\" Pediatrics (2009):[3] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[4] Canadian Vigilance program \"Notice to hospitals: Health Canada issued important safety informatin on ceftriaxone. Association of ceftriaxone with fatal outcome when administered intravenously with calcium-containing solutions. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/alt_\" ([2008 Jul 31]):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Arginine, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 60384, "ingredient1": "Ceftriaxone", "ingredient2": "Levoleucovorin", "severity": "Major", "effect": "Coadministration of ceftriaxone with calcium-containing solutions, even via different infusion lines, may cause precipitation of ceftriaxone-calcium salt. There have been cases of fatal reactions involving the presence of these precipitates in the lung and kidneys of both term and premature neonates as well as infants up to 1 year of age.", "source": "DDInter", "management_text": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.g., Ringer's or Hartmann's solution; parenteral nutrition containing calcium) via a Y-site in any patient regardless of age. Concomitant use of ceftriaxone and intravenous calcium-containing products (or within 48 hours of each other) is considered contraindicated in neonates 28 days of age or younger, even when administered via different infusion lines at different sites. Ceftriaxone should not be used in neonates if they are receiving, or are expected to receive, calcium-containing intravenous products. In patients older than 28 days, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. No data or recommendations are available for concomitant use of intravenous ceftriaxone and oral calcium-containing products or intramuscular ceftriaxone and calcium-containing products (IV or oral).", "mechanism_text": "Others", "recommendation": "Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60469/", "reference_text": "[1] CDER. Center for Drug Evaluation and Research. FDA. U.S. Food and Drug Admninistration \"Information for health care professionals: ceftriaxone (marketed as Rocephin and its generics). Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/ceftriaxone042009HCP.htm.\" ([2009 Apr 14]):[2] Bradley JS, Wassel RT, Lee L, Nambiar S \"Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events.\" Pediatrics (2009):[3] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[4] Canadian Vigilance program \"Notice to hospitals: Health Canada issued important safety informatin on ceftriaxone. Association of ceftriaxone with fatal outcome when administered intravenously with calcium-containing solutions. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/alt_\" ([2008 Jul 31]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Arginine, More", "updated_at": 1767369485}, {"id": 60385, "ingredient1": "Ceftriaxone", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60470/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60386, "ingredient1": "Ceftriaxone", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60471/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60387, "ingredient1": "Ceftriaxone", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60472/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Polymyxin B, Fidaxomicin, Rifaximin, Paromomycin, Flurbiprofen, Povidone-iodine, Bacitracin, Rifamycin, Oxytetracycline, Bacitracin, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60388, "ingredient1": "Ceftriaxone", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60473/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefonicid, Cefditoren, Meropenem, Cefdinir, Cefalotin, Cefmetazole, Cefamandole, More", "updated_at": 1767369485}, {"id": 60389, "ingredient1": "Ceftriaxone", "ingredient2": "Phenytoin", "severity": "Minor", "effect": "Ceftriaxone may displace phenytoin from serum protein-binding sites. Plasma levels of free phenytoin may increase. Some investigators have recommended monitoring of free phenytoin levels in patients who must receive both ceftriaxone and phenytoin.", "source": "DDInter", "management_text": "-", "mechanism_text": "Distribution", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60475/", "reference_text": "[1] Dasgupta A, Dennen DA, Dean R, McLawhon RW \"Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin, and sulfamethoxazole.\" Clin Chem 37 (1991): 98-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[6] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[7] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[8] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[9] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[10] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[11] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[12] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[13] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[14] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[17] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12", "alternatives_a": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More", "alternatives_b": "Imipenem, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, Cefalotin, More", "updated_at": 1767369485}, {"id": 60390, "ingredient1": "Ceftriaxone", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60476/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60391, "ingredient1": "Ceftriaxone", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60477/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Capreomycin, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Aztreonam, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Cefdinir, Ertapenem, More", "updated_at": 1767369485}, {"id": 60392, "ingredient1": "Ceftriaxone", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60478/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine", "alternatives_b": "Imipenem, Loracarbef, Cefadroxil, Ceftibuten, Cefaclor, Meropenem, Cefiderocol, Cefditoren, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60393, "ingredient1": "Ceftriaxone", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60479/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Ciclopirox, Vemurafenib, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60394, "ingredient1": "Ceftriaxone", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60480/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60395, "ingredient1": "Ceftriaxone", "ingredient2": "Verapamil", "severity": "Moderate", "effect": "According to a single case report, when ceftriaxone and clindamycin were added to the regimen of a patient who was receiving a stable dosage of verapamil and other medications, acute verapamil toxicity resulted. The patient developed complete heart block. The mechanism is unknown and causality was not clearly determined. The purported mechanism (displacement of verapamil from protein binding sites) has been disputed.", "source": "DDInter", "management_text": "Until more information is available, patients should be monitored for verapamil toxicity.", "mechanism_text": "Distribution", "recommendation": "Until more information is available, patients should be monitored for verapamil toxicity.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60481/", "reference_text": "[1] Kishore K, Raina A, Misra V, Jonas E \"Acute verapamil toxicity in a patient with chronic toxicity: possible interaction with ceftriaxone and clindamycin.\" Ann Pharmacother 27 (1993): 877-80[2] Bailey DG, Dresser GK \"Natural products and adverse drug interactions.\" Can Med Assoc J 170 (2004): 1531-2[3] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[4] Pillai U, Muzaffar J, Sandeep S, Yancey A \"Grapefruit juice and verapamil: a toxic cocktail.\" South Med J 102 (2009): 308-9[5] McAllister RG, Jr \"Clinical pharmacology of slow channel blocking agents.\" Prog Cardiovasc Dis 25 (1982): 83-102[6] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[7] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[8] Arayne MS, Sultana N, Bibi Z \"Review: grape fruit juice - drug interactions.\" Pak J Pharm Sci 18 (2005): 45-57[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions. 1998.\" Br J Clin Pharmacol 58 (2004): S831-40; discussion S841-3[10] Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A \"The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil.\" Eur J Clin Pharmacol 54 (1998): 337-40", "alternatives_a": "Trandolapril, Moexipril, Benazepril", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, More", "updated_at": 1767369485}, {"id": 60396, "ingredient1": "Ceftriaxone", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60482/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, More", "alternatives_b": "Meropenem, Doripenem", "updated_at": 1767369485}, {"id": 60397, "ingredient1": "Aluminum hydroxide", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60483/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60398, "ingredient1": "Amikacin (liposome)", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60484/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Cefuroxime, Benzylpenicillin, Ampicillin, Sulfisoxazole, Chlorhexidine, Levofloxacin, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 60399, "ingredient1": "Anisindione", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60485/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, Vancomycin, Sulfamethizole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60400, "ingredient1": "Cefuroxime", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60486/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Famciclovir, Tobramycin, Benzylpenicillin, Gentamicin, Amikacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60401, "ingredient1": "Cefuroxime", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60487/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Calcium glucoheptonate, Calcium lactate, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Calcium Phosphate, Ascorbic acid, Calcium citrate, Calcium acetate", "updated_at": 1767369485}, {"id": 60402, "ingredient1": "Chloramphenicol", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60488/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Rifamycin, Oxytetracycline, Rifaximin, Demeclocycline, Rifamycin, Chlorhexidine, Miconazole, Minocycline, Vitamin A, Isotretinoin, Fluorometholone, More", "alternatives_b": "Tetracycline, Gatifloxacin, Norfloxacin, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Lomefloxacin, Famciclovir, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 60403, "ingredient1": "Cefuroxime", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60489/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Chlorhexidine, Povidone-iodine, Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60404, "ingredient1": "Cimetidine", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60490/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin", "alternatives_b": "Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 60405, "ingredient1": "Dexlansoprazole", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60491/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Trifluridine, Moxifloxacin, More", "alternatives_b": "Tinidazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 60406, "ingredient1": "Dicoumarol", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60492/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, More", "alternatives_b": "Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Lomefloxacin, Famciclovir, Trifluridine, Vancomycin, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 60407, "ingredient1": "Didanosine", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60493/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "alternatives_b": "Amikacin, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Tobramycin, Ampicillin, Benzylpenicillin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60408, "ingredient1": "Disulfiram", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "An isolated case report suggests that the disulfiram reaction can occur during coadministration of cefuroxime axetil. Because the axetil moiety is metabolized to acetaldehyde in vivo, the reaction was presumably caused by an accumulation of acetaldehyde in the presence of disulfiram, which blocks the conversion of acetaldehyde to acetate. High levels of acetaldehyde can produce an unpleasant physiologic response referred to as the 'disulfiram reaction'. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion.", "source": "DDInter", "management_text": "Until more information is available, the possibility of a disulfiram reaction should be considered when prescribing cefuroxime axetil to patients treated with disulfiram.", "mechanism_text": "Others", "recommendation": "Until more information is available, the possibility of a disulfiram reaction should be considered when prescribing cefuroxime axetil to patients treated with disulfiram.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60494/", "reference_text": "[1] Mattes JA \"Antabuse reaction with ceftin.\" Am J Psychiatry 163 (2006): 2019-20[2] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "Lindane, Diamorphine, Acamprosate, Lofexidine, Naltrexone, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine", "alternatives_b": "Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 60409, "ingredient1": "Entecavir", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60495/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "alternatives_b": "Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, Trifluridine, Chloramphenicol, Sulfisoxazole, Azithromycin, Erythromycin, Chlorhexidine, Povidone-iodine, More", "updated_at": 1767369485}, {"id": 60410, "ingredient1": "Esomeprazole", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60496/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Fenoprofen, Meclofenamic acid, Phenylbutazone, Misoprostol, Glucosamine, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Polymyxin B, Ciprofloxacin, Famciclovir, Trifluridine, More", "updated_at": 1767369485}, {"id": 60411, "ingredient1": "Etacrynic acid", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60497/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Gatifloxacin, Acyclovir, Rifamycin, Ganciclovir, Famciclovir, Sulfamethizole, Trifluridine, Moxifloxacin, Ampicillin, Benzylpenicillin, Chloramphenicol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60412, "ingredient1": "Gentamicin", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60498/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Cefuroxime, Benzylpenicillin, Ampicillin, Sulfisoxazole, Chlorhexidine, Levofloxacin, More", "alternatives_b": "Tetracycline, Gatifloxacin, Ganciclovir, Rifamycin, Oxytetracycline, Norfloxacin, Lomefloxacin, Sulfamethizole, Trifluridine, Moxifloxacin, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 60413, "ingredient1": "Givosiran", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60499/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 60414, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cefuroxime", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60500/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Ganciclovir, Acyclovir, Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60415, "ingredient1": "Cefuroxime", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60501/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Acyclovir, Ciprofloxacin, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, More", "alternatives_b": "Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Cefuroxime, Benzylpenicillin, Ampicillin, Sulfisoxazole, Chlorhexidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 60416, "ingredient1": "Cefuroxime", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60502/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Famciclovir, Tobramycin, Benzylpenicillin, Gentamicin, Amikacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60417, "ingredient1": "Cefuroxime", "ingredient2": "Lansoprazole", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60503/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin", "alternatives_b": "Norfloxacin, Rifamycin, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Levofloxacin, Povidone-iodine, Imipenem, More", "updated_at": 1767369485}, {"id": 60418, "ingredient1": "Cefuroxime", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60504/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60419, "ingredient1": "Cefuroxime", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60505/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 60420, "ingredient1": "Cefuroxime", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60506/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 60421, "ingredient1": "Cefuroxime", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60507/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "updated_at": 1767369485}, {"id": 60422, "ingredient1": "Cefuroxime", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60508/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60423, "ingredient1": "Cefuroxime", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60509/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "updated_at": 1767369485}, {"id": 60424, "ingredient1": "Cefuroxime", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60510/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Miconazole, Fidaxomicin, Rifaximin, Paromomycin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Rifamycin, Oxytetracycline, Rifaximin, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Levofloxacin, Neomycin, More", "updated_at": 1767369485}, {"id": 60425, "ingredient1": "Cefuroxime", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60511/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Cefuroxime, Benzylpenicillin, Ampicillin, Sulfisoxazole, Chlorhexidine, Levofloxacin, Povidone-iodine", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, Famciclovir, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 60426, "ingredient1": "Cefuroxime", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60512/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Mibefradil", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 60427, "ingredient1": "Cefuroxime", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60513/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Moxifloxacin, Tobramycin, More", "updated_at": 1767369485}, {"id": 60428, "ingredient1": "Cefuroxime", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60514/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Tinidazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin", "alternatives_b": "Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Chloramphenicol, Sulfisoxazole, Levofloxacin, Povidone-iodine, More", "updated_at": 1767369485}, {"id": 60429, "ingredient1": "Cefuroxime", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60515/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Tioguanine, Capecitabine", "alternatives_b": "Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, Trifluridine, Sulfisoxazole, Azithromycin, Erythromycin, Chlorhexidine, Povidone-iodine, Cefepime, More", "updated_at": 1767369485}, {"id": 60430, "ingredient1": "Cefuroxime", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60516/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Azithromycin, Ofloxacin, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, Levofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60431, "ingredient1": "Cefuroxime", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60517/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "Rifamycin, Kanamycin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Tobramycin, Gentamicin, Erythromycin, Neomycin, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 60432, "ingredient1": "Cefuroxime", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "INTERVAL: Administration of quinapril with some oral medications may significantly decrease their absorption and may result in subtherapeutic serum concentrations. The proposed mechanism is chelation of the drug by the magnesium hydroxide excipient in quinapril tablets.", "source": "DDInter", "management_text": "The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.", "mechanism_text": "Absorption", "recommendation": "The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60518/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[4] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[5] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[7] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6", "alternatives_a": "Trandolapril, Moexipril, Benazepril, Trandolapril, Moexipril, Bisoprolol, Benazepril", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "updated_at": 1767369485}, {"id": 60433, "ingredient1": "Cefuroxime", "ingredient2": "Ranitidine (bismuth citrate)", "severity": "Moderate", "effect": "The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60519/", "reference_text": "[1] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[2] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9[3] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[4] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71", "alternatives_a": "Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, Polymyxin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60434, "ingredient1": "Cefuroxime", "ingredient2": "Sodium bicarbonate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.", "source": "DDInter", "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.", "mechanism_text": "Absorption", "recommendation": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60520/", "reference_text": "[1] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[2] Saathoff N, Lode H, Neider K, et al \"Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist.\" Antimicrob Agents Chemother 36 (1992): 796-800[3] Hughes GS, Heald DL, Barker KB, et al. \"The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.\" Clin Pharmacol Ther 46 (1989): 674-85[4] Sommers DK, van Wyk M, Moncrieff J, Schoeman HS \"Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.\" Br J Clin Pharmacol 18 (1984): 535-9", "alternatives_a": "Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, Sulfisoxazole, Amikacin, More", "alternatives_b": "Sorbitol, Sulfamethizole, Magnesium citrate, Sodium chloride, Chlorhexidine, Sodium acetate, Zinc sulfate, Magnesium sulfate, Arginine, Sodium glycerophosphate, Zinc chloride, More", "updated_at": 1767369485}, {"id": 60435, "ingredient1": "Cefuroxime", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60521/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Acyclovir, Famciclovir, Trifluridine, Moxifloxacin, Benzylpenicillin, Erythromycin, More", "updated_at": 1767369485}, {"id": 60436, "ingredient1": "Cefuroxime", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.", "source": "DDInter", "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60522/", "reference_text": "[1] Yasuhara H, Kobayashi S, Sakamoto K, Kamijo K \"Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients.\" J Clin Pharmacol 22 (1982): 403-9[2] Engle JE, Drago J, Carlin B, Schoolwerth AC \"Letter: Reversible acute renal failure after cephalothin.\" Ann Intern Med 83 (1975): 232-3[3] Kabins SA, Cohen S \"Cephalothin serum levels in the azotemic patient.\" Antimicrob Agents Chemother 10 (1964): 207-14[4] Gonzalez-Vitale JC, hayes DM, Cvitkovic E, Sternberg SS \"Acute renal failure after cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.\" Cancer Treat Rep 62 (1978): 693-8[5] Schentag JJ, Cerra FB, Plaut ME \"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.\" Antimicrob Agents Chemother 21 (1982): 721-6[6] Plager JE \"Association of renal injury with combined cephalothin-gentamicin therapy among patients severely ill with malignant disease.\" Cancer 37 (1976): 1937-43[7] Cabanillas F, Burgos RC, Rodriguez C, Baldizon C \"Nephrotoxicity of combined cephalothin-gentamicin regimen.\" Arch Intern Med 135 (1975): 850-2[8] Tobias JS, Whitehouse JM, Wrigley PF \"Letter: Severe renal dysfunction after tobramycin/cephalothin therapy.\" Lancet 1 (1976): 425[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Rodjer S, Alestig K, Bergmark J, et al \"Treatment of septicaemia in immunocompromised patients with ceftazidime, or with tobramycin and cefuroxime, with special reference to renal effects.\" J Antimicrob Chemother 20 (1987): 109-16[11] Pasternak DP, Stephens BG \"Reversible nephrotoxicity associated with cephalothin therapy.\" Arch Intern Med 135 (1975): 599-602[12] Klastersky J, Hensgens C, Debusscher L \"Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.\" Antimicrob Agents Chemother 7 (1975): 640-5[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Fillastre JP, Laumonier R, Humbert G, et al \"Acute renal failure associated with combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 396-7[15] Schwartz JH, Schein P \"Fanconi syndrome associated with cephalothin and gentamicin therapy.\" Cancer 41 (1978): 769-72[16] Hansen MM, Kaaber K \"Nephrotoxicity in combined cephalothin and gentamicin therapy.\" Acta Med Scand 201 (1977): 463-7[17] Cockram CS, Richards P, Bax RP \"The safety of cefuroxime and gentamicin in patients with reduced renal function.\" Curr Med Res Opin 6 (1980): 398-403[18] \"Renal failure in combined gentamicin and cephalothin therapy.\" Br Med J 2 (1973): 776-7[19] Gurwich EL, Sula J, Hoy RH \"Gentamicin-cephalothin drug reaction.\" Am J Hosp Pharm 35 (1978): 1402-3[20] Fanning WL, Gump D, Jick H \"Gentamicin- and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[21] Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA \"Lack of pharmacokinetic interaction between cefepime and amikacin in humans.\" Antimicrob Agents Chemother 36 (1992): 1382-6[22] \"Product Information. Mycifradin (neomycin).\" Emerson Laboratories, Texarkana, TX.[23] Trollfors B, Alestig K, Rodjer S, Sandberg T, Westin J \"Renal function in patients treated with tobramycin-cefuroxime or tobramycin-penicillin G.\" J Antimicrob Chemother 12 (1983): 641-5[24] Krcmery V, Fuchsberger P, Gocar M, et al \"Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.\" Chemotherapy 37 (1991): 287-91[25] Wade JC, Smith CR, Petty BG, et al \"Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.\" Lancet 2 (1978): 604-6[26] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 05/19/73 (1973): 1129[27] Sanders WE, Jr Johnson JE, 3d Taggart JG \"Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses.\" N Engl J Med 290 (1974): 424-9[28] Kleinknecht D, Ganeval D, Droz D \"Acute renal failure after high doses of gentamicin and cephalothin.\" Lancet 1 (1973): 1129[29] Tvedegaard E \"Letter: Interaction between gentamicin and cephalothin as cause of acute renal failure.\" Lancet 2 (1976): 581[30] Carling PC, Idelson BA, Casano AA, Alexander EA, McCabe WR \"Nephrotoxicity associated with cephalothin administration.\" Arch Intern Med 135 (1975): 797-801[31] Fanning WL, Gump D, Jick H \"Gentamicin and cephalothin-associated rises in blood urea nitrogen.\" Antimicrob Agents Chemother 10 (1976): 80-2[32] Pickering MJ, Spooner GR, Quesada A, de Cade JR \"Declining renal function associated with administration of cephalothin.\" South Med J 63 (1970): 426-8[33] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[34] Bobrow SN, Jaffe E, Young RC \"Anuria and acute tubular necrosis associated with gentamicin and cephalothin.\" JAMA 222 (1972): 1546-7[35] Foord RD \"Cephaloridine, cephalothin and the kidney.\" J Antimicrob Chemother 1 (1975): 119-33[36] Aronoff GR, Brier RA, Sloan RS, Brier ME \"Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.\" Antimicrob Agents Chemother 34 (1990): 1139-42[37] Dellinger P, Murphy T, Barza M, et al \"Effect of cephalothin on renal cortical concentrations of gentamicin in rats.\" Antimicrob Agents Chemother 9 (1976): 587-8[38] Schultze RG, Winters RE, Kauffman H \"Possible nephrotoxicity of gentamicin.\" J Infect Dis 124 (1971): s145-7[39] Wade J, Smith C, Petty B, et al \"Nephrotoxicity of gentamicin or tobramycin with methicillin or cephalothin.\" Curr Chem 2 (1978): 971-2[40] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):", "alternatives_a": "Rifamycin, Oxytetracycline, Lomefloxacin, Sulfamethizole, Trifluridine, Cefuroxime, Benzylpenicillin, Ampicillin, Sulfisoxazole, Chlorhexidine, Levofloxacin, Povidone-iodine", "alternatives_b": "Tetracycline, Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Tobramycin, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 60437, "ingredient1": "Cefuroxime", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60523/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, More", "alternatives_b": "Ganciclovir, Rifamycin, Polymyxin B, Famciclovir, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, Sulfisoxazole, Azithromycin, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 60438, "ingredient1": "Cefuroxime", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60524/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Chlorhexidine, Povidone-iodine, Fluconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60439, "ingredient1": "Cefuroxime", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60525/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, More", "alternatives_b": "Ganciclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Trifluridine, Amikacin, Povidone-iodine, Meropenem, Doripenem, Amikacin, Secnidazole", "updated_at": 1767369485}, {"id": 60440, "ingredient1": "Celecoxib", "ingredient2": "Bromfenac", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60526/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More", "alternatives_b": "Fluocinolone acetonide, Salicylic acid, Fluorometholone", "updated_at": 1767369485}, {"id": 60441, "ingredient1": "Chlorpromazine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60527/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "Naloxone, Naltrexone, Ketoprofen, Piroxicam, Meclofenamic acid, Sulindac, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More", "updated_at": 1767369485}, {"id": 60442, "ingredient1": "Ciprofloxacin", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60528/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Dihydrocodeine, Naloxone, Nalbuphine, Chondroitin sulfate, More", "alternatives_b": "Tinidazole, Cefixime, Secnidazole, Polymyxin B, Chloramphenicol, Neomycin, Polymyxin B, Chloramphenicol, Rifamycin, Neomycin, Ganciclovir, More", "updated_at": 1767369485}, {"id": 60443, "ingredient1": "Clozapine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60529/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "Naloxone, Naltrexone, Valdecoxib, Fenoprofen, Meclofenamic acid, Ketorolac, Mefenamic acid, Indomethacin, Ketoprofen, Meloxicam, Glucosamine, More", "updated_at": 1767369485}, {"id": 60444, "ingredient1": "Cyclosporine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60530/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "alternatives_b": "Oliceridine, Oxymorphone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, Naloxone, Codeine, More", "updated_at": 1767369485}, {"id": 60445, "ingredient1": "Dabrafenib", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60531/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Pentazocine, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, More", "updated_at": 1767369485}, {"id": 60446, "ingredient1": "Darifenacin", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of darifenacin such as severe abdominal pain or constipation for 3 or more days.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60532/", "reference_text": "[1] \"Product Information. Enablex (darifenacin).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naloxone, Naltrexone, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 60447, "ingredient1": "Deflazacort", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.", "source": "DDInter", "management_text": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60533/", "reference_text": "[1] Wilcox CM, Shalek KA, Cotsonis G \"Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage.\" Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R \"Anti-inflammatory drugs and bowel perforations and haemorrhage.\" Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al \"Association of adrenocorticosteroid therapy and peptic-ulcer disease.\" N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S \"Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.\" Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR \"Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication.\" J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A \"Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs.\" Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S \"Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics.\" Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA \"Gastrointestinal ulceration with NSAIDs.\" Am J Med 99 (1995): 440-1[9] Thomas TP \"The complications of systemic corticosteroid therapy in the elderly.\" Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC \"Bowel perforation in steroid-treated patients.\" Ann Surg 192 (1980): 581-6", "alternatives_a": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60448, "ingredient1": "Delavirdine", "ingredient2": "Celecoxib", "severity": "Minor", "effect": "Theoretically, celecoxib may inhibit the CYP450 2D6 metabolism of delavirdine, and delavirdine may inhibit the CYP450 2C9 metabolism of celecoxib. The clinical significance of this interaction is unknown. Patients who are poor metabolizers of CYP450 2C9 may be at a greater risk of developing high celecoxib plasma levels. Patients should be observed for altered effects of both celecoxib and delavirdine. Dose adjustments may be required if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60534/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, Pentazocine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 60449, "ingredient1": "Diflunisal", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60535/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Morphine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Hydromorphone, Dezocine, More", "alternatives_b": "Salicylic acid, Choline salicylate, Ziconotide, Salsalate", "updated_at": 1767369485}, {"id": 60450, "ingredient1": "Donepezil", "ingredient2": "Celecoxib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of donepezil, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60536/", "reference_text": "[1] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses.\" Br J Clin Pharmacol 46 (1998): 30-4[2] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[3] Rojas-Fernandez C, Fisher C \"Drug interactions and donepezil.\" J Am Geriat Soc 40 (2000): 597-8", "alternatives_a": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, Pentazocine, Dihydrocodeine, Naloxone, More", "alternatives_b": "Tacrine, Aducanumab", "updated_at": 1767369485}, {"id": 60451, "ingredient1": "Efavirenz", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60537/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Tapentadol, Oxymorphone, Meperidine, Hydromorphone, Dezocine, Opium, Pentazocine, Naloxone, Nalbuphine, Misoprostol, Chondroitin sulfate, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 60452, "ingredient1": "Enzalutamide", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60538/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc, Deerfield, IL.[3] Benoist G, van Oort I, et al \"Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.\" Br J Clin Pharmacol 0 (2017): epub[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, More", "alternatives_b": "Darolutamide, Abarelix, Relugolix, Degarelix, Nilutamide, Aminoglutethimide", "updated_at": 1767369485}, {"id": 60453, "ingredient1": "Epoprostenol", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.", "source": "DDInter", "management_text": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents. Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.", "mechanism_text": "Synergism", "recommendation": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60539/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Hydromorphone, Dezocine, Opium, More", "alternatives_b": "Selexipag, Drotrecogin alfa", "updated_at": 1767369485}, {"id": 60454, "ingredient1": "Etodolac", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60540/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Naloxone, Tapentadol, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "updated_at": 1767369485}, {"id": 60455, "ingredient1": "Etravirine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with etravirine may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 and/or 2C9 isoenzymes. The mechanism is decreased clearance due to inhibition of these isoenzymes by etravirine.", "source": "DDInter", "management_text": "Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 2C19 and/or 2C9 , particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever etravirine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 2C19 and/or 2C9 , particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60541/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Acetylsalicylic acid, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 60456, "ingredient1": "Fenoprofen", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60542/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "updated_at": 1767369485}, {"id": 60457, "ingredient1": "Fluconazole", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Administration of celecoxib with fluconazole 200 mg daily resulted in a twofold increase in celecoxib plasma concentration. This is due to the inhibition of celecoxib metabolism via CYP450 2C9 by fluconazole.", "source": "DDInter", "management_text": "The manufacturer recommends initiating celecoxib therapy with the lowest recommended dose.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends initiating celecoxib therapy with the lowest recommended dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60543/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Tinidazole, Cefixime, Secnidazole, Micafungin, Caspofungin, Posaconazole, Oteseconazole, Anidulafungin, Salicylic acid, Thiabendazole, Griseofulvin, More", "alternatives_b": "Tapentadol, Oxymorphone, Dezocine, Opium, Pentazocine, Dihydrocodeine, Codeine, Fenoprofen, Meclofenamic acid, Phenylbutazone, Chondroitin sulfate, More", "updated_at": 1767369485}, {"id": 60458, "ingredient1": "Fludrocortisone", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.", "source": "DDInter", "management_text": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60544/", "reference_text": "[1] Wilcox CM, Shalek KA, Cotsonis G \"Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage.\" Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R \"Anti-inflammatory drugs and bowel perforations and haemorrhage.\" Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al \"Association of adrenocorticosteroid therapy and peptic-ulcer disease.\" N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S \"Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.\" Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR \"Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication.\" J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A \"Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs.\" Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S \"Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics.\" Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA \"Gastrointestinal ulceration with NSAIDs.\" Am J Med 99 (1995): 440-1[9] Thomas TP \"The complications of systemic corticosteroid therapy in the elderly.\" Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC \"Bowel perforation in steroid-treated patients.\" Ann Surg 192 (1980): 581-6", "alternatives_a": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, More", "alternatives_b": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "updated_at": 1767369485}, {"id": 60459, "ingredient1": "Fluoxetine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60545/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Naloxone, Naltrexone, Chondroitin sulfate, Esomeprazole, Glucosamine, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 60460, "ingredient1": "Fluphenazine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60546/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Acetaminophen, Naloxone, Naltrexone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60461, "ingredient1": "Flurbiprofen", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60547/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Codeine, Nalbuphine, Tramadol, More", "alternatives_b": "Tolazoline, Dimethyl sulfoxide, Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib, Neomycin, Povidone-iodine, Bacitracin, Fluocinolone acetonide, Salicylic acid, Fluorometholone", "updated_at": 1767369485}, {"id": 60462, "ingredient1": "Grepafloxacin", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60548/", "reference_text": "[1] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[2] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[3] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988): 97-107[4] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994): 685-706[5] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[6] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[7] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[8] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[9] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21[10] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[11] \"Product Information. Penetrex (enoxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996): 343-8[14] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.", "alternatives_a": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60463, "ingredient1": "Haloperidol", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60549/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naloxone, Naltrexone, Ketoprofen, Piroxicam, Meclofenamic acid, Sulindac, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60464, "ingredient1": "Hydrocodone", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60550/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Acetylsalicylic acid, Acetaminophen, Ibuprofen, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, More", "alternatives_b": "Benzonatate, Clofedanol, Pentoxyverine", "updated_at": 1767369485}, {"id": 60465, "ingredient1": "Idelalisib", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.", "source": "DDInter", "management_text": "The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.", "mechanism_text": "Synergism", "recommendation": "The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60551/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Morphine, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Acetylsalicylic acid, Nalbuphine, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, More", "updated_at": 1767369485}, {"id": 60466, "ingredient1": "Iloprost", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.", "source": "DDInter", "management_text": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents. Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.", "mechanism_text": "Synergism", "recommendation": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60552/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Dezocine, Opium, Dextropropoxyphene, More", "alternatives_b": "Selexipag, Drotrecogin alfa", "updated_at": 1767369485}, {"id": 60467, "ingredient1": "Imatinib", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.", "source": "DDInter", "management_text": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60553/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tapentadol, Oxymorphone, Meperidine, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Naloxone, Nalbuphine, Fenoprofen, Meclofenamic acid, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, More", "updated_at": 1767369485}, {"id": 60468, "ingredient1": "Indomethacin", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60554/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib, Fluocinolone acetonide, Salicylic acid, Fluorometholone, Tolazoline, Dimethyl sulfoxide, More", "alternatives_b": "Codeine, Oliceridine, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, More", "updated_at": 1767369485}, {"id": 60469, "ingredient1": "Ivacaftor", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60555/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 60470, "ingredient1": "Celecoxib", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60556/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Dezocine, Opium, Dextropropoxyphene, Methadone, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 60471, "ingredient1": "Celecoxib", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60557/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naloxone, Tramadol, Tapentadol, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60472, "ingredient1": "Celecoxib", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with letermovir may decrease the plasma concentrations of drugs that are metabolized by CYP450 2C9 and/or 2C19.", "source": "DDInter", "management_text": "Caution is advised when letermovir is used concomitantly with drugs that are substrates of CYP450 2C9 and/or 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when letermovir is used concomitantly with drugs that are substrates of CYP450 2C9 and/or 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60558/", "reference_text": "[1] \"Product Information. Prevymis (letermovir).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 60473, "ingredient1": "Celecoxib", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism involves decreased metabolic clearance due to induction of CYP450 2C9 by lorlatinib.", "source": "DDInter", "management_text": "Caution is advised when lorlatinib is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lorlatinib is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60559/", "reference_text": "[1] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, More", "updated_at": 1767369485}, {"id": 60474, "ingredient1": "Celecoxib", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60560/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 60475, "ingredient1": "Celecoxib", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60561/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Naloxone, Oxycodone, Butorphanol, Tapentadol, Meperidine, Hydromorphone, Tramadol, Dezocine, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "updated_at": 1767369485}, {"id": 60476, "ingredient1": "Celecoxib", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60562/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Nalbuphine, Dihydrocodeine, Naloxone, More", "alternatives_b": "Chloroprocaine, Levobupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "updated_at": 1767369485}, {"id": 60477, "ingredient1": "Celecoxib", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60563/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60478, "ingredient1": "Celecoxib", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60564/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, More", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "updated_at": 1767369485}, {"id": 60479, "ingredient1": "Celecoxib", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60565/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60480, "ingredient1": "Celecoxib", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "Coadministration of methoxyflurane with other nephrotoxic agents may increase the risk of renal impairment. The precise mechanism has not been delineated.", "source": "DDInter", "management_text": "Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60566/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Dezocine, Acetylsalicylic acid, Naloxone, Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Oxaprozin, More", "alternatives_b": "Salicylic acid, Choline salicylate, Ziconotide, Salsalate", "updated_at": 1767369485}, {"id": 60481, "ingredient1": "Celecoxib", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.", "source": "DDInter", "management_text": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60567/", "reference_text": "[1] Wilcox CM, Shalek KA, Cotsonis G \"Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage.\" Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R \"Anti-inflammatory drugs and bowel perforations and haemorrhage.\" Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al \"Association of adrenocorticosteroid therapy and peptic-ulcer disease.\" N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S \"Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.\" Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR \"Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication.\" J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A \"Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs.\" Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S \"Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics.\" Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA \"Gastrointestinal ulceration with NSAIDs.\" Am J Med 99 (1995): 440-1[9] Thomas TP \"The complications of systemic corticosteroid therapy in the elderly.\" Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC \"Bowel perforation in steroid-treated patients.\" Ann Surg 192 (1980): 581-6", "alternatives_a": "Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, Dihydrocodeine, Buprenorphine, More", "alternatives_b": "Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Azelaic acid, Fluocinolone acetonide, Beclomethasone dipropionate, Fluorometholone, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, More", "updated_at": 1767369485}, {"id": 60482, "ingredient1": "Celecoxib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of metoprolol. The mechanism is celecoxib inhibition of metoprolol metabolism via CYP450 2D6.", "source": "DDInter", "management_text": "Although metoprolol has a wide therapeutic range, caution is advised during coadministration with celecoxib because hemodynamic effects of metoprolol may be related to plasma concentration. Patients should be monitored for increased pharmacologic effects that may result in bradycardia or hypotension.", "mechanism_text": "Metabolism", "recommendation": "Although metoprolol has a wide therapeutic range, caution is advised during coadministration with celecoxib because hemodynamic effects of metoprolol may be related to plasma concentration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60568/", "reference_text": "[1] Bengtsson C, Johnsson G, Regardh C-G \"Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment.\" Clin Pharmacol Ther 17 (1975): 400-8[2] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.[3] Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K \"Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.\" Clin Pharmacol Ther 74 (2003): 130-137[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Lopressor (metoprolol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Ivabradine", "alternatives_b": "Tapentadol, Naltrexone, Oxymorphone, Chondroitin sulfate, Esomeprazole, Glucosamine, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, More", "updated_at": 1767369485}, {"id": 60483, "ingredient1": "Celecoxib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of celecoxib, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of celecoxib should be considered.", "source": "DDInter", "management_text": "Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor. Dosage adjustments may be required if an interaction is suspected. Patients should be advised to notify their physician if they experience potential signs and symptoms of celecoxib toxicity such as abdominal pain, black or tarry stools, nausea, vomiting, lethargy, fluid retention, swelling of legs, and worsening heart failure.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60569/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, More", "alternatives_b": "Rifamycin, Polymyxin B, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Caspofungin, Posaconazole, Oteseconazole, Anidulafungin, More", "updated_at": 1767369485}, {"id": 60484, "ingredient1": "Celecoxib", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of CYP450 2C8 and/or 2C9. The mechanism is decreased clearance due to inhibition of CYP450 2C8/2C9 activity by mifepristone.", "source": "DDInter", "management_text": "Caution is advised if mifepristone must be used concomitantly with medications that are substrates of CYP450 2C8 and/or 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy. The lowest dosage of sensitive substrates (e.g., repaglinide, warfarin) should be used whenever possible. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if mifepristone must be used concomitantly with medications that are substrates of CYP450 2C8 and/or 2C9, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60570/", "reference_text": "[1] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[2] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[3] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, More", "alternatives_b": "Ulipristal, Danazol, Ospemifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 60485, "ingredient1": "Celecoxib", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60571/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "alternatives_b": "Codeine, Oliceridine, Oxymorphone, Naloxone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 60486, "ingredient1": "Celecoxib", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60572/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oliceridine, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine, More", "alternatives_b": "Ritodrine, Bremelanotide, Flibanserin, Bromocriptine, Tolazoline, Dimethyl sulfoxide, Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "updated_at": 1767369485}, {"id": 60487, "ingredient1": "Celecoxib", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60573/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone, Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, More", "alternatives_b": "Ivabradine, Sacubitril", "updated_at": 1767369485}, {"id": 60488, "ingredient1": "Celecoxib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.", "source": "DDInter", "management_text": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.", "mechanism_text": "Metabolism", "recommendation": "If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60574/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Naltrexone, Oxymorphone, Oxycodone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More", "updated_at": 1767369485}, {"id": 60489, "ingredient1": "Celecoxib", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60575/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "Naloxone, Fenoprofen, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Flurbiprofen, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid, More", "updated_at": 1767369485}, {"id": 60490, "ingredient1": "Celecoxib", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60576/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Acetylsalicylic acid, Oliceridine, Ibuprofen, Acetaminophen, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, More", "alternatives_b": "Tapentadol, Oxymorphone, Dezocine, Opium, Celecoxib, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 60491, "ingredient1": "Celecoxib", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60577/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "updated_at": 1767369485}, {"id": 60492, "ingredient1": "Celecoxib", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60578/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oxycodone, Fenoprofen, Chondroitin sulfate, Glucosamine, Flurbiprofen, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid, Tinidazole, Ascorbic acid, More", "alternatives_b": "Tapentadol, Oxymorphone, Dezocine, Opium, Celecoxib, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 60493, "ingredient1": "Celecoxib", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60579/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Naltrexone, Oxymorphone, Naloxone, Oxycodone, Tapentadol, Acetaminophen, Meperidine, Hydromorphone, Tramadol, Dezocine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60494, "ingredient1": "Celecoxib", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60580/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Pentazocine, Acetylsalicylic acid, Acetaminophen, Ibuprofen, Rabeprazole, Ketoprofen, Piroxicam, Meclofenamic acid, Sulindac, Etodolac, Ketorolac, More", "alternatives_b": "Tapentadol, Oxymorphone, Dezocine, Opium, Celecoxib, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 60495, "ingredient1": "Celecoxib", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60581/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naloxone, Naltrexone, Rabeprazole, Ketoprofen, Piroxicam, Meclofenamic acid, Sulindac, Etodolac, Ketorolac, Misoprostol, Glucosamine, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60496, "ingredient1": "Celecoxib", "ingredient2": "Pindolol", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60582/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naloxone, Naltrexone, Tapentadol, Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Esomeprazole, Valdecoxib, Tamsulosin, Tinidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60497, "ingredient1": "Celecoxib", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60583/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, Dihydrocodeine, Naloxone, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Salicylic acid, Fluorometholone", "updated_at": 1767369485}, {"id": 60498, "ingredient1": "Celecoxib", "ingredient2": "Porfimer sodium", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60584/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivity—an update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 60499, "ingredient1": "Celecoxib", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.", "source": "DDInter", "management_text": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60585/", "reference_text": "[1] Wilcox CM, Shalek KA, Cotsonis G \"Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage.\" Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R \"Anti-inflammatory drugs and bowel perforations and haemorrhage.\" Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al \"Association of adrenocorticosteroid therapy and peptic-ulcer disease.\" N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S \"Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.\" Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR \"Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication.\" J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A \"Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs.\" Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S \"Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics.\" Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA \"Gastrointestinal ulceration with NSAIDs.\" Am J Med 99 (1995): 440-1[9] Thomas TP \"The complications of systemic corticosteroid therapy in the elderly.\" Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC \"Bowel perforation in steroid-treated patients.\" Ann Surg 192 (1980): 581-6", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, More", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, Fluorometholone, Neomycin, More", "updated_at": 1767369485}, {"id": 60500, "ingredient1": "Celecoxib", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.", "source": "DDInter", "management_text": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60586/", "reference_text": "[1] Wilcox CM, Shalek KA, Cotsonis G \"Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage.\" Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R \"Anti-inflammatory drugs and bowel perforations and haemorrhage.\" Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al \"Association of adrenocorticosteroid therapy and peptic-ulcer disease.\" N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S \"Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.\" Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR \"Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication.\" J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A \"Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs.\" Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S \"Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics.\" Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA \"Gastrointestinal ulceration with NSAIDs.\" Am J Med 99 (1995): 440-1[9] Thomas TP \"The complications of systemic corticosteroid therapy in the elderly.\" Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC \"Bowel perforation in steroid-treated patients.\" Ann Surg 192 (1980): 581-6", "alternatives_a": "Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Codeine, Dihydrocodeine, Naloxone, Nalbuphine, More", "alternatives_b": "Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 60501, "ingredient1": "Celecoxib", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60587/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "Naltrexone, Fenoprofen, Meclofenamic acid, Phenylbutazone, Glucosamine, Chondroitin sulfate, Flurbiprofen, Esomeprazole, Tolmetin, Sulindac, Mefenamic acid, More", "updated_at": 1767369485}, {"id": 60502, "ingredient1": "Celecoxib", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60588/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, More", "updated_at": 1767369485}, {"id": 60503, "ingredient1": "Celecoxib", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60589/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Flurbiprofen, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid, Tinidazole, More", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "updated_at": 1767369485}, {"id": 60504, "ingredient1": "Celecoxib", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60590/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, More", "alternatives_b": "Suvorexant, Methohexital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, More", "updated_at": 1767369485}, {"id": 60505, "ingredient1": "Dextropropoxyphene", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60591/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Acetaminophen, Dextropropoxyphene, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, More", "alternatives_b": "Tapentadol, Oxymorphone, Dezocine, Opium, Celecoxib, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 60506, "ingredient1": "Celecoxib", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60592/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naloxone, Tapentadol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tinidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 60507, "ingredient1": "Celecoxib", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Coadministration with rifampin may decrease the plasma concentrations of celecoxib. The proposed mechanism is rifampin induction of celecoxib metabolism via CYP450 2C9.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of celecoxib should be considered during coadministration with rifampin. Dose adjustments or alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of celecoxib should be considered during coadministration with rifampin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60593/", "reference_text": "[1] Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao Y \"Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers.\" Drug Metabol Drug Interact 19 (2003): 287-95", "alternatives_a": "Tapentadol, Oxymorphone, Meperidine, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Naloxone, Nalbuphine, Ketoprofen, Piroxicam, More", "alternatives_b": "Capreomycin, Rifamycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 60508, "ingredient1": "Celecoxib", "ingredient2": "Rifapentine", "severity": "Moderate", "effect": "Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine. Enzyme activities may be induced within 4 days of the first dose and return to normal 14 days after discontinuation of rifapentine.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60594/", "reference_text": "[1] Thijssen HH, Flin ois JP, Beaune PH \"Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1284-90[2] \"Product Information. Priftin (rifapentine).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Pentazocine, More", "alternatives_b": "Capreomycin, Rifamycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 60509, "ingredient1": "Celecoxib", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60595/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naloxone, Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Flurbiprofen, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid, Tinidazole, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60510, "ingredient1": "Celecoxib", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60596/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Dihydrocodeine, Naloxone, Nalbuphine, Fenoprofen, Meclofenamic acid, Ketorolac, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 60511, "ingredient1": "Celecoxib", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 2C9.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60597/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 60512, "ingredient1": "Celecoxib", "ingredient2": "Sulindac", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60598/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Dezocine, Opium, Dextropropoxyphene, Methadone, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib", "updated_at": 1767369485}, {"id": 60513, "ingredient1": "Celecoxib", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60599/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, More", "updated_at": 1767369485}, {"id": 60514, "ingredient1": "Celecoxib", "ingredient2": "Timolol", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60600/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Diclofenamide, Apraclonidine, Guanethidine, Levobunolol", "alternatives_b": "Naloxone, Naltrexone, Tapentadol, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, More", "updated_at": 1767369485}, {"id": 60515, "ingredient1": "Celecoxib", "ingredient2": "Tolmetin", "severity": "Moderate", "effect": "Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.", "source": "DDInter", "management_text": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60601/", "reference_text": "[1] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Celecoxib, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 60516, "ingredient1": "Celecoxib", "ingredient2": "Treprostinil", "severity": "Moderate", "effect": "Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.", "source": "DDInter", "management_text": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents. Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.", "mechanism_text": "Synergism", "recommendation": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60602/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Selexipag, Drotrecogin alfa", "alternatives_b": "Naltrexone, Oxymorphone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More", "updated_at": 1767369485}, {"id": 60517, "ingredient1": "Celecoxib", "ingredient2": "Trifluoperazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60603/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60518, "ingredient1": "Celecoxib", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60604/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, More", "alternatives_b": "Asenapine, Pimavanserin, Lumateperone, Iloperidone, Amisulpride, Loxapine, Droperidol, Molindone, Cariprazine, Paliperidone, Lurasidone", "updated_at": 1767369485}, {"id": 60519, "ingredient1": "Alimemazine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60605/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, More", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "updated_at": 1767369485}, {"id": 60520, "ingredient1": "Celecoxib", "ingredient2": "Voriconazole", "severity": "Moderate", "effect": "Coadministration with voriconazole may increase the plasma concentrations of drugs that are substrates of CYP450 2C19, 2C9, and/or 3A4. The mechanism is decreased clearance due to inhibition of those isoenzymes by voriconazole. Increased plasma levels and/or pharmacologic effects of drugs such as cyclosporine, sirolimus, tacrolimus (3A4 substrates), and warfarin (2C9 substrate) have been reported during coadministration with voriconazole.", "source": "DDInter", "management_text": "Caution is advised if voriconazole must be used concomitantly with medications that undergo metabolism by CYP450 2C19, 2C9 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever voriconazole is added to or withdrawn from therapy. The manufacturer specifically recommends that a dosage reduction be considered for benzodiazepines, statins, long-acting opiates, and vinca alkaloids that are metabolized by the affected isoenzymes when used with voriconazole.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if voriconazole must be used concomitantly with medications that undergo metabolism by CYP450 2C19, 2C9 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60606/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Oxymorphone, Tapentadol, Meperidine, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine, Fenoprofen, More", "alternatives_b": "Micafungin, Caspofungin, Posaconazole, Oteseconazole, Anidulafungin", "updated_at": 1767369485}, {"id": 60521, "ingredient1": "Deflazacort", "ingredient2": "Cemiplimab", "severity": "Moderate", "effect": "INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.", "source": "DDInter", "management_text": "The manufacturers' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers' product labeling should be consulted for specific recommendations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60607/", "reference_text": "[1] Jove M, Vilarino N, Nadal E \"Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.\" Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. \"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.\" J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al \"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.\" J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al \"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.\" ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[8] Scott SC, Pennell NA \"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab.\" J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Fludrocortisone", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More", "updated_at": 1767369485}, {"id": 60522, "ingredient1": "Cemiplimab", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.", "source": "DDInter", "management_text": "The manufacturers' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers' product labeling should be consulted for specific recommendations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60608/", "reference_text": "[1] Jove M, Vilarino N, Nadal E \"Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.\" Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. \"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.\" J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al \"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.\" J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al \"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.\" ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[8] Scott SC, Pennell NA \"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab.\" J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More", "updated_at": 1767369485}, {"id": 60523, "ingredient1": "Cemiplimab", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.", "source": "DDInter", "management_text": "The manufacturers' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers' product labeling should be consulted for specific recommendations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60609/", "reference_text": "[1] Jove M, Vilarino N, Nadal E \"Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.\" Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. \"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.\" J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al \"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.\" J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al \"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.\" ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[8] Scott SC, Pennell NA \"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab.\" J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fludrocortisone, Indomethacin, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More", "updated_at": 1767369485}, {"id": 60524, "ingredient1": "Cemiplimab", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.", "source": "DDInter", "management_text": "The manufacturers' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers' product labeling should be consulted for specific recommendations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60610/", "reference_text": "[1] Jove M, Vilarino N, Nadal E \"Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.\" Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. \"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.\" J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al \"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.\" J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al \"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.\" ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc \"ANVISA Bulário Eletrônico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[8] Scott SC, Pennell NA \"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab.\" J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine, Fludrocortisone", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More", "updated_at": 1767369485}, {"id": 60525, "ingredient1": "Amoxapine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60611/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60526, "ingredient1": "Amprenavir", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60612/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Levetiracetam, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 60527, "ingredient1": "Cenobamate", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60613/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 60528, "ingredient1": "Cenobamate", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60614/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Tiagabine, Paramethadione, Phensuximide, Lamotrigine, Fosphenytoin, Phenacemide, Lacosamide", "updated_at": 1767369485}, {"id": 60529, "ingredient1": "Cenobamate", "ingredient2": "Bedaquiline", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to the major N-monodesmethyl metabolite, M2. Because M2 is 4- to 6-fold less active than the parent drug in terms of antimycobacterial potency, the interaction may diminish the therapeutic effect of bedaquiline.", "source": "DDInter", "management_text": "The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60615/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[4] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Clonazepam, Paramethadione, Perampanel, Ganaxolone, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Isoniazid, Ethambutol, More", "updated_at": 1767369485}, {"id": 60530, "ingredient1": "Cenobamate", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60616/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60531, "ingredient1": "Cenobamate", "ingredient2": "Boceprevir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer. Close clinical monitoring of the virologic response to the HCV NS3/4A protease inhibitor is recommended.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60617/", "reference_text": "[1] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Ezogabine, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Lamotrigine, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 60532, "ingredient1": "Cenobamate", "ingredient2": "Butabarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60618/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide, Methylphenobarbital", "updated_at": 1767369485}, {"id": 60533, "ingredient1": "Cenobamate", "ingredient2": "Pentoxyverine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60619/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 60534, "ingredient1": "Cenobamate", "ingredient2": "Caspofungin", "severity": "Moderate", "effect": "Coadministration with inducers or mixed inducer/inhibitors of certain metabolic pathways may produce clinically meaningful reductions in the plasma concentrations of caspofungin.", "source": "DDInter", "management_text": "Caspofungin product labeling recommends that during coadministration with efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone or carbamazepine, an increase in the daily dosage to 70 mg (following the usual 70 mg loading dose) should be considered in patients who are not clinically responding.", "mechanism_text": "Metabolism", "recommendation": "Caspofungin product labeling recommends that during coadministration with efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone or carbamazepine, an increase in the daily dosage to 70 mg (following the usual 70 mg loading dose) should be considered in patients who are not clinically responding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60620/", "reference_text": "[1] \"Product Information. Cancidas (caspofungin)\" Merck & Co, Inc, West Point, PA.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Fluconazole, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60535, "ingredient1": "Ceritinib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60621/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Ethotoin, Brivaracetam, Gabapentin, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Fenfluramine, Lamotrigine, Phensuximide, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60536, "ingredient1": "Cevimeline", "ingredient2": "Cenobamate", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may theoretically decrease the plasma concentrations of cevimeline, which is a substrate of the isoenzyme. However, the clinical relevance has not been established, since cevimeline is also metabolized by CYP450 2D6, which is not inducible to any significant extent.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60622/", "reference_text": "[1] \"Product Information. Evoxac (cevimeline)\" Daiichi Pharmaceuticals, Fort lee, NJ.", "alternatives_a": "Bethanechol, Neostigmine, Pyridostigmine, Ambenonium, Pilocarpine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60537, "ingredient1": "Clofedanol", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60623/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Benzonatate", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60538, "ingredient1": "Chloral hydrate", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60624/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60539, "ingredient1": "Chlorcyclizine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60625/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "alternatives_b": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "updated_at": 1767369485}, {"id": 60540, "ingredient1": "Chlordiazepoxide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60626/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60541, "ingredient1": "Chlormezanone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60627/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60542, "ingredient1": "Chlorphenesin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60628/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, More", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60543, "ingredient1": "Chlorpromazine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60629/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60544, "ingredient1": "Chlorpropamide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60630/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60545, "ingredient1": "Chlorzoxazone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60631/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60546, "ingredient1": "Cilostazol", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 and/or 2C19 inhibitor is added to or withdrawn from cilostazol therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 and/or 2C19 inhibitor is added to or withdrawn from cilostazol therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60632/", "reference_text": "[1] Suri A, Bramer SL \"Effect of omeprazole on the metabolism of cilostazol.\" Clin Pharmacokinet 37 (1999): 53-9[2] Herrlin K, Segerdahl M, Gustafsson LL, Kalso E \"Methadone, ciprofloxacin, and adverse drug reactions.\" Lancet 356 (2000): 2069-70[3] \"Product Information. Pletal (cilostazol).\" Otsuka American Pharmaceuticals, Rockville, MD.[4] Suri A, Forbes WP, Bramer SL \"Effects of CYP3A inhibition on the metabolism of cilostazol.\" Clin Pharmacokinet 37 (1999): 61-8[5] Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M \"Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers.\" Biopharm Drug Dispos 32 (2011): 168-74[6] Shahzadi A, Javed I, Aslam B, et al. \"Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers.\" Pak J Pharm Sci 24 (2011): 63-8[7] Sawant RD \"Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.\" Can J Clin Pharmacol 16 (2009): e78-9[8] Hedaya MA, El-Afify DR, El-Maghraby GM \"The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers.\" Biopharm Drug Dispos 27 (2006): 103-10[9] McLellan RA, Drobitch RK, Monshouwer M, Renton KW \"Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.\" Drug Metab Dispos 24 (1996): 1134-8[10] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[11] \"Product Information. Pletal (cilostazol).\" Otsuka American Pharmaceuticals, Rockville, MD.", "alternatives_a": "Betrixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Topiramate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60547, "ingredient1": "Cisapride", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60633/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60548, "ingredient1": "Citalopram", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of ventricular arrhythmia in association with QT prolongation is largely unpredictable, but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).", "source": "DDInter", "management_text": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Alternatives should be considered when possible, and hypokalemia or hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60634/", "reference_text": "[1] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[3] Priskorn M, Larsen F, Segonzac A, Moulin M \"Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects.\" Eur J Clin Pharmacol 52 (1997): 241-2[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60549, "ingredient1": "Clarithromycin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60635/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, More", "alternatives_b": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "updated_at": 1767369485}, {"id": 60550, "ingredient1": "Clemastine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60636/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60551, "ingredient1": "Clobazam", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration of clobazam with inhibitors of CYP450 2C19 may significantly increase the plasma concentrations of its active metabolite, N-desmethylclobazam, which is primarily metabolized by the isoenzyme. At therapeutic dosages of clobazam, plasma concentrations of N-desmethylclobazam are 3 to 5 times higher than those of the parent compound.", "source": "DDInter", "management_text": "Dosage adjustment of clobazam may be necessary when coadministered with strong (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate (e.g., omeprazole) inhibitors of CYP450 2C19.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustment of clobazam may be necessary when coadministered with strong (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60637/", "reference_text": "[1] \"Product Information. Onfi (clobazam).\" Lundbeck Inc, Deerfield, IL.[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Oxcarbazepine, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60552, "ingredient1": "Clomipramine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60638/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60553, "ingredient1": "Clonazepam", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60639/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 60554, "ingredient1": "Clonidine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60640/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60555, "ingredient1": "Clopidogrel", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation by the isoenzyme to a pharmacologically active metabolite.", "source": "DDInter", "management_text": "Based on existing data, it may be advisable to closely monitor the therapeutic efficacy of clopidogrel during concomitant treatment with CYP450 2C19 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Based on existing data, it may be advisable to closely monitor the therapeutic efficacy of clopidogrel during concomitant treatment with CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60641/", "reference_text": "[1] Moayyedi P, Sadowski DC \"Proton pump inhibitors and clopidogrel -- hazardous drug interaction or hazardous interpretation of data?\" Can J Gastroenterol 23 (2009): 251-2[2] Pezalla E, Day D, Pulliadath I \"Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.\" J Am Coll Cardiol 52 (2008): 1038-9[3] \"Product Information. Plavix (clopidogrel).\" Bristol-Myers Squibb, Princeton, NJ.[4] Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J \"Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.\" J Thromb Haemost 4 (2006): 2508-9[5] Lau WC, Gurbel PA \"The drug-drug interaction between proton pump inhibitors and clopidogrel.\" CMAJ 180 (2009): 699-700[6] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B \"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.\" Am Heart J 157 (2009): 148.e1-5[8] Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T \"Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions.\" Br J Clin Pharmacol 49 (2000): 244-53[9] \"Product Information. Kapidex (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Frere C, Cuisset T, Morange PE, et al. \"Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome.\" Am J Cardiol 101 (2008): 1088-1093[11] Mega JL, Close SL, Wiviott SD, et al. \"Cytochrome p-450 polymorphisms and response to clopidogrel.\" N Engl J Med 360 (2009): 354-62[12] Gilard M, Arnaud B, Cornily JC, et al \"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.\" J Am Coll Cardiol 51 (2008): 256-60[13] Li XQ, Andersson TB, Ahlstrom M, Weidolf L \"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.\" Drug Metab Dispos 32 (2004): 821-7[14] Juurlink DN, Gomes T, Ko DT, et al \"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.\" CMAJ 180 (2009): 713-8[15] Simon T, Verstuyft C, Mary-Krause M, et al \"Genetic determinants of response to clopidogrel and cardiovascular events.\" N Engl J Med 360 (2009): 363-75[16] Varenhorst C, Janes S, Erlinge D, et al \"Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.\" Eur Heart J 30 (2009): 1744-52[17] Small DS, Farid NA, Payne CD, et al. \"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.\" J Clin Pharmacol 48 (2008): 475-84[18] Hulot JS, Bura A, Villard E, et al. \"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.\" Blood (2006):[19] Collet JP, Hulot JS, Pena A, et al. \"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.\" Lancet 373 (2009): 309-17[20] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[21] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Betrixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Ethotoin, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Phensuximide, Phenobarbital, Ganaxolone, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 60556, "ingredient1": "Clorazepic acid", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60642/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60557, "ingredient1": "Clozapine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60643/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60558, "ingredient1": "Cobicistat", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with moderate or weak inducers of CYP450 3A4 may reduce the plasma concentrations of cobicistat, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of antiretroviral regimens containing cobicistat with these inducers should be avoided. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible. If concomitant use is required, close clinical and laboratory monitoring of antiretroviral response is recommended.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of antiretroviral regimens containing cobicistat with these inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60644/", "reference_text": "[1] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Smith DS, Fujimoto JM \"Alterations produced by novobiocin during biliary excretion of morphine, morphine-3-glucuronide and other compounds.\" J Pharmacol Exp Ther 188 (1974): 504-15", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 60559, "ingredient1": "Cobimetinib", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of cobimetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of cobimetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60645/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cotellic (cobimetinib).\" Genentech, South San Francisco, CA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cotellic (cobimetinib).\" Genentech, South San Francisco, CA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Cotellic (cobimetinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60560, "ingredient1": "Copanlisib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of copanlisib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of copanlisib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60646/", "reference_text": "[1] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60561, "ingredient1": "Crizotinib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and clinical monitoring should be considered if CYP450 3A4 inducers such as efavirenz are used with crizotinib.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring should be considered if CYP450 3A4 inducers such as efavirenz are used with crizotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60647/", "reference_text": "[1] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Xalkori (crizotinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] \"Product Information. Xalkori (crizotinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[10] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60562, "ingredient1": "Cyclizine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60648/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 60563, "ingredient1": "Cyclobenzaprine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60649/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60564, "ingredient1": "Cyclophosphamide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60650/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[3] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[4] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[8] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[9] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[10] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[11] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[12] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[13] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60565, "ingredient1": "Cyproheptadine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60651/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60566, "ingredient1": "Daclatasvir", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60652/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 60567, "ingredient1": "Dantrolene", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60653/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60568, "ingredient1": "Dapsone (topical)", "ingredient2": "Cenobamate", "severity": "Minor", "effect": "Theoretically, coadministration of dapsone with inducers of CYP450 3A4 such as rifamycins, anticonvulsants, barbiturates, and St. John's wort may increase the formation of dapsone hydroxylamine, a metabolite associated with hemolysis. Dose-related hemolysis is the most common adverse event associated with oral dapsone in both patients with or without glucose-6-phosphate dehydrogenase (G6PD) deficiency.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60654/", "reference_text": "[1] \"Product Information. Aczone (dapsone topical).\" QLT USA, Inc, Fort Collins, CO.[2] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Dapsone, Methylprednisolone, Azelaic acid, Adapalene, Dapsone, Clofazimine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60569, "ingredient1": "Darifenacin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of darifenacin, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60655/", "reference_text": "[1] \"Product Information. Enablex (darifenacin).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "alternatives_b": "Tiagabine, Ethotoin, Brivaracetam, Rufinamide, Valproic acid, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Phensuximide, More", "updated_at": 1767369485}, {"id": 60570, "ingredient1": "Darolutamide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of darolutamide should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of darolutamide should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60656/", "reference_text": "[1] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide", "updated_at": 1767369485}, {"id": 60571, "ingredient1": "Darunavir", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60657/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60572, "ingredient1": "Dasatinib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of dasatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of dasatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected, or a dosage increase for dasatinib depending on patient tolerability. Close monitoring for toxicities (e.g., myelosuppression, bleeding complications, fluid retention, QT prolongation) is recommended if the dosage of dasatinib is increased. The dosage should be reduced to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of dasatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60658/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[14] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Ethotoin, Brivaracetam, Gabapentin, Cannabidiol, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Phensuximide, Lamotrigine, More", "updated_at": 1767369485}, {"id": 60573, "ingredient1": "Deflazacort", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.", "source": "DDInter", "management_text": "Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60659/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Methylprednisolone, Betamethasone", "updated_at": 1767369485}, {"id": 60574, "ingredient1": "Delavirdine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of delavirdine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised when delavirdine is used with CYP450 3A4 inducers. Pharmacologic response to the antiretroviral regimen should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised when delavirdine is used with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60660/", "reference_text": "[1] Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW \"Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.\" Clin Pharmacol Ther 61 (1997): 544-53[2] \"Product Information. Rescriptor (delavirdine).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Ethotoin, Clonazepam, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 60575, "ingredient1": "Desipramine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60661/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60576, "ingredient1": "Desvenlafaxine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60662/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60577, "ingredient1": "Deutetrabenazine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60663/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 60578, "ingredient1": "Dexbrompheniramine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60664/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60579, "ingredient1": "Dexmedetomidine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60665/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide, Methylphenobarbital", "updated_at": 1767369485}, {"id": 60580, "ingredient1": "Dezocine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60666/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60581, "ingredient1": "Diazepam", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60667/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60582, "ingredient1": "Dihydroergotamine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60668/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Frovatriptan, Eptinezumab, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Almotriptan, Fremanezumab", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60583, "ingredient1": "Dimenhydrinate", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60669/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60584, "ingredient1": "Diphenhydramine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60670/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60585, "ingredient1": "Cenobamate", "ingredient2": "Valproic acid", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60671/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Lacosamide, Valproic acid", "updated_at": 1767369485}, {"id": 60586, "ingredient1": "Docetaxel", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of docetaxel, which is a substrate of the isoenzyme. Rifampin and hyperforin, a component of St. John's wort, have been shown to significantly induce the in vitro metabolism of docetaxel in human hepatocyte cultures.", "source": "DDInter", "management_text": "Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided unless the benefit outweighs the potential risk of docetaxel underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with docetaxel is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60672/", "reference_text": "[1] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[2] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[3] Baker SD \"Drug interactions with the taxanes.\" Pharmacotherapy 17(5 Pt 2) (1997): s126-32[4] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[5] Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R \"Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.\" Clin Cancer Res 11(19 Pt 1) (2005): 6972-9[6] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9[10] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[11] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[12] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[13] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[14] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60587, "ingredient1": "Donepezil", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of the CYP450 3A4 and/or 2D6 enzymatic pathways may decrease the plasma concentrations of donepezil. The mechanism is accelerated clearance of donepezil due to enhanced CYP450 activities.", "source": "DDInter", "management_text": "While clinical data are lacking, the possibility of a diminished therapeutic response to donepezil should be considered in patients receiving concomitant inducer agents.", "mechanism_text": "Metabolism", "recommendation": "While clinical data are lacking, the possibility of a diminished therapeutic response to donepezil should be considered in patients receiving concomitant inducer agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60673/", "reference_text": "[1] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[2] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses.\" Br J Clin Pharmacol 46 (1998): 30-4[3] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[4] Rojas-Fernandez C, Fisher C \"Drug interactions and donepezil.\" J Am Geriat Soc 40 (2000): 597-8[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "Ethotoin, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Paramethadione, Perampanel, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 60588, "ingredient1": "Doravirine", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, some authorities recommend that the doravirine dose be increased to 100 mg twice daily (approximately 12 hours apart).", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60674/", "reference_text": "[1] \"Product Information. Pifeltro (doravirine).\" Merck & Company Inc, Whitehouse Station, NJ.[2] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 60589, "ingredient1": "Doxepin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60675/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Tetracaine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60590, "ingredient1": "Doxepin (topical)", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60676/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Tetracaine", "alternatives_b": "Lamotrigine, Lacosamide, Levetiracetam, Tiagabine", "updated_at": 1767369485}, {"id": 60591, "ingredient1": "Doxorubicin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60677/", "reference_text": "[1] \"Product Information. Adriamycin PFS (doxorubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR \"Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects.\" Clin Pharmacol Ther 31 (1982): 263[3] \"Product Information. Doxil (doxorubicin liposomal).\" Sequis Pharmaceuticals Inc, Menlo Park, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Methsuximide, Paramethadione, Zonisamide, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, More", "updated_at": 1767369485}, {"id": 60592, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60678/", "reference_text": "[1] \"Product Information. Adriamycin PFS (doxorubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR \"Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects.\" Clin Pharmacol Ther 31 (1982): 263[3] \"Product Information. Doxil (doxorubicin liposomal).\" Sequis Pharmaceuticals Inc, Menlo Park, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Clonazepam, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60593, "ingredient1": "Doxylamine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60679/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60594, "ingredient1": "Dronabinol", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60680/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Dolasetron, Palonosetron", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60595, "ingredient1": "Dronedarone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of dronedarone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of dronedarone with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided. The extent to which other, less potent CYP450 3A4 inducers may interact with dronedarone is unknown. Caution is advised if they are used with dronedarone.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dronedarone with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60681/", "reference_text": "[1] \"Product Information. Multaq (dronedarone).\" sanofi-aventis , Bridgewater, NJ.[2] \"Product Information. Multaq (dronedarone).\" sanofi-aventis , Bridgewater, NJ.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Ethotoin, Brivaracetam, Gabapentin, Clonazepam, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Phensuximide, More", "updated_at": 1767369485}, {"id": 60596, "ingredient1": "Droperidol", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60682/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60597, "ingredient1": "Drospirenone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60683/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Estetrol, Megestrol acetate", "alternatives_b": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 60598, "ingredient1": "Duloxetine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60684/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60599, "ingredient1": "Duvelisib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of duvelisib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of duvelisib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60685/", "reference_text": "[1] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc., Needham, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60600, "ingredient1": "Efavirenz", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60686/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Methsuximide, Topiramate, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, Trimethadione, Lacosamide, Pregabalin, Vigabatrin", "updated_at": 1767369485}, {"id": 60601, "ingredient1": "Elagolix", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the metabolic isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments or a dose adjustment of elagolix may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60687/", "reference_text": "[1] \"Product Information. Orilissa (elagolix).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 60602, "ingredient1": "Eliglustat", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60688/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 60603, "ingredient1": "Elvitegravir", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60689/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 60604, "ingredient1": "Encorafenib", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may decrease the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. The extent to which CYP450 3A4 inducers may affect encorafenib exposure has not been studied.", "source": "DDInter", "management_text": "Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60690/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[2] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[3] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60605, "ingredient1": "Entacapone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60691/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Tiagabine, Lacosamide, Fosphenytoin", "updated_at": 1767369485}, {"id": 60606, "ingredient1": "Entrectinib", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60692/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60607, "ingredient1": "Enzalutamide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided. Moderate inducers such as bosentan, efavirenz, etravirine, modafinil, nafcillin, and nevirapine should also be avoided if possible. The extent to which other, less potent CYP450 3A4 inducers may interact with enzalutamide is unknown. Caution is advised if they are used with enzalutamide.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60693/", "reference_text": "[1] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Ethotoin, Gabapentin, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Phensuximide, Lamotrigine, Phenacemide, More", "alternatives_b": "Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide", "updated_at": 1767369485}, {"id": 60608, "ingredient1": "Erdafitinib", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.", "source": "DDInter", "management_text": "According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60694/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[7] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60609, "ingredient1": "Ergometrine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60695/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60610, "ingredient1": "Ergotamine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60696/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Frovatriptan, Eptinezumab, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Almotriptan, Fremanezumab", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60611, "ingredient1": "Erlotinib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib. If alternative treatment is unavailable and a potent inducer (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, St. John's wort) is to be used for more than a few days, an increase in the dosage of erlotinib should be considered as tolerated at 2-week intervals. Close clinical and laboratory monitoring for altered efficacy and safety, including renal and liver functions and serum electrolytes, is recommended.", "mechanism_text": "Metabolism", "recommendation": "Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60697/", "reference_text": "[1] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.[2] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[14] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60612, "ingredient1": "Erythromycin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60698/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Lincomycin, Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Dapsone, More", "alternatives_b": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Perampanel, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, More", "updated_at": 1767369485}, {"id": 60613, "ingredient1": "Escitalopram", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of escitalopram, which is primarily metabolized by the isoenzyme. High plasma levels of escitalopram may increase the risk of serious side effects such as QT prolongation, which may lead to arrhythmias including torsade de pointes and sudden death, as well as serotonin syndrome, which is a rare but potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "Caution is advised if escitalopram must be used in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Pharmacologic response to escitalopram should be monitored more closely whenever a CYP450 2C19 inhibitor is added to or withdrawn from therapy, and the escitalopram dosage adjusted as necessary. This may be particularly important in patients receiving escitalopram at the upper end of the dosage range. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heartbeat, shortness of breath, or syncope. Patients should also be closely monitored for symptoms of the serotonin syndrome during treatment.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if escitalopram must be used in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60699/", "reference_text": "[1] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[2] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[3] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[4] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[5] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[7] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[11] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[12] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[15] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[16] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[17] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[18] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60614, "ingredient1": "Esketamine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60700/", "reference_text": "[1] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60615, "ingredient1": "Eslicarbazepine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60701/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Eslicarbazepine", "alternatives_b": "Lacosamide, Cenobamate", "updated_at": 1767369485}, {"id": 60616, "ingredient1": "Esomeprazole", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60702/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, More", "alternatives_b": "Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60617, "ingredient1": "Estazolam", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60703/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60618, "ingredient1": "Esterified estrogens", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60704/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60619, "ingredient1": "Estradiol (topical)", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60705/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Diethylstilbestrol, Bazedoxifene, Prasterone, Methyltestosterone, Megestrol acetate, Estetrol, Nafarelin, Octreotide, Cetrorelix, Pasireotide, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60620, "ingredient1": "Estrone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60706/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Diethylstilbestrol, Bazedoxifene", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60621, "ingredient1": "Estrone sulfate", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60707/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60622, "ingredient1": "Eszopiclone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zopiclone, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60708/", "reference_text": "[1] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60623, "ingredient1": "Ethchlorvynol", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60709/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, More", "updated_at": 1767369485}, {"id": 60624, "ingredient1": "Ethosuximide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60710/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Tiagabine, Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Ethosuximide, Lacosamide", "updated_at": 1767369485}, {"id": 60625, "ingredient1": "Ethotoin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60711/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Ethotoin, Paramethadione, Mephenytoin, Zonisamide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Trimethadione, Lacosamide, Levetiracetam", "updated_at": 1767369485}, {"id": 60626, "ingredient1": "Etonogestrel", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60712/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Estetrol", "alternatives_b": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 60627, "ingredient1": "Etoposide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60713/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60628, "ingredient1": "Etravirine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C19, 2C9, and/or 3A4 may increase the plasma concentrations of etravirine, which is a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with CYP450 2C19, 2C9, and/or 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with CYP450 2C19, 2C9, and/or 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60714/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Ethotoin, Gabapentin, Rufinamide, Cannabidiol, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Phensuximide, Lamotrigine, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 60629, "ingredient1": "Everolimus", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the blood concentrations and pharmacologic effects of everolimus.", "source": "DDInter", "management_text": "Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine. If concomitant use is required, a dose adjustment of everolimus should be considered to achieve the recommended therapeutic range for the condition being treated. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase and 2 weeks after discontinuation of the inducer.", "mechanism_text": "Metabolism", "recommendation": "Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60715/", "reference_text": "[1] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60630, "ingredient1": "Exemestane", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. However, it has also been suggested that suppression of estrogen levels is not affected by the interaction, thus dosage adjustment of exemestane is not required. The extent to which other, less potent CYP450 3A4 inducers may interact with exemestane is unknown. Caution is advised if they are used with exemestane.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60716/", "reference_text": "[1] \"Product Information. Aromasin (exemestane)\" Pharmacia & Upjohn, Kalamazoo, MI.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide", "alternatives_b": "Brivaracetam, Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60631, "ingredient1": "Ezogabine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60717/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Lacosamide, Ezogabine", "updated_at": 1767369485}, {"id": 60632, "ingredient1": "Fedratinib", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60718/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60633, "ingredient1": "Felbamate", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60719/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione", "updated_at": 1767369485}, {"id": 60634, "ingredient1": "Felodipine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60720/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol, Clevidipine, Celecoxib, Mibefradil, Levamlodipine, More", "alternatives_b": "Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, More", "updated_at": 1767369485}, {"id": 60635, "ingredient1": "Fesoterodine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when fesoterodine is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fesoterodine is used with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60721/", "reference_text": "[1] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 60636, "ingredient1": "Flavoxate", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60722/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60637, "ingredient1": "Flibanserin", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of flibanserin, which is partially metabolized by the isoenzyme. High plasma levels of flibanserin may increase the risk of severe hypotension, syncope, and central nervous system depression.", "source": "DDInter", "management_text": "Caution is advised when flibanserin is used with CYP450 2C19 inhibitors. Patients should be monitored for signs and symptoms of hypotension, syncope, and central nervous system depression.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when flibanserin is used with CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60723/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Fenfluramine", "updated_at": 1767369485}, {"id": 60638, "ingredient1": "Fludrocortisone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60724/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Fluocinolone acetonide, Indomethacin, Fluocinolone acetonide, Diclofenac, Betamethasone, Fluorometholone, Methylprednisolone, Methylprednisolone, Betamethasone, Betamethasone", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60639, "ingredient1": "Fluoxetine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60725/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60640, "ingredient1": "Fluphenazine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60726/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60641, "ingredient1": "Flurazepam", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60727/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60642, "ingredient1": "Glasdegib", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided. If concomitant use cannot be avoided, the glasdegib dose should be increased as tolerated from 100 mg once a day to 200 mg once a day or from 50 mg once a day to 100 mg once a day. Once the moderate CYP450 3A4 inducer has been discontinued for 7 days, the glasdegib dose should return to the dose taken prior to initiating the moderate CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60728/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[7] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31[8] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60643, "ingredient1": "Granisetron", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60729/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Dolasetron, Palonosetron", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60644, "ingredient1": "Guanfacine", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers. For extended-release guanfacine, some manufacturers recommend increasing the dosage up to double the recommended level when initiating therapy in patients who are already receiving a CYP450 3A4 inducer. Further dosage adjustments may be required based on patient tolerance and response. If a CYP450 3A4 inducer is added to existing guanfacine therapy, the guanfacine dosage may be increased up to double the recommended level over 1 to 2 weeks. The dosage should be decreased to the recommended level over 1 to 2 weeks following discontinuation of the CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60730/", "reference_text": "[1] Kiechel JR, Lavene D, Guerret M, Comoy E, Godin M, Fillastre JP \"Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure.\" Eur J Clin Pharmacol 25 (1983): 463-6[2] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Deserpidine", "alternatives_b": "Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60645, "ingredient1": "Halazepam", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60731/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60646, "ingredient1": "Haloperidol", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60732/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60647, "ingredient1": "Halothane", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60733/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[3] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[4] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[8] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[9] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[10] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[11] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[12] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[13] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Carbamazepine, More", "updated_at": 1767369485}, {"id": 60648, "ingredient1": "Diamorphine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60734/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60649, "ingredient1": "Hydromorphone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60735/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60650, "ingredient1": "Hydroxyzine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60736/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Methylphenobarbital", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60651, "ingredient1": "Ibrutinib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of ibrutinib should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of ibrutinib adjusted as necessary in accordance with product labeling.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of ibrutinib should be considered when prescribed in combination with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60737/", "reference_text": "[1] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60652, "ingredient1": "Idelalisib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60738/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Gabapentin, Brivaracetam, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Fenfluramine, Lamotrigine, Phensuximide, Phenacemide, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60653, "ingredient1": "Ifosfamide", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60739/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60654, "ingredient1": "Iloperidone", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60740/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60655, "ingredient1": "Imatinib", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of imatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60741/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Bolton AE, Peng B, Hubert M, et al. \"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.\" Cancer Chemother Pharmacol 53 (2004): 102-6[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[19] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Paramethadione, Perampanel, Phensuximide, Phenacemide, Trimethadione, Vigabatrin, Mephenytoin", "updated_at": 1767369485}, {"id": 60656, "ingredient1": "Imipramine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60742/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60657, "ingredient1": "Indinavir", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60743/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60658, "ingredient1": "Irinotecan", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60744/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60659, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60745/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60660, "ingredient1": "Isavuconazonium", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60746/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60661, "ingredient1": "Isocarboxazid", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60747/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60662, "ingredient1": "Isradipine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60748/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Clevidipine, Celecoxib, Mibefradil, Levamlodipine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60663, "ingredient1": "Istradefylline", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.", "source": "DDInter", "management_text": "Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60749/", "reference_text": "[1] \"Product Information. Nourianz (istradefylline).\" Kyowa Kirin, Inc, Bedminster, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[3] \"Product Information. Nourianz (istradefylline).\" Kyowa Kirin, Inc, Bedminster, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60664, "ingredient1": "Itraconazole", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60750/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Fluconazole, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More", "updated_at": 1767369485}, {"id": 60665, "ingredient1": "Ivabradine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivabradine and its active N-desmethylated metabolite, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers. The potential for decreased efficacy of ivabradine should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60751/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[3] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[8] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[9] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, Ganaxolone, More", "alternatives_b": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Adenosine, Regadenoson, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, More", "updated_at": 1767369485}, {"id": 60666, "ingredient1": "Ivacaftor", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60752/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 60667, "ingredient1": "Cenobamate", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme. Subtherapeutic levels of ixabepilone may result.", "source": "DDInter", "management_text": "The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ixabepilone is unknown. Whenever possible, therapeutic agents with low enzyme induction potential should be considered in patients treated with ixabepilone.", "mechanism_text": "Metabolism", "recommendation": "The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60753/", "reference_text": "[1] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60668, "ingredient1": "Cenobamate", "ingredient2": "Ixazomib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ixazomib, which is a substrate of the isoenzyme. When ixazomib was administered with the potent CYP450 3A4 inducer rifampin, ixazomib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 54% and 74%, respectively.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ixazomib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ixazomib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60754/", "reference_text": "[1] \"Product Information. Ninlaro (ixazomib).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Product Information. Ninlaro (ixazomib).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60669, "ingredient1": "Cenobamate", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60755/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60670, "ingredient1": "Cenobamate", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60756/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[3] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[4] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[8] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[9] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[10] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[11] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[12] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[13] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60671, "ingredient1": "Cenobamate", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60757/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Tiagabine, Rufinamide, Topiramate, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Phensuximide, Lamotrigine, Methylphenobarbital, Phenacemide, More", "updated_at": 1767369485}, {"id": 60672, "ingredient1": "Cenobamate", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of lamotrigine. The mechanism is unknown.", "source": "DDInter", "management_text": "The potential for diminished therapeutic response to lamotrigine should be considered during coadministration with cenobamate. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the lamotrigine dosage adjusted as necessary.", "mechanism_text": "Others", "recommendation": "The potential for diminished therapeutic response to lamotrigine should be considered during coadministration with cenobamate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60758/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Ethotoin, Methsuximide, Paramethadione, Phensuximide, Lamotrigine, Methylphenobarbital, Phenacemide, Trimethadione, Mephenytoin", "updated_at": 1767369485}, {"id": 60673, "ingredient1": "Cenobamate", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60759/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Fenfluramine, Lamotrigine, More", "updated_at": 1767369485}, {"id": 60674, "ingredient1": "Cenobamate", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme as well as the efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers. Some authorities advise that concomitant use of larotrectinib with moderate CYP450 3A4 and/or P-gp inducers should be avoided (UK). Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60760/", "reference_text": "[1] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60675, "ingredient1": "Cenobamate", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions. Patients treated with lasmiditan are at risk of CNS depression, including dizziness and sedation, as well as driving impairment.", "source": "DDInter", "management_text": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation. Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60761/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Frovatriptan, Eptinezumab, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60676, "ingredient1": "Cenobamate", "ingredient2": "Lefamulin", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60762/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 60677, "ingredient1": "Cenobamate", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60763/", "reference_text": "[1] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.[2] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 60678, "ingredient1": "Cenobamate", "ingredient2": "Letrozole", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60764/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide", "alternatives_b": "Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, More", "updated_at": 1767369485}, {"id": 60679, "ingredient1": "Cenobamate", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60765/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Ethotoin, Methsuximide, Paramethadione, Mephenytoin, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide, Levetiracetam", "updated_at": 1767369485}, {"id": 60680, "ingredient1": "Cenobamate", "ingredient2": "Levobupivacaine", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60766/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine)\" Organon, West Orange, NJ.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Ropivacaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60681, "ingredient1": "Cenobamate", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60767/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer US Pharmaceuticals, New York, NY.[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc, Smyrna, GA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Fenfluramine", "alternatives_b": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "updated_at": 1767369485}, {"id": 60682, "ingredient1": "Cenobamate", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may increase the peak activity and/or decrease the duration of action of levomethadyl acetate, which is primarily metabolized by the isoenzyme. Induction of CYP450 3A4 also results in increased formation of the active metabolites, nor-LAAM and dinor-LAAM. High plasma levels of these metabolites may increase the risk of QT interval prolongation and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. The dose or dosing interval may require adjustment if an interaction is suspected. A 12-lead ECG should be performed before initiating levomethadyl acetate therapy, 12 to 14 days after initiating therapy, and periodically thereafter. Patients should be advised to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60768/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[2] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60683, "ingredient1": "Cenobamate", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60769/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Estetrol, Megestrol acetate", "alternatives_b": "Tiagabine, Ethotoin, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Mephenytoin, Zonisamide, Fenfluramine, Phensuximide, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60684, "ingredient1": "Cenobamate", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60770/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60685, "ingredient1": "Cenobamate", "ingredient2": "Linagliptin", "severity": "Moderate", "effect": "Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations of linagliptin, which is a substrate for both. The interaction may produce subtherapeutic and likely ineffective plasma concentrations of linagliptin.", "source": "DDInter", "management_text": "Due to the potential for reduced efficacy of linagliptin, coadministration with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. For patients requiring use of such drugs, an alternative to linagliptin is strongly recommended. Other known inducers of CYP450 3A4 include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, modafinil, nafcillin, nevirapine, and various other anticonvulsants, although the extent to which they interact with linagliptin is unknown. If concomitant use with these agents is necessary, glycemic control should be closely monitored.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for reduced efficacy of linagliptin, coadministration with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60771/", "reference_text": "[1] \"Product Information. Tradjenta (linagliptin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "updated_at": 1767369485}, {"id": 60686, "ingredient1": "Cenobamate", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60772/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60687, "ingredient1": "Cenobamate", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60773/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60688, "ingredient1": "Cenobamate", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1.", "source": "DDInter", "management_text": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60774/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Ethotoin, Brivaracetam, Gabapentin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Fenfluramine, Lamotrigine, Phensuximide, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 60689, "ingredient1": "Cenobamate", "ingredient2": "Lorazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60775/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60690, "ingredient1": "Cenobamate", "ingredient2": "Lorlatinib", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. In addition to the potential for diminished efficacy of lorlatinib, the risk of serious hepatotoxicity may be increased due to activation of the pregnane X receptor (PXR) by both lorlatinib and CYP450 3A4 inducers. The effect of concomitant use of moderate CYP450 3A4 inducers on lorlatinib pharmacokinetics or the risk of hepatotoxicity is unknown.", "source": "DDInter", "management_text": "Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is required, monitoring of AST, ALT and bilirubin is recommended 48 hours after initiating lorlatinib and at least 3 times during the first week of treatment. Depending upon the relative importance of each drug, lorlatinib or the CYP450 3A4 inducer should be discontinued for persistent Grade 2 or higher hepatotoxicity.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60776/", "reference_text": "[1] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Brivaracetam, Ezogabine, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Vigabatrin, Gabapentin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60691, "ingredient1": "Cenobamate", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60777/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60692, "ingredient1": "Cenobamate", "ingredient2": "Lumateperone", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60778/", "reference_text": "[1] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.[2] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60693, "ingredient1": "Cenobamate", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lurasidone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of lurasidone should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of lurasidone should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60779/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"", "alternatives_a": "Lacosamide", "alternatives_b": "Amisulpride", "updated_at": 1767369485}, {"id": 60694, "ingredient1": "Cenobamate", "ingredient2": "Lurbinectedin", "severity": "Major", "effect": "Coadministration with a strong or moderate CYP450 3A4 inducer is predicted to decrease lurbinectedin systemic exposure, which may reduce its efficacy.", "source": "DDInter", "management_text": "Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60780/", "reference_text": "[1] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60695, "ingredient1": "Cenobamate", "ingredient2": "Macimorelin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of macimorelin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The prescribing information for macimorelin recommends discontinuing potent CYP450 3A4 inducers (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, St. John's wort) as well as some moderate ones (e.g., bosentan, efavirenz, etravirine, modafinil) prior to macimorelin administration. A sufficient washout period following discontinuation of the inducers is also advised before using macimorelin. No recommendations are available for other, less potent CYP450 3A4 inducers; however, it may be appropriate to follow the same precaution.", "mechanism_text": "Metabolism", "recommendation": "The prescribing information for macimorelin recommends discontinuing potent CYP450 3A4 inducers (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60781/", "reference_text": "[1] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris, Charleston, SC.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris, Charleston, SC.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, More", "updated_at": 1767369485}, {"id": 60696, "ingredient1": "Cenobamate", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when macitentan is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when macitentan is used with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60782/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[2] Bruderer S, Aanismaa P, Homery MC, et al. \"Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.\" AAPS J 14 (2012): 68-78", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 60697, "ingredient1": "Cenobamate", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60783/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60698, "ingredient1": "Cenobamate", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may decrease the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers. A dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60784/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60699, "ingredient1": "Cenobamate", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60785/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Tiagabine, Ethotoin, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide, Levetiracetam", "updated_at": 1767369485}, {"id": 60700, "ingredient1": "Cenobamate", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of medroxyprogesterone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary. When administered as the depot formulation for contraception, no dosage adjustment for medroxyprogesterone is currently recommended during coadministration with CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60786/", "reference_text": "[1] Kobayashi K, Mimura N, Fujii H, et al \"Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate.\" Clin Cancer Res 6 (2000): 3297-303[2] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[3] \"Product Information. Provera (medroxyprogesterone).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005): 139-51[5] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006): 1419-22[6] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[7] \"Product Information. Depo-Provera (medroxyprogesterone).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Megestrol acetate, Estetrol, Megestrol acetate, Megestrol acetate, Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin", "alternatives_b": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60701, "ingredient1": "Cenobamate", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of mefloquine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from mefloquine therapy, and the dosage adjusted if necessary. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with mefloquine is unknown.", "mechanism_text": "Metabolism", "recommendation": "The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60787/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[3] Schmidt LE, Dalhoff K \"Food-drug interactions.\" Drugs 62 (2002): 1481-502[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Sulfadoxine, Chloroquine", "alternatives_b": "Fenfluramine", "updated_at": 1767369485}, {"id": 60702, "ingredient1": "Cenobamate", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The central nervous system and respiratory depressant effects of meperidine may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered, particularly in elderly or debilitated patients.", "source": "DDInter", "management_text": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol. A lower dosage of meperidine should be considered initially, then titrated carefully according to pain level and clinical response. Meperidine dosage reductions of 25% to 50% have been recommended for patients receiving phenothiazines and other tranquilizers.", "mechanism_text": "Synergism", "recommendation": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60788/", "reference_text": "[1] Lambertsen CJ, Wendel H, Longenhagen JB \"The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2.\" J Pharmacol Exp Ther 131 (1961): 381-93[2] Hoffman JC, Smith TC \"The respiratory effects of meperidine and propiomazine in man.\" Anesthesiology 32 (1970): 325-31[3] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Stambaugh JE, Wainer IW \"Drug interaction: meperidine and chlorpromazine, a toxic combination.\" J Clin Pharmacol 21 (1981): 140-6[5] \"Product Information. Meperidine Hydrochloride Injection, USP (meperidine)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60703, "ingredient1": "Cenobamate", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60789/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Ethotoin, Paramethadione, Mephenytoin, Zonisamide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Trimethadione, Lacosamide, Levetiracetam", "updated_at": 1767369485}, {"id": 60704, "ingredient1": "Cenobamate", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and pharmacologic effects of phenobarbital. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19, an isoenzyme involved in the hepatic metabolism of phenobarbital.", "source": "DDInter", "management_text": "Caution is recommended during concomitant use of cenobamate and phenobarbital. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the phenobarbital dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended during concomitant use of cenobamate and phenobarbital.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60790/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Lacosamide, Cenobamate, Nitrazepam, Zopiclone", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Methylphenobarbital, Felbamate, Ethosuximide, More", "updated_at": 1767369485}, {"id": 60705, "ingredient1": "Cenobamate", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60791/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide, Methylphenobarbital", "updated_at": 1767369485}, {"id": 60706, "ingredient1": "Cenobamate", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60792/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60707, "ingredient1": "Cenobamate", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60793/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Fosphenytoin, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60708, "ingredient1": "Cenobamate", "ingredient2": "Methadone", "severity": "Major", "effect": "Coadministration with inducers of various CYP450 isoenzymes may decrease the plasma concentrations of methadone, which is metabolized by CYP450 3A4, 2B6, 2C19, 2C9, and 2D6. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on methadone following the addition of an inducer. Conversely, discontinuation of the inducer may increase methadone plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers. Pharmacologic response to methadone should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60794/", "reference_text": "[1] Tong TG, Pond SM, Kreek MJ, et al \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981): 349-51[2] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976): 1104-6[3] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996): 925-6[4] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988): 623-9[5] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999): 1004-5[6] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991): 443-4[7] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999): 957-62[8] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc, Birmingham, AL.[9] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977): 1211[10] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976): 227[11] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984): 1287-8[12] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000): 405-7[13] Foster DJ, Somogyi AA, Bochner F \"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.\" Br J Clin Pharmacol 47 (1999): 403-12[14] Benmebarek M, Devaud C, Gex-Fabry M, et al. \"Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone.\" Clin Pharmacol Ther 76 (2004): 55-63[15] Oda Y, Kharasch ED \"Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.\" J Pharmacol Exp Ther 298 (2001): 1021-32[16] Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF \"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.\" Chem Res Toxicol 9 (1996): 365-73[17] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[18] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[19] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[20] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60709, "ingredient1": "Cenobamate", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60795/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Tiagabine, Ethotoin, Ezogabine, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Phenacemide, Felbamate, Lacosamide, Levetiracetam, Trimethadione", "updated_at": 1767369485}, {"id": 60710, "ingredient1": "Cenobamate", "ingredient2": "Methocarbamol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60796/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60711, "ingredient1": "Cenobamate", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60797/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Tiagabine, Ethotoin, Methsuximide, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Phenacemide, Trimethadione, Lacosamide, Levetiracetam", "updated_at": 1767369485}, {"id": 60712, "ingredient1": "Cenobamate", "ingredient2": "Methsuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60798/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Tiagabine, Clonazepam, Topiramate, Paramethadione, Methsuximide, Zonisamide, Phensuximide, Lamotrigine, Methylphenobarbital, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 60713, "ingredient1": "Cenobamate", "ingredient2": "Methyldopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60799/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Deserpidine", "alternatives_b": "Topiramate, Ezogabine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Paramethadione, Carbamazepine, More", "updated_at": 1767369485}, {"id": 60714, "ingredient1": "Cenobamate", "ingredient2": "Methylergometrine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60800/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60715, "ingredient1": "Cenobamate", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60801/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Frovatriptan, Eptinezumab, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Almotriptan, Fremanezumab", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60716, "ingredient1": "Cenobamate", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60802/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60717, "ingredient1": "Cenobamate", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60803/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Bosentan, Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60718, "ingredient1": "Cenobamate", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60804/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60719, "ingredient1": "Cenobamate", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60805/", "reference_text": "[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y \"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.\" Cancer Chemother Pharmacol 72 (2013): 1223-34[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60720, "ingredient1": "Cenobamate", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of mifepristone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, concomitant use with potent CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and rifamycins should generally be avoided. Other, less potent inducers such as aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants may also interact. Caution is advised if they are used with mifepristone.", "mechanism_text": "Metabolism", "recommendation": "When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, concomitant use with potent CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and rifamycins should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60806/", "reference_text": "[1] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[2] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[3] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[4] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Methsuximide, Perampanel, Fenfluramine, Eslicarbazepine, Lamotrigine, More", "updated_at": 1767369485}, {"id": 60721, "ingredient1": "Cenobamate", "ingredient2": "Mirabegron", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme and efflux transporter. No dosage adjustment is recommended when mirabegron is administered in combination with rifampin and probably other CYP450 3A4/P-gp inducers.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60807/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 60722, "ingredient1": "Cenobamate", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of mirtazapine, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of diminished therapeutic response to mirtazapine should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifampin, and St. John's wort. Pharmacologic response to mirtazapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of diminished therapeutic response to mirtazapine should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifampin, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60808/", "reference_text": "[1] Sitsen JM, Maris FA, Timmer CJ \"Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects.\" Eur J Drug Metab Pharmacokinet 26 (2001): 109-21[2] Timmer CJ, Sitsen JMA, Delbressine LP \"Clinical pharmacokinetics of mirtazapine.\" Clin Pharmacokinet 38 (2000): 461-74[3] Spaans E, Van Den Heuvel MW, Schnabel PG, et al. \"Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects.\" Eur J Clin Pharmacol 58 (2002): 423-9[4] \"Product Information. Remeron (mirtazapine).\" Organon, West Orange, NJ.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[15] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[16] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[17] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[18] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60723, "ingredient1": "Cenobamate", "ingredient2": "Modafinil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to modafinil or armodafinil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Dose adjustments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to modafinil or armodafinil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60809/", "reference_text": "[1] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.[2] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[14] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.", "alternatives_a": "Amphetamine, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Ethotoin, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Phensuximide, Phenacemide, Trimethadione, Lacosamide, Vigabatrin", "updated_at": 1767369485}, {"id": 60724, "ingredient1": "Cenobamate", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60810/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60725, "ingredient1": "Cenobamate", "ingredient2": "Montelukast", "severity": "Moderate", "effect": "Coadministration with inducers of hepatic CYP450 isoenzymes may decrease the plasma concentrations of montelukast, which is metabolized by CYP450 2C8, 2C9, and 3A4 .", "source": "DDInter", "management_text": "No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers. However, clinical monitoring for potentially reduced therapeutic effects may be appropriate, especially for potent inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60811/", "reference_text": "[1] \"Product Information. Singulair (montelukast).\" Merck & Co, Inc, West Point, PA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Ethotoin, Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60726, "ingredient1": "Cenobamate", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60812/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Paramethadione, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 60727, "ingredient1": "Cenobamate", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60813/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Dolasetron, Palonosetron", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60728, "ingredient1": "Cenobamate", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60814/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60729, "ingredient1": "Cenobamate", "ingredient2": "Naldemedine", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.", "source": "DDInter", "management_text": "Caution and monitoring for potential loss of efficacy is recommended with the concomitant use of naldemedine with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Caution and monitoring for potential loss of efficacy is recommended with the concomitant use of naldemedine with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60815/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.[3] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[4] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31[5] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[6] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[7] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[8] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[9] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 60730, "ingredient1": "Cenobamate", "ingredient2": "Naloxegol", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of naloxegol should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60816/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 60731, "ingredient1": "Cenobamate", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60817/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Fosphenytoin, Phenytoin", "updated_at": 1767369485}, {"id": 60732, "ingredient1": "Cenobamate", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60818/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Ethotoin, Brivaracetam, Rufinamide, Gabapentin, Topiramate, Ezogabine, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Lamotrigine, More", "updated_at": 1767369485}, {"id": 60733, "ingredient1": "Cenobamate", "ingredient2": "Neratinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided. According to some authorities, if the CYP450 3A4 inducer cannot be avoided, the dose of neratinib should be increased to 320 mg once daily. The daily dose of neratinib should not exceed 320 mg. The previous dose of neratinib may be resumed following discontinuation of the CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60819/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[5] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[6] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60734, "ingredient1": "Cenobamate", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60820/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Methylphenobarbital, Lacosamide, Levetiracetam, Ethotoin, Rufinamide, Paramethadione, Fosphenytoin, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60735, "ingredient1": "Cenobamate", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60821/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Clevidipine, Celecoxib, Mibefradil, Levamlodipine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60736, "ingredient1": "Cenobamate", "ingredient2": "Nicotine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60822/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[3] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[4] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[8] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[9] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[10] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[11] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[12] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[13] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene", "alternatives_b": "Brivaracetam, Ezogabine, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60737, "ingredient1": "Cenobamate", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60823/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Phensuximide, Lamotrigine, More", "updated_at": 1767369485}, {"id": 60738, "ingredient1": "Cenobamate", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60824/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Clevidipine, Celecoxib, Mibefradil, Levamlodipine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60739, "ingredient1": "Cenobamate", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60825/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60740, "ingredient1": "Cenobamate", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60826/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Clevidipine, Celecoxib, Mibefradil, Levamlodipine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Clonazepam, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60741, "ingredient1": "Cenobamate", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60827/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60742, "ingredient1": "Cenobamate", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60828/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Megestrol acetate, Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 60743, "ingredient1": "Cenobamate", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60829/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60744, "ingredient1": "Cenobamate", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60830/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60745, "ingredient1": "Cenobamate", "ingredient2": "Olaparib", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of olaparib with potent and moderate CYP450 3A4 inducers should generally be avoided. If coadministration with a moderate CYP450 3A4 inducer such as bosentan, dexamethasone, efavirenz, etravirine, modafinil or nafcillin is required, the potential for decreased efficacy of olaparib should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of olaparib with potent and moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60831/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60746, "ingredient1": "Cenobamate", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60832/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[5] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[11] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[12] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 60747, "ingredient1": "Cenobamate", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60833/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Fenfluramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60748, "ingredient1": "Cenobamate", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60834/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Dolasetron, Palonosetron", "alternatives_b": "Brivaracetam, Methylphenobarbital, Ethosuximide, Lacosamide, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Fosphenytoin, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 60749, "ingredient1": "Cenobamate", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60835/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 60750, "ingredient1": "Cenobamate", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60836/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 60751, "ingredient1": "Cenobamate", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60837/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60752, "ingredient1": "Cenobamate", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or 2B6 may decrease the plasma concentrations of osilodrostat, which is partially metabolized by these isoenzymes. According to the product labeling, multiple CYP450 isoenzymes (CYP450 3A4, 2B6, and 2D6) and UDP-glucuronosyltransferases contribute to osilodrostat metabolism, and no single pathway contributes greater than 25% to the total clearance. Some of the known CYP450 3A4 and 2B6 inducers also induce UDP-glucuronosyltransferases.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer. An increase in the dosage of osilodrostat may be required. Dosage adjustments should be based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations of their signs and symptoms. A reduction in dosage of osilodrostat may be required if the CYP450 3A4 and/or 2B6 inducer is discontinued during treatment with osilodrostat.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60838/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Methsuximide, Perampanel, Phensuximide, Lamotrigine, Phenacemide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60753, "ingredient1": "Cenobamate", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. Reduced therapeutic efficacy of osimertinib may occur. However, no pharmacokinetic data are available from drug interaction studies.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60839/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60754, "ingredient1": "Cenobamate", "ingredient2": "Oxazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60840/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60755, "ingredient1": "Cenobamate", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60841/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Oxcarbazepine, Lacosamide", "updated_at": 1767369485}, {"id": 60756, "ingredient1": "Cenobamate", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60842/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "alternatives_b": "Brivaracetam, Ezogabine, Methylphenobarbital, Ethosuximide, Lacosamide, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Fosphenytoin, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60757, "ingredient1": "Cenobamate", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60843/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[5] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[11] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[12] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60758, "ingredient1": "Cenobamate", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60844/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60759, "ingredient1": "Cenobamate", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.", "mechanism_text": "Metabolism", "recommendation": "Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60845/", "reference_text": "[1] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM \"Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract).\" Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[2] \"Product Information. Abraxane (paclitaxel protein-bound).\" American Pharmaceutical Partners, Schaumberg, IL.[3] \"Product Information. Taxol (paclitaxel).\" Bristol-Myers Squibb, Princeton, NJ.[4] Spencer CM, Faulds D \"Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.\" Drugs 48 (1994): 794-847[5] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[6] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[11] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[12] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[13] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60760, "ingredient1": "Cenobamate", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60846/", "reference_text": "[1] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60761, "ingredient1": "Cenobamate", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60847/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60762, "ingredient1": "Cenobamate", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme. The interaction has not been evaluated clinically, but simulations using physiologically-based pharmacokinetic (PBPK) models suggest an approximately 70% decrease in panobinostat systemic exposure in the presence of potent CYP450 3A4 inducers.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers. The potential for decreased efficacy of panobinostat should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60848/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60763, "ingredient1": "Cenobamate", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60849/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, More", "alternatives_b": "Ezogabine, Methylphenobarbital, Ethosuximide, Lacosamide, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 60764, "ingredient1": "Cenobamate", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60850/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 60765, "ingredient1": "Cenobamate", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60851/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 60766, "ingredient1": "Cenobamate", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60852/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60767, "ingredient1": "Cenobamate", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of pazopanib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. Alternative treatment lacking CYP450 3A4-inducing activity should be considered in patients receiving pazopanib; otherwise, pazopanib should not be used. Other known CYP450 3A4 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they may interact with pazopanib is unknown.", "mechanism_text": "Metabolism", "recommendation": "The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60853/", "reference_text": "[1] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60768, "ingredient1": "Cenobamate", "ingredient2": "Pemigatinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60854/", "reference_text": "[1] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60769, "ingredient1": "Cenobamate", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60855/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60770, "ingredient1": "Cenobamate", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60856/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60771, "ingredient1": "Cenobamate", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60857/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Perampanel", "alternatives_b": "Lacosamide, Cenobamate", "updated_at": 1767369485}, {"id": 60772, "ingredient1": "Cenobamate", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60858/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60773, "ingredient1": "Cenobamate", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60859/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60774, "ingredient1": "Cenobamate", "ingredient2": "Pexidartinib", "severity": "Moderate", "effect": "Coadministration of pexidartinib with moderate CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of pexidartinib. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of pexidartinib.", "source": "DDInter", "management_text": "Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inducer. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60860/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60775, "ingredient1": "Cenobamate", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60861/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Zonisamide, Phensuximide, Lamotrigine, Fosphenytoin, More", "updated_at": 1767369485}, {"id": 60776, "ingredient1": "Cenobamate", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60862/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60777, "ingredient1": "Cenobamate", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60863/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Tiagabine, Ethotoin, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, More", "updated_at": 1767369485}, {"id": 60778, "ingredient1": "Cenobamate", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and pharmacologic effects of phenobarbital. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19, an isoenzyme involved in the hepatic metabolism of phenobarbital.", "source": "DDInter", "management_text": "Caution is recommended during concomitant use of cenobamate and phenobarbital. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the phenobarbital dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended during concomitant use of cenobamate and phenobarbital.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60864/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Lacosamide, Cenobamate", "alternatives_b": "Phenobarbital", "updated_at": 1767369485}, {"id": 60779, "ingredient1": "Cenobamate", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60865/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Clonazepam, Topiramate, Paramethadione, Methsuximide, Zonisamide, Phensuximide, Lamotrigine, Methylphenobarbital, Phenacemide, Felbamate, Ethosuximide, More", "updated_at": 1767369485}, {"id": 60780, "ingredient1": "Cenobamate", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration of cenobamate and phenytoin may lead to increased plasma concentrations of phenytoin and reduced plasma concentrations of cenobamate. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19, one of the isoenzymes involved in the hepatic metabolism of phenytoin, and phenytoin-mediated induction of some of the metabolic routes of elimination of cenobamate, including CYP450 3A4 and glucuronidation.", "source": "DDInter", "management_text": "The manufacturer of cenobamate recommends that the daily dose of phenytoin be gradually reduced by up to 50% when the dosage of cenobamate is being titrated. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the phenytoin dosage adjusted accordingly. Patients should be advised to contact their physician if they experience signs and symptoms of phenytoin toxicity such as nausea, vomiting, tremors, ataxia, lethargy, slurred speech, visual disturbances, or changes in mental status.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer of cenobamate recommends that the daily dose of phenytoin be gradually reduced by up to 50% when the dosage of cenobamate is being titrated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60866/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[6] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[7] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[8] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[9] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[10] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[11] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[12] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[13] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[14] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[17] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Ethotoin, Paramethadione, Phenacemide, Phenytoin, Trimethadione, Mephenytoin", "updated_at": 1767369485}, {"id": 60781, "ingredient1": "Cenobamate", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60867/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Amisulpride", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60782, "ingredient1": "Cenobamate", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60868/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60783, "ingredient1": "Cenobamate", "ingredient2": "Pirfenidone", "severity": "Moderate", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 may increase the plasma concentrations of pirfenidone, especially when used in addition to a moderate or potent CYP450 1A2 inhibitor. Pirfenidone is primarily (70% to 80%) metabolized by CYP450 1A2, with minor contribution from CYP450 2C9, 2C19, 2D6, and 2E1.", "source": "DDInter", "management_text": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.g., certain fluoroquinolones, oral contraceptives, deferasirox, methoxsalen, mexiletine, thiabendazole, ticlopidine, zileuton) should be avoided. No particular precaution is necessary if pirfenidone and CYP450 2C9, 2C19, 2D6, and/or 2E1 inhibitors are coadministered without a moderate or potent CYP450 1A2 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60869/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 60784, "ingredient1": "Cenobamate", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60870/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 60785, "ingredient1": "Cenobamate", "ingredient2": "Polatuzumab vedotin", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60871/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 60786, "ingredient1": "Cenobamate", "ingredient2": "Pomalidomide", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60872/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 60787, "ingredient1": "Cenobamate", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided unless the benefit outweighs the potential risk of ponatinib underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ponatinib is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60873/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[4] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60788, "ingredient1": "Cenobamate", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A may decrease the plasma concentrations of pralsetinib which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60874/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60789, "ingredient1": "Cenobamate", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60875/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Fosphenytoin, Lacosamide", "updated_at": 1767369485}, {"id": 60790, "ingredient1": "Cenobamate", "ingredient2": "Praziquantel", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of praziquantel, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved. Alternative agents for schistosomiasis should be considered whenever possible in patients receiving treatment with a CYP450 3A4 inducer. Otherwise, clinical response to praziquantel should be closely monitored.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60876/", "reference_text": "[1] Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M \"Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers.\" Clin Pharmacol Ther 72 (2002): 505-13[2] Bittencourt PR, Gracia CM, Martins R, et al \"Phenytoin and carbamazepine decrease oral bioavailability of praziquantel.\" Neurology 42 (1992): 492-6[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Biltricide (praziquantel).\" Bayer, West Haven, CT.[5] Castro N, Medina R, Sotelo J, Jung H \"Bioavailability of praziquantel increases with concomitant administration of food.\" Antimicrob Agents Chemother 44 (2000): 2903-4[6] Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J \"Interaction between grapefruit juice and praziquantel in humans.\" Antimicrob Agents Chemother 46 (2002): 1614-6", "alternatives_a": "Triclabendazole, Oxamniquine", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60791, "ingredient1": "Cenobamate", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60877/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Methylprednisolone, Betamethasone, Fluorometholone, Clobetasol, Beclomethasone dipropionate, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60792, "ingredient1": "Cenobamate", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60878/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Betamethasone, Beclomethasone dipropionate, Mesalazine, Methylprednisolone, Betamethasone", "alternatives_b": "Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Ganaxolone, Phenacemide, More", "updated_at": 1767369485}, {"id": 60793, "ingredient1": "Cenobamate", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60879/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Lacosamide, Pregabalin", "updated_at": 1767369485}, {"id": 60794, "ingredient1": "Cenobamate", "ingredient2": "Pretomanid", "severity": "Major", "effect": "Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60880/", "reference_text": "[1] \"Product Information. Pretomanid (pretomanid).\" The Global Alliance for TB Drug Development, New York, NY.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] \"Product Information. Pretomanid (pretomanid).\" The Global Alliance for TB Drug Development, New York, NY.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Isoniazid, Ethambutol, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "updated_at": 1767369485}, {"id": 60795, "ingredient1": "Cenobamate", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60881/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Lacosamide, Cenobamate", "alternatives_b": "Lacosamide, Primidone", "updated_at": 1767369485}, {"id": 60796, "ingredient1": "Cenobamate", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60882/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60797, "ingredient1": "Cenobamate", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60883/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Paramethadione, Phenacemide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60798, "ingredient1": "Cenobamate", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60884/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Megestrol acetate", "alternatives_b": "Tiagabine, Ethotoin, Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Zonisamide, Fenfluramine, Phensuximide, More", "updated_at": 1767369485}, {"id": 60799, "ingredient1": "Cenobamate", "ingredient2": "Progesterone (topical)", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60885/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60800, "ingredient1": "Cenobamate", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60886/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60801, "ingredient1": "Cenobamate", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60887/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Tetracaine, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, More", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60802, "ingredient1": "Cenobamate", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60888/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Ezogabine, Paramethadione, Phensuximide, Phenacemide, Lacosamide", "updated_at": 1767369485}, {"id": 60803, "ingredient1": "Dextropropoxyphene", "ingredient2": "Cenobamate", "severity": "Major", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.", "source": "DDInter", "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60889/", "reference_text": "[1] Hansen BS, Dam M, Brandt J, et al \"Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.\" Acta Neurol Scand 61 (1980): 357-67[2] Peterson GR, Covault HP, Hostetler RM \"Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice.\" Life Sci 22 (1978): 2087-96[3] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI \"Interaction of propoxyphene with diazepam, alprazolam and lorazepam.\" Br J Clin Pharmacol 19 (1985): 51-7[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982): 223-4[5] Puckett WH Jr, Visconti JA \"Orphenadrine and propoxyphene.\" N Engl J Med 283 (1970): 544[6] Pearson RE, Salter FJ \"Drug interaction? Orphenadrine with propoxyphene.\" N Engl J Med 282 (1970): 1215[7] Shorr RI, Griffin MR, Daugherty JR, Ray WA \"Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.\" J Gerontol 47 (1992): m111-5[8] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company, Indianapolis, IN.[9] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Fenfluramine, Perampanel, Eslicarbazepine, Lacosamide, Stiripentol", "updated_at": 1767369485}, {"id": 60804, "ingredient1": "Cenobamate", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60890/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, Metoprolol, More", "alternatives_b": "Ethotoin, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Fosphenytoin, More", "updated_at": 1767369485}, {"id": 60805, "ingredient1": "Cenobamate", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60891/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60806, "ingredient1": "Cenobamate", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60892/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "updated_at": 1767369485}, {"id": 60807, "ingredient1": "Cenobamate", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60893/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60808, "ingredient1": "Cenobamate", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be advised to notify their physician if their symptoms worsen or their condition changes.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60894/", "reference_text": "[1] \"Quetiapine for schizophrenia.\" Med Lett Drugs Ther 39 (1997): 117-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Wong YWJ, Yeh C, Thyrum PT \"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.\" J Clin Psychopharmacol 21 (2001): 89-93[4] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB \"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.\" Br J Clin Pharmacol 61 (2006): 58-69[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Amisulpride", "alternatives_b": "Ethotoin, Lacosamide, Mephenytoin", "updated_at": 1767369485}, {"id": 60809, "ingredient1": "Cenobamate", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60895/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60810, "ingredient1": "Cenobamate", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60896/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Methsuximide, Paramethadione, Zonisamide, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, More", "updated_at": 1767369485}, {"id": 60811, "ingredient1": "Cenobamate", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St. John's wort. The possibility of diminished therapeutic efficacy should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60897/", "reference_text": "[1] Fabre C, Criddle J, Nolder D, Klein JL \"Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.\" Trans R Soc Trop Med Hyg 99 (2005): 871-3[2] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[3] Twum-Barima Y, Carruthers SG \"Quinidine-rifampin interaction.\" N Engl J Med 304 (1981): 1466-9[4] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[5] Pukrittayakamee S, Prakongpan S, Wanwimolruk S, Clemens R, Looareesuwan S, White NJ \"Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria.\" Antimicrob Agents Chemother 47 (2003): 1509-1513[6] Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S \"Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man.\" Br J Clin Pharmacol 40 (1995): 87-91[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[18] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S \"Grapefruit juice has no effect on quinine pharmacokinetics.\" Eur J Clin Pharmacol 55 (1999): 393-8[19] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[20] Hermans K, Stockman D, Van den Branden F \"Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome.\" Am J Med 114 (2003): 511-2[21] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, More", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60812, "ingredient1": "Cenobamate", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes.", "source": "DDInter", "management_text": "The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John's wort. Other known inducers include aminoglutethimide, bexarotene, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, mitotane, modafinil, nafcillin, nevirapine, rifabutin, rifapentine, barbiturates and various other anticonvulsants, although the extent to which they interact with ramelteon is unknown.", "mechanism_text": "Metabolism", "recommendation": "The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60898/", "reference_text": "[1] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60813, "ingredient1": "Cenobamate", "ingredient2": "Ranolazine", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. The extent to which other, less potent CYP450 3A4 inducers may interact with ranolazine is unknown. Caution is advised if they are used with ranolazine.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60899/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Adenosine, Regadenoson", "alternatives_b": "Brivaracetam, Topiramate, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60814, "ingredient1": "Cenobamate", "ingredient2": "Rasagiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60900/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60815, "ingredient1": "Cenobamate", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60901/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, More", "updated_at": 1767369485}, {"id": 60816, "ingredient1": "Cenobamate", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60902/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60817, "ingredient1": "Cenobamate", "ingredient2": "Remimazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60903/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 60818, "ingredient1": "Cenobamate", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of repaglinide, which is metabolized by the isoenzyme in the intestine and liver.", "source": "DDInter", "management_text": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, patients treated concomitantly with rifampin may require a higher dosage of repaglinide. Blood glucose should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy in patients stabilized on their existing antidiabetic regimen, and the repaglinide dosage adjusted as necessary. Patients should be advised to contact their physician if they experience loss of glycemic control.", "mechanism_text": "Metabolism", "recommendation": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, patients treated concomitantly with rifampin may require a higher dosage of repaglinide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60904/", "reference_text": "[1] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT \"Rifampin decreases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 68 (2000): 495-500[2] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT \"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.\" Br J Clin Pharmacol 56 (2003): 305-14[3] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60819, "ingredient1": "Cenobamate", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ribociclib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine. Pharmacologic effects of ribociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy. Alternative treatment may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60905/", "reference_text": "[1] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[5] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Clonazepam, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60820, "ingredient1": "Cenobamate", "ingredient2": "Rifabutin", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60906/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Isoniazid, Ethambutol, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 60821, "ingredient1": "Cenobamate", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, caution and clinical monitoring may be advisable if CYP450 3A4 inducers are coadministered with rilpivirine.", "mechanism_text": "Metabolism", "recommendation": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, caution and clinical monitoring may be advisable if CYP450 3A4 inducers are coadministered with rilpivirine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60907/", "reference_text": "[1] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 60822, "ingredient1": "Cenobamate", "ingredient2": "Rimegepant", "severity": "Major", "effect": "Coadministration with strong or moderate inducers of CYP450 3A4 may significantly reduce the plasma concentrations and therapeutic effects of rimegepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60908/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Frovatriptan, Eptinezumab, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Almotriptan, Fremanezumab", "updated_at": 1767369485}, {"id": 60823, "ingredient1": "Cenobamate", "ingredient2": "Riociguat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of riociguat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of riociguat adjusted as necessary. Data are not available to guide dosing of riociguat when coadministered with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort. Alternative agents with no or minimal CYP450 3A4-inducing activity should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60909/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[5] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[6] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 60824, "ingredient1": "Cenobamate", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the ripretinib dosage adjusted as necessary. Patients should be monitored for loss of anti-tumor activity.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60910/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60825, "ingredient1": "Cenobamate", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60911/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60826, "ingredient1": "Cenobamate", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60912/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Vigabatrin, Mephenytoin", "updated_at": 1767369485}, {"id": 60827, "ingredient1": "Cenobamate", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme as well as the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein. Pharmacologic effects of rivaroxaban should be monitored more closely whenever the inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60913/", "reference_text": "[1] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, More", "alternatives_b": "Betrixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 60828, "ingredient1": "Cenobamate", "ingredient2": "Roflumilast", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60914/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "updated_at": 1767369485}, {"id": 60829, "ingredient1": "Cenobamate", "ingredient2": "Rolapitant", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of rolapitant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60915/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Dolasetron, Palonosetron", "updated_at": 1767369485}, {"id": 60830, "ingredient1": "Cenobamate", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60916/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60831, "ingredient1": "Cenobamate", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60917/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Fosphenytoin, Lacosamide", "updated_at": 1767369485}, {"id": 60832, "ingredient1": "Cenobamate", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60918/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60833, "ingredient1": "Cenobamate", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60919/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Rufinamide, Zonisamide", "alternatives_b": "Lacosamide, Cenobamate", "updated_at": 1767369485}, {"id": 60834, "ingredient1": "Cenobamate", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer. However, patients should be closely monitored and the dose titrated based on safety and efficacy.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60920/", "reference_text": "[1] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60835, "ingredient1": "Cenobamate", "ingredient2": "Saquinavir", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60921/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Ethotoin, Brivaracetam, Rufinamide, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Phensuximide, Lamotrigine, More", "updated_at": 1767369485}, {"id": 60836, "ingredient1": "Cenobamate", "ingredient2": "Saxagliptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of saxagliptin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers. However, glycemic control should be closely monitored, and the physician notified if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60922/", "reference_text": "[1] \"Product Information. Onglyza (saxagliptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[13] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[14] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[15] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[16] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[17] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[19] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[20] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "updated_at": 1767369485}, {"id": 60837, "ingredient1": "Cenobamate", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60923/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60838, "ingredient1": "Cenobamate", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60924/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[3] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[4] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[5] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[6] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc, Tampa, FL.[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[8] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[9] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb, Princeton, NJ.[10] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[11] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[12] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[13] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60839, "ingredient1": "Cenobamate", "ingredient2": "Selpercatinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60925/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, Stiripentol, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60840, "ingredient1": "Cenobamate", "ingredient2": "Selumetinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.", "source": "DDInter", "management_text": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60926/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60841, "ingredient1": "Cenobamate", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60927/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60842, "ingredient1": "Cenobamate", "ingredient2": "Sibutramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60928/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Lamotrigine, Lacosamide, Tiagabine, Fosphenytoin", "updated_at": 1767369485}, {"id": 60843, "ingredient1": "Cenobamate", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Theoretically, coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of a diminished therapeutic response to sildenafil should be considered.", "source": "DDInter", "management_text": "Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60929/", "reference_text": "[1] \"Product Information. Revatio (sildenafil).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Hyland R, Roe GH, Jones BC, Smith DA \"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.\" Br J Clin Pharmaacol 51 (2001): 239-48[3] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ \"In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions.\" Drug Metab Disposition 28 (2000): 392-7[4] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Ethotoin, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Zonisamide, Fenfluramine, Phensuximide, More", "updated_at": 1767369485}, {"id": 60844, "ingredient1": "Cenobamate", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of silodosin, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60930/", "reference_text": "[1] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, More", "alternatives_b": "Finasteride, Dutasteride, Alfuzosin, Terazosin", "updated_at": 1767369485}, {"id": 60845, "ingredient1": "Cenobamate", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration with drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 may decrease the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/strong CYP450 3A4 dual inducer or a moderate CYP450 2C9 inducer in combination with a separate strong CYP450 3A4 inducer.", "source": "DDInter", "management_text": "Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.g., carbamazepine, enzalutamide, rifampin) is not recommended for all patients. Concomitant use of siponimod and moderate or strong CYP450 3A4 inducers (e.g., apalutamide, bosentan, dabrafenib, dexamethasone, efavirenz, eslicarbazepine, etravirine, fosphenytoin, lorlatinib, lumacaftor, mitotane, modafinil, nafcillin, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, St. John's wort) is not recommended for patients with CYP450 2C9*1/*3 and *2/*3 genotypes.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60931/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Clonazepam, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 60846, "ingredient1": "Cenobamate", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60932/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[6] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Cyclosporine, Acetylcysteine, Nandrolone, Heparin, Golimumab, Cyclosporine, Ustekinumab, More", "alternatives_b": "Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Lamotrigine, Ganaxolone, Phensuximide, More", "updated_at": 1767369485}, {"id": 60847, "ingredient1": "Cenobamate", "ingredient2": "Sodium oxybate", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.", "source": "DDInter", "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60933/", "reference_text": "[1] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical, Minnetonka, MN.[2] \"Product Information. Xywav (calcium/magnesium/potass/sodium oxybates).\" Jazz Pharmaceuticals, Palo Alto, CA.[3] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical, Minnetonka, MN.[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate, Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60848, "ingredient1": "Cenobamate", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of solifenacin, which has been shown to be a substrate of the isoenzyme in vitro.", "source": "DDInter", "management_text": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60934/", "reference_text": "[1] \"Product Information. VESIcare (solifenacin).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "alternatives_b": "Brivaracetam, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60849, "ingredient1": "Cenobamate", "ingredient2": "Sonidegib", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60935/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60850, "ingredient1": "Cenobamate", "ingredient2": "Sorafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sorafenib, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of sorafenib should be considered during coadministration with CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of sorafenib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60936/", "reference_text": "[1] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Tiagabine, Ethotoin, Brivaracetam, Methsuximide, Paramethadione, Zonisamide, Perampanel, Fenfluramine, Phensuximide, Lamotrigine, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60851, "ingredient1": "Cenobamate", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60937/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lamotrigine, Topiramate, Clonazepam, Fosphenytoin", "updated_at": 1767369485}, {"id": 60852, "ingredient1": "Cenobamate", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60938/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Stiripentol", "alternatives_b": "Lacosamide, Cenobamate", "updated_at": 1767369485}, {"id": 60853, "ingredient1": "Cenobamate", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60939/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60854, "ingredient1": "Cenobamate", "ingredient2": "Sunitinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or dose increase for sunitinib may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60940/", "reference_text": "[1] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60855, "ingredient1": "Cenobamate", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of suvorexant should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the suvorexant dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60941/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 60856, "ingredient1": "Cenobamate", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60942/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[6] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Ethotoin, Brivaracetam, Methsuximide, Paramethadione, Fenfluramine, Perampanel, Eslicarbazepine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 60857, "ingredient1": "Cenobamate", "ingredient2": "Tadalafil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers. However, the possibility of diminished pharmacologic effects of tadalafil should be considered. For the treatment of pulmonary arterial hypertension, use of tadalafil should be avoided in patients chronically taking potent inducers of CYP450 3A4.", "mechanism_text": "Metabolism", "recommendation": "For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60943/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.[4] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[5] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "alternatives_b": "Brivaracetam, Ezogabine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60858, "ingredient1": "Cenobamate", "ingredient2": "Tamoxifen", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.", "source": "DDInter", "management_text": "In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60944/", "reference_text": "[1] Biochem Pharmacol \"Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.\" Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al \"Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.\" Cancer Res 50 (1990): 5851-7[3] \"Product Information. Targretin (bexarotene)\" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ \"Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.\" Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[8] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[9] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide", "alternatives_b": "Tiagabine, Ethotoin, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Mephenytoin, Perampanel, Zonisamide, Eslicarbazepine, Phensuximide, More", "updated_at": 1767369485}, {"id": 60859, "ingredient1": "Cenobamate", "ingredient2": "Tamsulosin", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60945/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Finasteride, Dutasteride, Alfuzosin, Terazosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More", "alternatives_b": "Brivaracetam, Ezogabine, Ethosuximide, Lacosamide, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, Fosphenytoin, Vigabatrin, More", "updated_at": 1767369485}, {"id": 60860, "ingredient1": "Cenobamate", "ingredient2": "Tapentadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60946/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 60861, "ingredient1": "Cenobamate", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60947/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 60862, "ingredient1": "Cenobamate", "ingredient2": "Tazemetostat", "severity": "Major", "effect": "Coadministration with moderate or potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60948/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[2] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Rufinamide, Paramethadione, Vigabatrin, Mephenytoin, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60863, "ingredient1": "Cenobamate", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer. Close clinical monitoring of the virologic response to the HCV NS3/4A protease inhibitor is recommended.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60949/", "reference_text": "[1] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Ezogabine, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Lamotrigine, More", "updated_at": 1767369485}, {"id": 60864, "ingredient1": "Cenobamate", "ingredient2": "Telithromycin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers. Pharmacologic response to telithromycin should be monitored closely during coadministration, and alternative treatment given if an interaction is suspected. Whenever possible, telithromycin should preferably not be used during or within 2 weeks after discontinuation of treatment with a CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60950/", "reference_text": "[1] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[2] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Lincomycin", "alternatives_b": "Ethotoin, Brivaracetam, Methsuximide, Paramethadione, Mephenytoin, Fenfluramine, Phensuximide, Phenacemide, Trimethadione, Vigabatrin, Levetiracetam", "updated_at": 1767369485}, {"id": 60865, "ingredient1": "Cenobamate", "ingredient2": "Temazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60951/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60866, "ingredient1": "Cenobamate", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of temsirolimus with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.", "source": "DDInter", "management_text": "In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided. When used for the treatment of renal cell carcinoma, some authorities advise a dose increase from the recommended 25 mg IV once weekly to 50 mg IV once weekly depending on patient tolerability. The dosage should be reduced to the normally recommended dose following discontinuation of the potent CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60952/", "reference_text": "[1] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60867, "ingredient1": "Cenobamate", "ingredient2": "Teniposide", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60953/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 60868, "ingredient1": "Cenobamate", "ingredient2": "Terfenadine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60954/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 60869, "ingredient1": "Cenobamate", "ingredient2": "Tetrabenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60955/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60870, "ingredient1": "Cenobamate", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Dosage reductions may be necessary. Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence. Alcohol use is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60956/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Fenfluramine, Eslicarbazepine", "updated_at": 1767369485}, {"id": 60871, "ingredient1": "Cenobamate", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60957/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Tiagabine, Ethotoin, Ezogabine, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Phenacemide, Felbamate, Lacosamide, Levetiracetam, Trimethadione", "updated_at": 1767369485}, {"id": 60872, "ingredient1": "Cenobamate", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60958/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Zopiclone", "alternatives_b": "Tiagabine, Topiramate, Methsuximide, Lamotrigine, Fosphenytoin, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Stiripentol", "updated_at": 1767369485}, {"id": 60873, "ingredient1": "Cenobamate", "ingredient2": "Thioridazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60959/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60874, "ingredient1": "Cenobamate", "ingredient2": "Thiothixene", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60960/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60875, "ingredient1": "Cenobamate", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60961/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Tiagabine, Methsuximide, Paramethadione, Methylphenobarbital, Phenacemide, Trimethadione, Ethosuximide, Lacosamide", "updated_at": 1767369485}, {"id": 60876, "ingredient1": "Cenobamate", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided. Otherwise, caution is advised, and patients should be closely monitored for diminished clinical response to ticagrelor therapy. Alternative treatment may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60962/", "reference_text": "[1] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Weeks P, Sieg A, Vahdat K, Raissi F, Nathan S \"Improved ticagrelor antiplatelet effect on discontinuation of phenytoin.\" Ann Pharmacother 48 (2014): 644-7[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Teng R, Mitchell P, Butler K \"Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.\" Eur J Clin Pharmacol 69 (2013): 877-83[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Betrixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 60877, "ingredient1": "Cenobamate", "ingredient2": "Tinidazole", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60963/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Tetracycline, Fluconazole, Cefepime, Norfloxacin, Ciprofloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 60878, "ingredient1": "Cenobamate", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60964/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Brivaracetam, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60879, "ingredient1": "Cenobamate", "ingredient2": "Tizanidine", "severity": "Moderate", "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.", "source": "DDInter", "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60965/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Fenfluramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60880, "ingredient1": "Cenobamate", "ingredient2": "Tofacitinib", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of tofacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response; however, the extent to which these medications interact with tofacitinib has not been established.", "source": "DDInter", "management_text": "Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended when possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60966/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 60881, "ingredient1": "Cenobamate", "ingredient2": "Tolcapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60967/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Fosphenytoin, Lacosamide", "updated_at": 1767369485}, {"id": 60882, "ingredient1": "Cenobamate", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60968/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, Phenyl salicylate, Magnesium hydroxide, More", "alternatives_b": "Brivaracetam, Ezogabine, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Fosphenytoin, More", "updated_at": 1767369485}, {"id": 60883, "ingredient1": "Cenobamate", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tolvaptan, which is primarily metabolized by the isoenzyme. When tolvaptan was administered with the potent CYP450 3A4 inducer rifampin, tolvaptan peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 85%.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60969/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Conivaptan", "updated_at": 1767369485}, {"id": 60884, "ingredient1": "Cenobamate", "ingredient2": "Topiramate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60970/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Methsuximide, Topiramate, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 60885, "ingredient1": "Cenobamate", "ingredient2": "Toremifene", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of toremifene. According to the product labeling, toremifene is primarily metabolized by CYP450 3A4 to N-demethyltoremifene, an antiestrogenic metabolite with weak in vivo antitumor potency but whose serum concentrations are 2 to 4 times higher than those of toremifene at steady state. The extent to which other, less potent CYP450 3A4 inducers may affect toremifene is unknown.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of toremifene may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60971/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ \"Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.\" Clin Pharmacol Ther 64 (1998): 648-54[5] Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P \"Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes.\" Biochem Pharmacol 47 (1994): 1883-95[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[16] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[17] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60886, "ingredient1": "Cenobamate", "ingredient2": "Trabectedin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60972/", "reference_text": "[1] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Machiels JP, Staddon A, Herremans C, et al. \"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.\" Cancer Chemother Pharmacol 74 (2014): 729-37[4] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Clonazepam, Paramethadione, Perampanel, More", "updated_at": 1767369485}, {"id": 60887, "ingredient1": "Cenobamate", "ingredient2": "Tranylcypromine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60973/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60888, "ingredient1": "Cenobamate", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60974/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60889, "ingredient1": "Cenobamate", "ingredient2": "Tretinoin", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60975/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "alternatives_b": "Brivaracetam, Ezogabine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, More", "updated_at": 1767369485}, {"id": 60890, "ingredient1": "Cenobamate", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60976/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60891, "ingredient1": "Cenobamate", "ingredient2": "Trifluoperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60977/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60892, "ingredient1": "Cenobamate", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60978/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60893, "ingredient1": "Cenobamate", "ingredient2": "Trihexyphenidyl", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60979/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Paramethadione, Phenacemide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60894, "ingredient1": "Alimemazine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60980/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60895, "ingredient1": "Cenobamate", "ingredient2": "Trimethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60981/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Topiramate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60896, "ingredient1": "Cenobamate", "ingredient2": "Trimethobenzamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60982/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60897, "ingredient1": "Cenobamate", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60983/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60898, "ingredient1": "Cenobamate", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60984/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Tetracaine", "alternatives_b": "Lacosamide, Paramethadione, Phensuximide, Phenacemide", "updated_at": 1767369485}, {"id": 60899, "ingredient1": "Cenobamate", "ingredient2": "Triprolidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60985/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60900, "ingredient1": "Cenobamate", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60986/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 60901, "ingredient1": "Cenobamate", "ingredient2": "Tucatinib", "severity": "Moderate", "effect": "Coadministration with CYP450 3A4 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by CYP450 2C8 and to a lesser extent by CYP450 3A4.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60987/", "reference_text": "[1] \"Product Information. Tukysa (tucatinib).\" Seattle Genetics Inc, Bothell, WA.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, Stiripentol, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60902, "ingredient1": "Cenobamate", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with moderate or weak inducers of CYP450 3A4 may decrease the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme. Dedicated drug interaction studies have not been conducted to assess concomitant use of ubrogepant with moderate or weak CYP450 3A4 inducers.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers. If needed, a second 100 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60988/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Frovatriptan, Eptinezumab, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Almotriptan, Fremanezumab", "updated_at": 1767369485}, {"id": 60903, "ingredient1": "Cenobamate", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response.", "source": "DDInter", "management_text": "Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inducers. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60989/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[7] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 60904, "ingredient1": "Cenobamate", "ingredient2": "Valbenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60990/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 60905, "ingredient1": "Cenobamate", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60991/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 60906, "ingredient1": "Cenobamate", "ingredient2": "Vandetanib", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60992/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 60907, "ingredient1": "Cenobamate", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of vemurafenib, which has been shown in vitro to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of vemurafenib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of vemurafenib may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of vemurafenib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60993/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Vigabatrin, More", "alternatives_b": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 60908, "ingredient1": "Cenobamate", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of venetoclax, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of venetoclax with potent and moderate CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of venetoclax with potent and moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60994/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[4] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[5] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[6] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[7] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[8] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 60909, "ingredient1": "Cenobamate", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60995/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60910, "ingredient1": "Cenobamate", "ingredient2": "Vigabatrin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60996/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide, Cenobamate", "alternatives_b": "Lacosamide, Vigabatrin", "updated_at": 1767369485}, {"id": 60911, "ingredient1": "Cenobamate", "ingredient2": "Vilazodone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to vilazodone should be considered during coadministration with CYP450 3A4 inducers. Pharmacologic effects of vilazodone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of a diminished therapeutic response to vilazodone should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60997/", "reference_text": "[1] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Clonazepam, Cannabidiol", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 60912, "ingredient1": "Cenobamate", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60998/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 60913, "ingredient1": "Cenobamate", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/60999/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Ezogabine, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, Stiripentol, More", "updated_at": 1767369485}, {"id": 60914, "ingredient1": "Cenobamate", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61000/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Rufinamide, Clonazepam, More", "updated_at": 1767369485}, {"id": 60915, "ingredient1": "Cenobamate", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61001/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Topotecan", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 60916, "ingredient1": "Cenobamate", "ingredient2": "Voriconazole", "severity": "Moderate", "effect": "Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61002/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Fluconazole, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Ethotoin, Valproic acid, Topiramate, Paramethadione, Methsuximide, Fenfluramine, Phensuximide, Lamotrigine, Phenacemide, Trimethadione, Pregabalin, More", "updated_at": 1767369485}, {"id": 60917, "ingredient1": "Cenobamate", "ingredient2": "Vortioxetine", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of vortioxetine, which is primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "An increase in the dosage of vortioxetine should be considered when used in combination with potent CYP450 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifamycins) for greater than 14 days, up to a maximum of three times the original dosage depending on clinical response. Following discontinuation of the potent CYP450 inducer, vortioxetine dosage should be returned to the original level within 14 days. Other known CYP450 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, enzalutamide, efavirenz, etravirine, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with vortioxetine is unknown.", "mechanism_text": "Metabolism", "recommendation": "An increase in the dosage of vortioxetine should be considered when used in combination with potent CYP450 inducers (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61003/", "reference_text": "[1] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[14] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Clonazepam, Cannabidiol, Stiripentol", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 60918, "ingredient1": "Cenobamate", "ingredient2": "Voxelotor", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations and pharmacologic effects of voxelotor. The proposed mechanism is accelerated clearance of voxelotor due to induction of the CYP450 3A4 isoenzyme, which is the primary route of elimination of voxelotor.", "source": "DDInter", "management_text": "The use of voxelotor with moderate to potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible. If coadministration is required, the manufacturer recommends increasing the voxelotor dose to 2500 mg once daily. Pharmacologic response to voxelotor should also be monitored more closely.", "mechanism_text": "Metabolism", "recommendation": "The use of voxelotor with moderate to potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61004/", "reference_text": "[1] \"Product Information. Oxbryta (voxelotor).\" Global Blood Therapeutics, Inc., South San Francisco, CA.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 60919, "ingredient1": "Cenobamate", "ingredient2": "Zaleplon", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61005/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide, Rufinamide", "updated_at": 1767369485}, {"id": 60920, "ingredient1": "Cenobamate", "ingredient2": "Zanubrutinib", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of zanubrutinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of zanubrutinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61006/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Dabrafenib, Asciminib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60921, "ingredient1": "Cenobamate", "ingredient2": "Ziconotide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61007/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 60922, "ingredient1": "Cenobamate", "ingredient2": "Zileuton", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61008/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc., Paramus, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60923, "ingredient1": "Cenobamate", "ingredient2": "Ziprasidone", "severity": "Minor", "effect": "Coadministration with drugs that are inducers of the CYP450 3A4 isoenzyme may only modestly decrease the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61009/", "reference_text": "[1] Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A \"The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.\" Br J Clin Pharmacol 49(suppl 1) (2000): s65-70[2] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[14] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[15] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Amisulpride", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60924, "ingredient1": "Cenobamate", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Coadministration with CYP450 inducers may decrease the plasma concentrations of zolpidem, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of zolpidem should be considered during coadministration with CYP450 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John's wort. Alternative treatments or a dosage adjustment for zolpidem may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of zolpidem should be considered during coadministration with CYP450 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61010/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Villikka K, Kivisto KT, Luurila H, Neuvonen PJ \"Rifampin reduces plasma concentrations and effects of zolpidem.\" Clin Pharmacol Ther 62 (1997): 629-34[3] Vlase L, Popa A, Neag M, Muntean D, Baldea I, Leucuta SE \"Pharmacokinetic Interaction Between Zolpidem and Carbamazepine in Healthy Volunteers.\" J Clin Pharmacol (2010):[4] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[6] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 60925, "ingredient1": "Cenobamate", "ingredient2": "Zonisamide", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of zonisamide, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to zonisamide should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the zonisamide dosage adjusted as necessary. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to zonisamide should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the zonisamide dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61011/", "reference_text": "[1] \"Product Information. Zonegran (zonisamide)\" Elan Pharmaceuticals, S. San Francisco, CA.[2] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M \"Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.\" Eur J Clin Pharmacol 54 (1998): 177-83[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[14] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[15] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lacosamide, Cenobamate, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "alternatives_b": "Ethotoin, Rufinamide, Methsuximide, Zonisamide, Phensuximide, Phenacemide, Trimethadione, Lacosamide, Mephenytoin", "updated_at": 1767369485}, {"id": 60926, "ingredient1": "Anisindione", "ingredient2": "Cephalexin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61012/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60927, "ingredient1": "Cephalexin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61013/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60928, "ingredient1": "Chloramphenicol", "ingredient2": "Cephalexin", "severity": "Moderate", "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.", "source": "DDInter", "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.", "mechanism_text": "Antagonism", "recommendation": "The manufacturers recommend to avoid concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61014/", "reference_text": "[1] Brown TH, Alford RH \"Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.\" Antimicrob Agents Chemother 25 (1984): 405-7[2] Asmar BI, Prainito M, Dajani AS \"Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone.\" Antimicrob Agents Chemother 32 (1988): 1375-8[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Brown TH, Alford RH \"Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism.\" South Med J 78 (1985): 869-71[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] French GL, Ling TK, Davies DP, Leung DT \"Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis.\" Br Med J (Clin Res Ed) 291 (1985): 636-7[8] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Rifamycin, Bacitracin, Demeclocycline, Rifaximin, Amikacin, Polymyxin B, Rifamycin, Vitamin A, Azelaic acid, Isotretinoin, Norfloxacin, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60929, "ingredient1": "Cephalexin", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "mechanism_text": "Antagonism", "recommendation": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61015/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60930, "ingredient1": "Dicoumarol", "ingredient2": "Cephalexin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61016/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, More", "alternatives_b": "Loracarbef, Cefonicid, Ceftizoxime, Cefamandole, Meropenem, Ertapenem, Cefapirin, Doripenem, Cefalotin, Cefmetazole", "updated_at": 1767369485}, {"id": 60931, "ingredient1": "Entecavir", "ingredient2": "Cephalexin", "severity": "Moderate", "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "mechanism_text": "Excretion", "recommendation": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61017/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "alternatives_b": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Ceftriaxone, Cefotetan", "updated_at": 1767369485}, {"id": 60932, "ingredient1": "Etacrynic acid", "ingredient2": "Cephalexin", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61018/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60933, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Cephalexin", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61019/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60934, "ingredient1": "Cephalexin", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61020/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60935, "ingredient1": "Cephalexin", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61021/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60936, "ingredient1": "Cephalexin", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61022/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60937, "ingredient1": "Cephalexin", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.", "source": "DDInter", "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61023/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Cefepime, Ceftibuten, Ceftazidime, Cefiderocol, Ceftaroline fosamil, Cefotetan", "alternatives_b": "Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Cytarabine, Pralatrexate, Decitabine, Azacitidine, Tioguanine", "updated_at": 1767369485}, {"id": 60938, "ingredient1": "Cephalexin", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "Coadministration with probenecid may increase and prolong the serum concentrations of some cephalosporins. The proposed mechanism is competitive inhibition of renal tubular secretion by probenecid.", "source": "DDInter", "management_text": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction. Adjustment of the cephalosporin dosage may be required in accordance with the individual product labeling. For example, cefotaxime dosage should generally not exceed 6 grams/day when administered with probenecid. Probenecid reportedly does not affect the elimination of ceftazidime or ceftriaxone.", "mechanism_text": "Excretion", "recommendation": "Although probenecid has been used therapeutically to enhance serum levels of various beta-lactam antibiotics, the potential for increased adverse effects should be considered when probenecid is added to existing cephalosporin therapy, particularly when the latter is given at high dosages or to patients who are elderly or have renal dysfunction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61024/", "reference_text": "[1] Ko H, Cathcart KS, Peters GR, Griffith DL, Adams WJ \"Comparative single dose pharmacokinetics of cefmetazole and cefoxitin and the effects of probenecid on cefmetazole disposition in humans.\" Pharm Res 5 (1988): s152[2] Meister F, et al \"Reduction of ceftizoxime dosing interval by coadministration of probenecid.\" Clin Pharmacol Ther 39 (1986): 210[3] \"Product Information. Vantin (cefpodoxime proxetil).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Shukla UA, Pittman KA, Barbhaiya RH \"Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.\" J Clin Pharmacol 32 (1992): 725-31[5] Santoro J, Agarwal BN, Martinelli R, et al \"Pharmacology of cefaclor in normal volunteers and patients with renal failure.\" Antimicrob Agents Chemother 13 (1978): 951-4[6] Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD \"Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.\" J Antimicrob Chemother 40 (1997): 903-6[7] Luthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W \"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.\" Antimicrob Agents Chemother 20 (1981): 567-75[8] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[9] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[10] Brown GR \"Cephalosporin-probenecid drug interactions.\" Clin Pharmacokinet 24 (1993): 289-300[11] Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP \"The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.\" Br J Clin Pharmacol 11 (1981): 353-9[12] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[13] Mischler TW, Sugerman AA, Willard DA, et al \"Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.\" J Clin Pharmacol 14 (1974): 604-11[14] Brown G, Zemcov SJ, Clarke AM \"Effect of probenecid on cefazolin serum concentrations.\" J Antimicrob Chemother 31 (1993): 1009-11[15] Kercsmar CM, Stern RC, Reed MD, et al \"Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.\" J Antimicrob Chemother 12 (1983): 289-95[16] Pitkin D, Dubb J, Actor P, et al \"Kinetics and renal handling of cefonicid.\" Clin Pharmacol Ther 30 (1981): 587-93[17] LeBel M, Paone RP, Lewis GP \"Effect of probenecid on the pharmacokinetics of ceftizoxime.\" J Antimicrob Chemother 12 (1983): 147-55[18] Spina SP, Dillon EC \"Effect of chronic probenecid therapy on cefazolin serum concentrations.\" Ann Pharmacother 37 (2003): 621-4[19] Nooyen SM, Overbeek BP, Delariviere AB, Storm AJ, Langemeyer JJ \"Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting.\" Eur J Clin Microbiol Infect Dis 13 (1994): 1033-7[20] Griffith RS, Black HR, Brier GL, Wolny JD \"Effect of probenecid on the blood levels and urinary excretion of cefamandole.\" Antimicrob Agents Chemother 11 (1977): 809-12[21] Welling PG, Dean S, Selen A, et al \"Probenecid: an unexplained effect on cephalosporin pharmacology.\" Br J Clin Pharmacol 8 (1979): 491-5[22] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[23] Ings RM, Reeves DS, White LO, et al \"The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.\" J Pharmacokinet Biopharm 13 (1985): 121-42[24] \"Product Information. Tazicef (ceftazidime).\" SmithKline Beecham, Philadelphia, PA.[25] Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB \"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin.\" Antimicrob Agents Chemother 17 (1980): 847-55[26] Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ \"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.\" Antimicrob Agents Chemother 33 (1989): 356-61[27] Stoeckel K, Trueb V, Dubach UC, McNamara PJ \"Effect of probenecid on the elimination and protein binding of ceftriaxone.\" Eur J Clin Pharmacol 34 (1988): 151-6[28] Marino EL, Dominguez-Gil A \"The pharmacokinetics of cefadroxil associated with probenecid.\" Int J Clin Pharmacol Ther Toxicol 19 (1981): 506-8[29] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[30] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[34] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[37] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[38] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[39] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[40] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[41] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[42] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[43] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[44] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[45] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[46] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[47] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[48] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Ceftriaxone, Ceftazidime, Aztreonam, Cefiderocol", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, More", "updated_at": 1767369485}, {"id": 60939, "ingredient1": "Cephalexin", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.", "source": "DDInter", "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.", "mechanism_text": "Synergism", "recommendation": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61025/", "reference_text": "[1] Norrby R, Stenqvist K, Elgefors B \"Interaction between cephaloridine and furosemide in man.\" Scand J Infect Dis 8 (1976): 209-12[2] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J \"Pharmacokinetic interactions of ceftazidime and frusemide.\" J Chemother 7 Suppl (1995): 107-10[3] Dodds MG, Foord RD \"Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine.\" Br J Pharmacol 40 (1970): 227-36[4] Simpson IJ \"Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine.\" N Z Med J 74 (1971): 312-5[5] Korn A, Eichler HG, Gasic S \"A drug interaction study of ceftriaxone and frusemide in healthy volunteers.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4[6] Trollfors B, Norrby R, Kristianson K, Nilsson NJ \"Effects on renal function of treatment with cefoxitin alone or in combination with furosemide.\" Scand J Infect Dis 13 (1978): 73-7[7] Lawson DH, Macadam RF, Singh H, et al \"Effect of furosemide on antibiotic-induced renal damage in rats.\" J Infect Dis 126 (1972): 593-600[8] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977): 389-94[9] \"Product Information. Lorabid (loracarbef).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, More", "alternatives_b": "Imipenem, Aztreonam, Meropenem, Cefiderocol, Ertapenem, Doripenem", "updated_at": 1767369485}, {"id": 60940, "ingredient1": "Cephalexin", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61026/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60941, "ingredient1": "Cephalexin", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.", "source": "DDInter", "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.", "mechanism_text": "Synergism", "recommendation": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61027/", "reference_text": "[1] \"Product Information. Suprax (cefixime).\" Lupin Pharmaceuticals Inc, Baltimore, MD.[2] Wood T, Johnson K, Naylor S, Weinshilboum R \"Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia.\" Drug Metab Dispos 30 (2002): 1123-1128[3] Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr \"Influence of cephalosporin antibiotics on blood coagulation and platelet function.\" Antimicrob Agents Chemother 9 (1976): 91-3[4] Chen LJ, Hsiao FY, et al \"Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.\" PLoS One 11 (2016): 1-11[5] Osborne JC \"Hypoprothrombinemia and bleeding due to cefoperazone.\" Ann Intern Med 102 (1985): 721-2[6] Weitekamp MR, Aber RC \"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.\" JAMA 249 (1983): 69-71[7] \"Product Information. Omnicef (cefdinir).\" Parke-Davis, Morris Plains, NJ.[8] Khaleeli M, Giorgio AJ \"Defective platelet function after cephalosporin administration.\" Blood 48 (1976): 791-2[9] \"Product Information. Cefzil (cefprozil).\" Bristol-Myers Squibb, Princeton, NJ.[10] Angaran DM, Dias VC, Arom KV, et al \"The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient.\" Ann Surg 206 (1987): 155-61[11] Joehl RJ, Rasbach DA, Ballard JO, et al \"Moxalactam: evaluation of clinical bleeding in patients with abdominal infection.\" Arch Surg 118 (1983): 1259-61[12] \"Product Information. Keflex (cephalexin).\" Dista Products Company, Indianapolis, IN.[13] Mackie IJ, Walshe K, et al \"Effects of N-methyl-thiotetrazole cephalosporin on haemostasis in patients with reduced serum vitamin K1 concentrations.\" J Clin Pathol 39 (1986): 1245-1249[14] \"Product Information. Maxipime (cefepime).\" Bristol-Myers Squibb, Princeton, NJ.[15] \"Product Information. Rocephin (ceftriaxone).\" Roche Laboratories, Nutley, NJ.[16] Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E \"Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.\" J Clin Pharmacol 28 (1988): 88-95[17] \"Product Information. Vantin (cefpodoxime).\" Pharmacia and Upjohn, Kalamazoo, MI.[18] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] \"Product Information. Spectracef (cefditoren).\" TAP Pharmaceuticals Inc, Deerfield, IL.[20] \"Product Information. Cedax (ceftibuten).\" Schering-Plough, Liberty Corner, NJ.[21] Manson JM, Zolna LE, Kang YJ, Johnson CM \"Effects of cefonicid and other cephalosporin antibiotics on male sexual development in rats.\" Antimicrob Agents Chemother 31 (1987): 991-997[22] Lipsky JJ \"N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia.\" Lancet 2 (1983): 192-3[23] Cerner Multum, Inc. \"Australian Product Information.\" O 0[24] \"Product Information. Ceftin (cefuroxime).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Haubenstock A, Schmidt P, Zazgornik J, et al \"Hypoprothrombinaemic bleeding associated with ceftriaxone.\" Lancet 1 (1983): 1215-6[26] Cristiano P \"Hypoprothrombinemia associated with cefoperazone treatment.\" Drug Intell Clin Pharm 18 (1984): 314-6[27] Reddy J, Bailey RR \"Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics.\" N Z Med J 92 (1980): 378-80[28] \"Product Information. Cefotan (cefotetan).\" Stuart Pharmaceuticals, Wilmington, DE.[29] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[30] \"Product Information. Fortaz (ceftazidime).\" Glaxo Wellcome, Research Triangle Park, NC.[31] \"Product Information. Mefoxin (cefoxitin).\" Merck & Co, Inc, West Point, PA.[32] Parker SW, Baxter J, Beam TR \"Cefoperazone-induced coagulopathy.\" Lancet 1 (1984): 1016[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Duricef (cefadroxil).\" Bristol-Myers Squibb, Princeton, NJ.[35] Sieradzan RR, Bottner WA, Fasco MJ, Bertino JS Jr \"Comparative effects of cefoxitin and cefotetan on vitamin K metabolism.\" Antimicrob Agents Chemother 32 (1988): 1446-9[36] \"Product Information. Ceclor (cefaclor).\" Lilly, Eli and Company, Indianapolis, IN.[37] Lerner PI, Lubin A \"Coagulopathy with cefazolin in uremia.\" N Engl J Med 290 (1974): 1324[38] Bang NU, Tessler SS, Heidenreich RO, et al \"Effects of moxalactam on blood coagulation and platelet function.\" Rev Infect Dis 4 (1982): s546-54[39] \"Product Information. Ancef (cefazolin).\" SmithKline Beecham, Philadelphia, PA.[40] \"Product Information. Claforan (cefotaxime).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[41] Meisel S \"Hypoprothrombinemia due to cefoperazone.\" Drug Intell Clin Pharm 18 (1984): 316[42] Brown RB, Klar J, Lemeshow S, et al \"Enhanced bleeding with cefoxitin or moxalactam.\" Arch Intern Med 146 (1986): 2159-64[43] Agnelli G, Del Favero A, et al \"Cephalosporin-Induced Hypoprothrombinemia: Is the N-Methylthiotetrazole Side Chain the Culprit?\" Antimicrob Agents Chemother 29 (1986): 1108-1109[44] \"Product Information. Teflaro (ceftaroline).\" Forest Pharmaceuticals, St. Louis, MO.[45] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[46] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[47] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[48] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[49] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[50] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[51] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[52] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[53] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[54] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[55] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[56] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[57] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[58] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[59] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[60] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[61] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[62] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[63] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[64] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[65] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[66] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[67] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[68] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[69] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[70] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[71] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[72] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[73] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[74] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[75] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[76] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[77] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[78] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[79] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[80] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[81] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70", "alternatives_a": "Meropenem, Doripenem", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, More", "updated_at": 1767369485}, {"id": 60942, "ingredient1": "Abarelix", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61028/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Anastrozole, Exemestane, Fulvestrant", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 60943, "ingredient1": "Ceritinib", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61029/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 60944, "ingredient1": "Aluminum hydroxide", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been formally studied; however, the solubility of ceritinib has been found to be pH-dependent in vitro and the drug becomes poorly soluble as pH increases.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if ceritinib is used with drugs that can alter the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids. The potential for diminished therapeutic effects of ceritinib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if ceritinib is used with drugs that can alter the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61030/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60945, "ingredient1": "Aminoglutethimide", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61031/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Anastrozole, Exemestane, Fulvestrant", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Fedratinib, Vandetanib, Afatinib, Tivozanib, Lorlatinib, Regorafenib, More", "updated_at": 1767369485}, {"id": 60946, "ingredient1": "Amoxapine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61032/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Bupropion, Esketamine, Paroxetine", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 60947, "ingredient1": "Amprenavir", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of ceritinib during and for 2 weeks after treatment with itraconazole. If coadministration is required, the manufacturer recommends a reduction of the ceritinib dosage by approximately one-third, rounded to the nearest 150 mg dosage strength. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the potent CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61033/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Futibatinib, Tucatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 60948, "ingredient1": "Ceritinib", "ingredient2": "Artesunate", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the intestinal P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters, such as dabigatran, rosuvastatin, sulfasalazine, and topotecan. The proposed mechanism, based on in vitro data, is decreased clearance due to ceritinib-mediated inhibition of intestinal P-gp and/or BCRP efflux transport proteins.", "source": "DDInter", "management_text": "Caution is advised if ceritinib is used concomitantly with drugs that are substrates of the intestinal P-gp and/or BCRP transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever ceritinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if ceritinib is used concomitantly with drugs that are substrates of the intestinal P-gp and/or BCRP transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61034/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 60949, "ingredient1": "Ceritinib", "ingredient2": "Astemizole", "severity": "Major", "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61035/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 60950, "ingredient1": "Ceritinib", "ingredient2": "Bedaquiline", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to its less active N-monodesmethyl metabolite, M2. Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk. Because these agents may also cause QT interval prolongation, caution is recommended when they are used together with bedaquiline. ECG, serum electrolytes (potassium, magnesium, calcium), and liver function tests (ALT, AST, alkaline phosphatase, bilirubin) should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration. All QT-prolonging drugs including bedaquiline should be interrupted in patients who develop clinically significant ventricular arrhythmia or a QTcF interval greater than 500 msec confirmed by repeat ECG.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Concomitant use of potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61036/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Ripretinib, Alpelisib, Ruxolitinib, More", "updated_at": 1767369485}, {"id": 60951, "ingredient1": "Ceritinib", "ingredient2": "Bepridil", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61037/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Duvelisib, Tivozanib, Zanubrutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60952, "ingredient1": "Ceritinib", "ingredient2": "Berotralstat", "severity": "Major", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat. Berotralstat is a substrate of both P-gp and BCRP.", "source": "DDInter", "management_text": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors. Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61038/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Copanlisib, Lenvatinib, Erdafitinib, Dabrafenib, Abemaciclib, Vandetanib, Trametinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 60953, "ingredient1": "Ceritinib", "ingredient2": "Boceprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of ceritinib during and for 2 weeks after treatment with itraconazole. If coadministration is required, the manufacturer recommends a reduction of the ceritinib dosage by approximately one-third, rounded to the nearest 150 mg dosage strength. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the potent CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61039/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Futibatinib, Tucatinib, Alpelisib, Lenvatinib, Trametinib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 60954, "ingredient1": "Ceritinib", "ingredient2": "Butabarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61040/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ethchlorvynol, Zopiclone, Remimazolam, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Vandetanib, Afatinib, Tivozanib, Lorlatinib, More", "updated_at": 1767369485}, {"id": 60955, "ingredient1": "Ceritinib", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been formally studied; however, the solubility of ceritinib has been found to be pH-dependent in vitro and the drug becomes poorly soluble as pH increases.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if ceritinib is used with drugs that can alter the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids. The potential for diminished therapeutic effects of ceritinib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if ceritinib is used with drugs that can alter the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61041/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 60956, "ingredient1": "Ceritinib", "ingredient2": "Carteolol", "severity": "Major", "effect": "Coadministration of ceritinib with other drugs that can slow the heart rate such as beta-blockers, calcium channel blockers, digitalis, and clonidine may increase the risk of bradycardia, which can lead to heart block and QT prolongation.", "source": "DDInter", "management_text": "Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible. All patients treated with ceritinib should have their heart rate and blood pressure monitored regularly. Consult the product labeling for dosage adjustment and management recommendations if symptomatic or life-threatening bradycardia occurs. Patients should be advised to notify their doctor if they experience irregular heartbeat, slow pulse, dizziness, or syncope.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61042/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Bailey DG, Dresser GK \"Natural products and adverse drug interactions.\" Can Med Assoc J 170 (2004): 1531-2[6] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[7] Pillai U, Muzaffar J, Sandeep S, Yancey A \"Grapefruit juice and verapamil: a toxic cocktail.\" South Med J 102 (2009): 308-9[8] McAllister RG, Jr \"Clinical pharmacology of slow channel blocking agents.\" Prog Cardiovasc Dis 25 (1982): 83-102[9] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[10] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[11] Arayne MS, Sultana N, Bibi Z \"Review: grape fruit juice - drug interactions.\" Pak J Pharm Sci 18 (2005): 45-57[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions. 1998.\" Br J Clin Pharmacol 58 (2004): S831-40; discussion S841-3[13] Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A \"The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil.\" Eur J Clin Pharmacol 54 (1998): 337-40", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 60957, "ingredient1": "Frangula purshiana bark", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61043/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60958, "ingredient1": "Ceritinib", "ingredient2": "Castor oil", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61044/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 60959, "ingredient1": "Cerivastatin", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9 and/or 3A4. In vitro data suggest that ceritinib may inhibit these isoenzymes at clinical concentrations.", "source": "DDInter", "management_text": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include alfentanil, colchicine, cyclosporine, ergot derivatives, fentanyl, lovastatin, simvastatin, oral midazolam, triazolam, phenytoin, pimozide, quinidine, sildenafil, sirolimus, tacrolimus, and warfarin. If coadministration is required, dosage reductions for the CYP450 2C9 or 3A4 substrates should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61045/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Yoovathaworn KC, Sriwatanakul K, Thithapandha A \"Influence of caffeine on aspirin pharmacokinetics.\" Eur J Drug Metab Pharmacokinet 11 (1986): 71-6[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[6] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR \"Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics.\" Pharmacotherapy 16 (1996): 1046-52", "alternatives_a": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 60960, "ingredient1": "Cevimeline", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of cevimeline, which is metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience excessive adverse cholinergic effects of cevimeline such as nausea, vomiting, diarrhea, sweating, salivation, urinary frequency, visual disturbance, confusion, tremor, palpitations, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61046/", "reference_text": "[1] \"Product Information. Evoxac (cevimeline)\" Daiichi Pharmaceuticals, Fort lee, NJ.", "alternatives_a": "Bethanechol, Neostigmine, Pyridostigmine, Ambenonium, Pilocarpine", "alternatives_b": "Acalabrutinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 60961, "ingredient1": "Chloramphenicol", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to ceritinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the ceritinib dosage adjusted as necessary. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor if an adjustment was made.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61047/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More", "updated_at": 1767369485}, {"id": 60962, "ingredient1": "Chloroquine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.", "source": "DDInter", "management_text": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.", "mechanism_text": "Synergism", "recommendation": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61048/", "reference_text": "[1] Mercuro NJ, Yen CF, Shim DJ, et.al \"Risk of QT interval prolongation associated with the use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)\" JAMA Cardiol May 1:e201834 (2020): epub ahead of print[2] \"Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine).\" Prasco Laboratories, Cincinnati, OH.[3] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF HYDROXYCHLOROQUINE SULFATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/\" ({2020, Apr 27]):[4] \"Product Information. Plaquenil (R). (hydroxychloroquine).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] \"Product Information. Chloroquine Phosphate (chloroquine).\" West-Ward Pharmaceutical Corporation, Eatontown, NJ.[6] Bessiere F, Roccia H, Deliniere A, et.al \"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit.\" JAMA Cardiol May 1 (2020): epub ahead of print[7] National Institutes of Health (NIH) \"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: URL: https://covid19treatmentguidelines.nih.gov/\" ([2020, Apr 21]):[8] Sacher F, Fauchier L, Boveda S, et.al \"Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.\" Arch Cardiovasc Dis Apr 24 (2020): epub ahead of print[9] Kapoor A, Pandurangi U, Arora V, et.al \"Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.\" Indian Pacing Electorphysiol J Apr 8 (2020): epub ahead of print[10] Borba MGS, Val FFA, Sampaio VS, et.al \"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-2) infection: A randomized clinical trial.\" JAMA Netw Open Apr 1 (2020): epub ahead of print[11] Sapp JL, Alqarawi W, MacIntyre CJ, et.al \"Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society.\" Can J Cardiol Apr 8 (2020): epub ahead of print[12] Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ \"Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties.\" Clin Pharmacokinet Ar 18 (2020): epub ahead of print[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C \"COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients?\" Br J Clin Pharmacol Apr 29 (2020): epub ahead of print[15] US Food and Drug Administration \"Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Available from: URL: https://www.fda.gov/safety/medical-product-\" ([2020, Apr 24]):[16] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ \"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)\" Mayo Clin Proc Apr 7 (2020): epub ahead of print[17] Roden DM, Harrington RA, Poppas A, Russo AM \"Considerations for drug interactions on QTc in exploratory COVID-19 (Coroanvirus disease 2019) treatment.\" Heart Rhythm Apr 14 (2020): epub ahead of print[18] mitra RL, Greenstein SA, Epstein lm \"An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin; Possible benefits of intravenous lidocaine.\" HeartRythm Case Rep Apr 1 (2020): epub ahead of print[19] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CHLOROQUINE PHOSPHATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/13653\" ([2020, Apr 27]):[20] Saleh M, Gabriels J, ChangD, et.al \"The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection.\" Circ Arrhythm Electrophysiol Apr 29 (2020): epub ahead of print[21] Bonow RO, Hernandez AF, Turakhia M \"Hydroxychloroquine, coronavirus disease 2019, and QT prolongation.\" JAMA Cardiol May 1 (2020): epub ahead of print[22] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 60963, "ingredient1": "Chlorpromazine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61049/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 60964, "ingredient1": "Chlorpropamide", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61050/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 60965, "ingredient1": "Chlorzoxazone", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentration and the risk of adverse effects of drugs that are substrates of CYP450 2A6 and/or 2E1. The proposed mechanism, based on in vitro data, is decreased clearance due to ceritinib-mediated inhibition of CYP450 2A6 and 2E1.", "source": "DDInter", "management_text": "Caution is advised if ceritinib is used concomitantly with drugs that are substrates of CYP450 2A6 and/or 2E1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever ceritinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ceritinib is used concomitantly with drugs that are substrates of CYP450 2A6 and/or 2E1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61051/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Carisoprodol, Orphenadrine, Baclofen, Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 60966, "ingredient1": "Ciclesonide", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration of inhaled ciclesonide with potent inhibitors of CYP450 3A4 may increase systemic bioavailability of the pharmacologically active metabolite, des-ciclesonide, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors. Alternatively, a less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone may be considered. Beclomethasone is also less dependent on CYP450 3A4 metabolism. Patients should be monitored for systemic glucocorticoid effects including symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, irregular menstruations), adrenal suppression (which reduces patient's ability to respond to stress situations), immunosuppression, osteoporosis, glucose intolerance, and exacerbation of diabetes mellitus.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61052/", "reference_text": "[1] \"Product Information. Alvesco (ciclesonide).\" Nycomed USA, Florham Park, NJ.[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] \"Product Information. Omnaris (ciclesonide nasal).\" Sepracor Inc, Marlborough, MA.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Tiotropium, Beclomethasone dipropionate, Mupirocin, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 60967, "ingredient1": "Ciclesonide (nasal)", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration of inhaled ciclesonide with potent inhibitors of CYP450 3A4 may increase systemic bioavailability of the pharmacologically active metabolite, des-ciclesonide, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors. Alternatively, a less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone may be considered. Beclomethasone is also less dependent on CYP450 3A4 metabolism. Patients should be monitored for systemic glucocorticoid effects including symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, irregular menstruations), adrenal suppression (which reduces patient's ability to respond to stress situations), immunosuppression, osteoporosis, glucose intolerance, and exacerbation of diabetes mellitus.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61053/", "reference_text": "[1] \"Product Information. Alvesco (ciclesonide).\" Nycomed USA, Florham Park, NJ.[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] Agencia Española de Medicamentos y Productos Sanitarios Healthcare \"Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] \"Product Information. Omnaris (ciclesonide nasal).\" Sepracor Inc, Marlborough, MA.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Tiotropium, Beclomethasone dipropionate, Mupirocin, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 60968, "ingredient1": "Cilostazol", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.", "source": "DDInter", "management_text": "A 50% dosage reduction of cilostazol (i.e., 50 mg twice a day) should be considered when used with potent or moderate CYP450 3A4 and/or 2C19 inhibitors. Close clinical and laboratory monitoring is advised whenever the inhibitor is added to or withdrawn from therapy, and the cilostazol dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "A 50% dosage reduction of cilostazol (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61054/", "reference_text": "[1] Suri A, Bramer SL \"Effect of omeprazole on the metabolism of cilostazol.\" Clin Pharmacokinet 37 (1999): 53-9[2] Suri A, Forbes WP, Bramer SL \"Effects of CYP3A inhibition on the metabolism of cilostazol.\" Clin Pharmacokinet 37 (1999): 61-8[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Pletal (cilostazol).\" Otsuka American Pharmaceuticals, Rockville, MD.[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[6] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[7] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Pletal (cilostazol).\" Otsuka American Pharmaceuticals, Rockville, MD.", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "alternatives_b": "Dacomitinib, Pexidartinib, Tepotinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 60969, "ingredient1": "Cimetidine", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been formally studied; however, the solubility of ceritinib has been found to be pH-dependent in vitro and the drug becomes poorly soluble as pH increases.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if ceritinib is used with drugs that can alter the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids. The potential for diminished therapeutic effects of ceritinib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if ceritinib is used with drugs that can alter the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61055/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin", "alternatives_b": "Vemurafenib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erdafitinib, More", "updated_at": 1767369485}, {"id": 60970, "ingredient1": "Cinacalcet", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ketoconazole or other potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cinacalcet, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to cinacalcet (i.e., parathyroid hormone and serum calcium levels) should be monitored more closely whenever potent inhibitors of CYP450 3A4 are added to or withdrawn from therapy, and the cinacalcet dosage adjusted accordingly.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to cinacalcet (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61056/", "reference_text": "[1] \"Product Information. Sensipar (cinacalcet).\" Amgen USA, Thousand Oaks, CA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Sensipar (cinacalcet).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 60971, "ingredient1": "Ciprofloxacin", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61057/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Tetracycline, Polymyxin B, Gentamicin, Chlorhexidine, More", "alternatives_b": "Futibatinib, Tucatinib, Regorafenib, Alpelisib, Trametinib, Erdafitinib, Dabrafenib, Nintedanib, Afatinib, Everolimus, Dacomitinib, More", "updated_at": 1767369485}, {"id": 60972, "ingredient1": "Cisapride", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61058/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[4] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999): 251[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[7] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[8] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[9] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG \"Red wine-cisapride interaction: Comparison with grapefruit juice.\" Clin Pharmacol Ther 70 (2001): 17-23[10] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[11] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[12] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ \"Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.\" Clin Pharmacol Ther 66 (1999): 448-53[13] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[14] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[15] Gross AS, Goh YD, Addison RS, Shenfield GM \"Influence of grapefruit juice on cisapride pharmacokinetics.\" Clin Pharmacol Ther 65 (1999): 395-401[16] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8", "alternatives_a": "Metoclopramide", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 60973, "ingredient1": "Citalopram", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61059/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Bupropion, Esketamine, Paroxetine", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 60974, "ingredient1": "Clarithromycin", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of ceritinib during and for 2 weeks after treatment with itraconazole. If coadministration is required, the manufacturer recommends a reduction of the ceritinib dosage by approximately one-third, rounded to the nearest 150 mg dosage strength. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the potent CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61060/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Lincomycin, Dirithromycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 60975, "ingredient1": "Clevidipine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration of ceritinib with other drugs that can slow the heart rate such as beta-blockers, calcium channel blockers, digitalis, and clonidine may increase the risk of bradycardia, which can lead to heart block and QT prolongation.", "source": "DDInter", "management_text": "Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible. All patients treated with ceritinib should have their heart rate and blood pressure monitored regularly. Consult the product labeling for dosage adjustment and management recommendations if symptomatic or life-threatening bradycardia occurs. Patients should be advised to notify their doctor if they experience irregular heartbeat, slow pulse, dizziness, or syncope.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61061/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Bailey DG, Dresser GK \"Natural products and adverse drug interactions.\" Can Med Assoc J 170 (2004): 1531-2[6] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[7] Pillai U, Muzaffar J, Sandeep S, Yancey A \"Grapefruit juice and verapamil: a toxic cocktail.\" South Med J 102 (2009): 308-9[8] McAllister RG, Jr \"Clinical pharmacology of slow channel blocking agents.\" Prog Cardiovasc Dis 25 (1982): 83-102[9] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[10] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[11] Arayne MS, Sultana N, Bibi Z \"Review: grape fruit juice - drug interactions.\" Pak J Pharm Sci 18 (2005): 45-57[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions. 1998.\" Br J Clin Pharmacol 58 (2004): S831-40; discussion S841-3[13] Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A \"The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil.\" Eur J Clin Pharmacol 54 (1998): 337-40", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60976, "ingredient1": "Clindamycin", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with strong CYP450 3A4 inhibitors may increase plasma concentrations and the risk of adverse effects of clindamycin, which is metabolized predominantly by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors. The possibility of adverse reactions to clindamycin should be considered during coadministration with strong CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring of clindamycin should be considered whenever a strong CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61062/", "reference_text": "[1] \"Product Information. Cleocin (clindamycin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Minocycline, Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene, Lincomycin, Dirithromycin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 60977, "ingredient1": "Clofarabine", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.", "source": "DDInter", "management_text": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61063/", "reference_text": "[1] \"Product Information. Clolar (clofarabine).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Avapritinib, Ibrutinib, Tivozanib, Zanubrutinib, Lorlatinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 60978, "ingredient1": "Clofazimine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61064/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Ribociclib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60979, "ingredient1": "Clomipramine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61065/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Bupropion, Esketamine, Paroxetine", "alternatives_b": "Pexidartinib, Tepotinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Lorlatinib, Axitinib, More", "updated_at": 1767369485}, {"id": 60980, "ingredient1": "Clonazepam", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9 and/or 3A4. In vitro data suggest that ceritinib may inhibit these isoenzymes at clinical concentrations.", "source": "DDInter", "management_text": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include alfentanil, colchicine, cyclosporine, ergot derivatives, fentanyl, lovastatin, simvastatin, oral midazolam, triazolam, phenytoin, pimozide, quinidine, sildenafil, sirolimus, tacrolimus, and warfarin. If coadministration is required, dosage reductions for the CYP450 2C9 or 3A4 substrates should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61066/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Yoovathaworn KC, Sriwatanakul K, Thithapandha A \"Influence of caffeine on aspirin pharmacokinetics.\" Eur J Drug Metab Pharmacokinet 11 (1986): 71-6[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[6] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR \"Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics.\" Pharmacotherapy 16 (1996): 1046-52", "alternatives_a": "Ethotoin, Brivaracetam, Gabapentin, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Fenfluramine, Lamotrigine, Phensuximide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 60981, "ingredient1": "Clorazepic acid", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9 and/or 3A4. In vitro data suggest that ceritinib may inhibit these isoenzymes at clinical concentrations.", "source": "DDInter", "management_text": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include alfentanil, colchicine, cyclosporine, ergot derivatives, fentanyl, lovastatin, simvastatin, oral midazolam, triazolam, phenytoin, pimozide, quinidine, sildenafil, sirolimus, tacrolimus, and warfarin. If coadministration is required, dosage reductions for the CYP450 2C9 or 3A4 substrates should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61067/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Yoovathaworn KC, Sriwatanakul K, Thithapandha A \"Influence of caffeine on aspirin pharmacokinetics.\" Eur J Drug Metab Pharmacokinet 11 (1986): 71-6[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[6] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR \"Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics.\" Pharmacotherapy 16 (1996): 1046-52", "alternatives_a": "Clobazam, Meprobamate, Lorazepam, Chlordiazepoxide, Halazepam, Diazepam, Oxazepam", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 60982, "ingredient1": "Clotrimazole", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to ceritinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the ceritinib dosage adjusted as necessary. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor if an adjustment was made.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61068/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, More", "alternatives_b": "Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Regorafenib, Alpelisib, More", "updated_at": 1767369485}, {"id": 60983, "ingredient1": "Clozapine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function, such as antineoplastic, antimalarial, and antirheumatic agents. Caution is recommended if clozapine is used in combination with other drugs that can prolong the QT interval. Serum electrolytes, including potassium, magnesium and calcium, should be measured at baseline and periodically during treatment, and any abnormalities corrected prior to initiating clozapine. Clozapine treatment should be discontinued if the QTc interval exceeds 500 msec. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function, such as antineoplastic, antimalarial, and antirheumatic agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61069/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Dabrafenib, Pexidartinib, Tepotinib, Larotrectinib, Selumetinib, Cobimetinib, Afatinib, Tivozanib, Lorlatinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 60984, "ingredient1": "Cobicistat", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of ceritinib during and for 2 weeks after treatment with itraconazole. If coadministration is required, the manufacturer recommends a reduction of the ceritinib dosage by approximately one-third, rounded to the nearest 150 mg dosage strength. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the potent CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61070/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lenvatinib, Trametinib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 60985, "ingredient1": "Cobimetinib", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. The risk and/or severity of adverse effects such as diarrhea, nausea, vomiting, stomatitis, hemorrhage, cardiomyopathy, rash, photosensitivity, retinopathy, retinal vein occlusion, liver enzyme abnormalities, and rhabdomyolysis may be increased.", "source": "DDInter", "management_text": "Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of cobimetinib during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61071/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cotellic (cobimetinib).\" Genentech, South San Francisco, CA.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Cotellic (cobimetinib).\" Genentech, South San Francisco, CA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trametinib, Nintedanib, Ceritinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 60986, "ingredient1": "Colchicine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the isoenzyme. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur.", "source": "DDInter", "management_text": "Due to the risk of life-threatening and fatal toxicity, concomitant use of colchicine with potent CYP450 3A4 inhibitors should generally be avoided if possible. Otherwise, caution is advised. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with potent CYP450 3A4 inhibitors or within 14 days of using them. For the treatment of acute gout flares, the recommended dose is 0.6 mg for one dose, followed by 0.3 mg one hour later. Administration should not be repeated for at least three days. For the prophylaxis of gout flares, the adjusted dosage should be 0.3 mg once a day if the original regimen was 0.6 mg twice a day, and 0.3 mg once every other day if the original regimen was 0.6 once a day. For the treatment of familial Mediterranean fever, the maximum dosage of colchicine is 0.6 mg/day (may be given as 0.3 mg twice a day) when used in the presence of potent CYP450 3A4 inhibitors. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paresthesia, and numbness. Coadministration of colchicine with potent CYP450 3A4 inhibitors in patients with renal or hepatic impairment is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Due to the risk of life-threatening and fatal toxicity, concomitant use of colchicine with potent CYP450 3A4 inhibitors should generally be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61072/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[5] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[6] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[7] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[8] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[9] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[10] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[11] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[12] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[13] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[14] Cohen O, Locketz G, Hershko AY, Gorshtein A, Levy Y \"Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori.\" Rheumatol Int (2015):[15] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[16] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[17] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[18] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[19] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[20] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[21] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[22] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[23] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[24] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[25] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[26] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[27] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[28] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[29] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[30] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[31] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[32] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[33] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[34] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[35] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[36] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[37] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[38] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[39] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[40] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[41] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[42] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[43] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[44] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Pegloticase, Febuxostat, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 60987, "ingredient1": "Conivaptan", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vasopressin receptor antagonists conivaptan and tolvaptan, both of which are almost exclusively metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities recommend avoiding concomitant use of conivaptan or tolvaptan during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61073/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] \"Product Information. Vaprisol (conivaptan).\" Cumberland Pharmaceuticals Inc, Nashville, TN.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Alpelisib, Lenvatinib, Trametinib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 60988, "ingredient1": "Copanlisib", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61074/", "reference_text": "[1] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More", "alternatives_b": "Trametinib, Nintedanib, Ceritinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 60989, "ingredient1": "Crizotinib", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of crizotinib, which is primarily metabolized by the isoenzyme. Because crizotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of crizotinib during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61075/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Xalkori (crizotinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] \"Product Information. Xalkori (crizotinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Trametinib, Nintedanib, Ceritinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Regorafenib, Alpelisib, Trametinib, Erlotinib, Erdafitinib, Crizotinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 60990, "ingredient1": "Cyclophosphamide", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9 and/or 3A4. In vitro data suggest that ceritinib may inhibit these isoenzymes at clinical concentrations.", "source": "DDInter", "management_text": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include alfentanil, colchicine, cyclosporine, ergot derivatives, fentanyl, lovastatin, simvastatin, oral midazolam, triazolam, phenytoin, pimozide, quinidine, sildenafil, sirolimus, tacrolimus, and warfarin. If coadministration is required, dosage reductions for the CYP450 2C9 or 3A4 substrates should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61076/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Yoovathaworn KC, Sriwatanakul K, Thithapandha A \"Influence of caffeine on aspirin pharmacokinetics.\" Eur J Drug Metab Pharmacokinet 11 (1986): 71-6[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[6] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR \"Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics.\" Pharmacotherapy 16 (1996): 1046-52", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 60991, "ingredient1": "Cyclosporine", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative treatment that do not interfere with cyclosporine metabolism should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61077/", "reference_text": "[1] \"Product Information. Rescriptor (delavirdine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 60992, "ingredient1": "Dabrafenib", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61078/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Trametinib, Nintedanib, Ceritinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 60993, "ingredient1": "Daclatasvir", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61079/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 60994, "ingredient1": "Danazol", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to ceritinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the ceritinib dosage adjusted as necessary. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor if an adjustment was made.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61080/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Prasterone, Raloxifene, Bazedoxifene", "alternatives_b": "Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Regorafenib, Alpelisib, More", "updated_at": 1767369485}, {"id": 60995, "ingredient1": "Dapagliflozin", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61081/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 60996, "ingredient1": "Dapsone", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentration and the risk of adverse effects of drugs that are substrates of CYP450 2A6 and/or 2E1. The proposed mechanism, based on in vitro data, is decreased clearance due to ceritinib-mediated inhibition of CYP450 2A6 and 2E1.", "source": "DDInter", "management_text": "Caution is advised if ceritinib is used concomitantly with drugs that are substrates of CYP450 2A6 and/or 2E1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever ceritinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ceritinib is used concomitantly with drugs that are substrates of CYP450 2A6 and/or 2E1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61082/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Minocycline, Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 60997, "ingredient1": "Darifenacin", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by the isoenzyme. Darifenacin is also metabolized by CYP450 2D6, but 3A4 is the major pathway of metabolism in so-called poor metabolizers of 2D6.", "source": "DDInter", "management_text": "The dosage of darifenacin should not exceed 7.5 mg/day when used with potent CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of darifenacin during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "The dosage of darifenacin should not exceed 7.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61083/", "reference_text": "[1] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Enablex (darifenacin).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Oxybutynin, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 60998, "ingredient1": "Darolutamide", "ingredient2": "Ceritinib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61084/", "reference_text": "[1] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.[2] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, More", "alternatives_b": "Anastrozole, Exemestane, Fulvestrant", "updated_at": 1767369485}, {"id": 60999, "ingredient1": "Darunavir", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.", "source": "DDInter", "management_text": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to ceritinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the ceritinib dosage adjusted as necessary. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor if an adjustment was made.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61085/", "reference_text": "[1] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Sunitinib, Futibatinib, Regorafenib, Imatinib, Alpelisib, Lenvatinib, Erdafitinib, Trametinib, Nintedanib, Vandetanib, Ribociclib, More", "updated_at": 1767369485}, {"id": 61000, "ingredient1": "Dasatinib", "ingredient2": "Ceritinib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of dasatinib during and for 2 weeks after treatment with itraconazole. Close monitoring for toxicity (e.g., myelosuppression, bleeding complications, fluid retention, excessive slowing of heart rate or other conduction disturbances) and a reduction of dasatinib dosage to a range of 20 to 40 mg daily should be considered if there are no alternatives and concomitant use with these agents is necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/61086/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Trametinib, Nintedanib, Ceritinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Futibatinib, Alpelisib, Trametinib, Erdafitinib, Neratinib, Nintedanib, Dasatinib, Capmatinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}]